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Abstract 
 
Essential oils derived from dried and fresh leaves of Aloysia citrodora were obtained 
by hydrodistillation, and were investigated for a range of pharmacological properties: 
receptor binding, in vitro acetylcholinesterase (AChE) inhibitory, antioxidant activities, 
and neuroprotection properties relevant to neurodegenerative diseases. Fresh leaf A. 
citrodora essential oil inhibited [3H] nicotine binding to well washed rat forebrain 
membranes, with mean apparent IC50 of 0.0018 mg/ml.  No significant binding activity 
was observed for A. citrodora essential oil derived from fresh or dried leaves, for 
GABAAR and NMDARs. A. citrodora essential oil, both dried and fresh, exhibited 
radical scavenging activity (up to 100%, IC50 < 0.0001 mg/ml) and iron (II) chelating 
properties (approx. IC50 = 0.05 mg/ml), and showed neuroprotective characteristics 
against the toxic effects of H2O2 (100%, 0.001 mg/ml) and β-amyloid (approx. 50%, 
0.01 mg/ml) in CAD neuronal cell culture. Both EOs from dried and fresh leaves also 
displayed effective AChE inhibitory activity, with the dried leaves oil displaying more 
clear AChE inhibitory activity than fresh oil, which could be related to the higher 
respective levels of caryophyllene oxide. Recombinant human anticholinesterase 
enzyme was used for structure based in silico screening of A. citrodora essential oil 
constituents for AChE Inhibitors, and the top scoring hits with highest pharmacophore 
fit values showed common interactions with residues at the active site of that of 
donepezil. The top seven hits in order of fit score, were β-curcumene, curcumene 
bisabolene, trans-calamenene, caryophyllene oxide, β-sesquiphellandrene and 
geranyl acetate. This indicates that plants may yield novel effective and safe AChE 
inhibitors, other than alkaloids. To begin to identify the chemicals underpinning the 
pharmacological properties of A. citrodora, GC/MS analysis of the chemical 
composition of the essential oil from leaves of A. citrodora identified eighty three major 
chemicals, including the presence of terpenoids, monoterpenes and sesquiterpenes, 
and 6-methyl-5-hepten-2-one, the main constituents being limonene, caryophyllene 
oxide, curcumene, spathulenol, 1,8-cineole constituting 47% of the total oil.  Finally, 
a simple, inexpensive solid phase extraction method was developed for fractionation 
of essential oils. Collectively, this thesis provides a better understanding of the 
pharmacology of the Aloysia essential oil and its constituents relating to its potential 
use in the treatment neurodegenerative disease. 
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Chapter 1 
Introduction  
1.1 Neurodegenerative Diseases 
 Overview 
Neurodegenerative diseases affect a significant number of individuals in all age 
groups. For the subset of disorders that affect older individuals, the number of cases 
is rapidly growing worldwide with increasing life expectancies. For example, 
approximately 18 million people currently suffer from Alzheimer’s disease (AD) and 
that number is expected to increase to 34 million by 2025 (Thies, 2013). In addition 
to reduceding life expectancy and quality of life, neurodegenerative diseases inflict 
significant financial burdens on family members and on healthcare systems (Cuny, 
2012). Neurodegenerative diseases include AD, where neurons die initially in the 
nucleus basalis, Parkinson’s disease (PD) which affects the substantia nigra, 
Huntington disease where striatal medium spiny neurons are lost, amyotrophic 
lateral sclerosis (ALS) and prion diseases which are characterized by damage and 
loss of motor neurons in the brain and spinal cord. All these diseases share common 
features including histopathology, clinical course and molecular mechanisms of 
pathogenesis. A common feature of neurodegenerative diseases is an extended time 
course until sufficient abnormal protein accumulates, followed by a cascade of 
symptoms over many years with increasing disability (Jellinger, 2009). Although 
these conditions are characterized clinically, advances in live imaging, histological 
analysis, genetic studies and proteomic interrogation has refined the diagnosis 
(Przedborski et al., 2003). For instance, in the case of PD, radiotracer imaging can 
identify abnormal dopaminergic function, while newer MRI techniques can assess 
connectivity and microstructural damage. Volumetric analysis of regional tissue loss 
can be useful for differential diagnosis in dementias. In AD, specific imaging markers 
of abnormal protein deposition are available. Also the use of multimodal imaging, 
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especially when combined with other biomarkers, shows increasing promise for the 
detection of preclinical disease in high risk individuals (Stoessl, 2012). 
 
Neurodegenerative diseases are often age-related, increasing in frequency with 
advancing age and often accompanied by four stages of microscopic signs: neuronal 
pathology, neuronal cell death, disappearance of neuronal cell bodies and glial 
proliferation (Przedborski et al., 2003). 
 
 Clinical Features of Neurodegenerative Diseases 
Neurodegenerative diseases have a chronic clinical course that is relentlessly 
progressive and irreversible by any known therapy, although drug therapy or gene 
therapy may give marginal or temporary improvement. The major risk factor for 
neurodegenerative diseases is advancing age. Phenotypic variability is also 
commonly seen. These conditions appear to be heritable in a small percentage of 
cases. In the familial form of the disease, the onset occurs up to a decade before the 
onset of the sporadic form of the disease. Several different neurodegenerative 
diseases may appear together within a family. Different clinical manifestations are 
mediated by dysfunction of different anatomical regions of degeneration. Cognitive 
impairment and dementia although common, are not seen in all forms.  
 
Neurodegenerative diseases are diagnosed primarily on the basis of history and 
clinical examination (Fig 1.1) (Hardiman, 2011). The most important risk factors are 
age, positive family history, unhealthy lifestyle, endogenous factors and exposure to 
toxic environment (Fig 1.2) (Farooqui, 2007) supporting the view that neural cell 
death is a multifactorial process (Fig 1.3). Normal aging is accompanied by a modest 
upregulation of excitotoxicity, oxidative stress and neuroinflammation (Facheris et 
al., 2004). It is not clear whether exicitotoxicity, oxidative stress or neuroinflammation 
are the cause or consequence of neural cell death (Andersen, 2004, Juranek and 
Bezek, 2005). Evidence suggests that these are closely associated with mechanisms 
of apoptotic cell death (Farooqui et al., 2007, Kabashi et al., 2007, Shibata and 
Kobayashi, 2008). 
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Unfortunately, effective therapies are currently lacking for the vast majority of 
neurodegenerative diseases. For some conditions, such as AD and PD, therapeutic 
agents that provide symptomatic relief are available. However, symptom alleviation 
is only temporary without significant alteration in the underlying disease progression. 
Several difficulties stand in the way of  progress in the discovery and development 
of drugs for neurodegenerative diseases, including our undeveloped understanding 
of the CNS and the aetiology of these diseases (Cuny, 2012).  
 
Neurons in general represent a vulnerable group of cells. Because they facilitate 
neurotransmission and maintain the metabolic needs required for long axonal 
projections, Neurons also have high energy requirements and are reliant on axonal 
transport combined with a larger surface area that make them more exposed to 
environmental toxins. Hence, once damaged, regeneration is difficult. The 
dopaminergic neurons located in the substantia nigra in PD are particularly prone to 
reactive oxygen species (ROS) induced injury. This selective vulnerability is believed 
to be driven from the fact that neurons in the substantia nigra have very high levels 
of iron and copper, both of which are capable of catalysing ROS formation. Additional 
evidence suggests that substantia nigra may have low stores of antioxidant 
molecules such as glutathione, thereby increasing neuronal susceptibility to the 
damaging effects of ROS. However, this does not explain the vulnerability of neurons 
associated with PD in other regions of the brain such as brainstem and spinal cord. 
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Fig 1.1 
Clinical classification of neurodegenerative diseases (Hardiman and Doherty, 2011)  
 
 
 
Fig 1.2   
Factors effecting neurodegeneration in neurological disorders (Farooqui, 2010) 
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Factors associated with the pathogenesis of neurodegenerative diseases 
(Hardiman and Doherty, 2011) 
 
 
 
 
 
 
 
 
 
Fig 1.3 
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  Neuropathology 
In neurodegenerative diseases only a specific neuronal population in a particular 
region neuronal degeneration occurs (Table 1.1) (Dwyer et al., 2005, Migliore et al., 
2005) the nature of connections as well as the interactions between neurons and 
glial cells is essential for determining neuronal vulnerability of neurons (Farooqui et 
al.,2007). Despite the topographical differences in neurodegenerative diseases, 
histopathological findings are similar; regional atrophy with neuronal loss as well as 
abnormal accumulation of protein.  Loss of synapses is another feature that plays an 
important role in loss of skilled movements, decision making, cognition, and memory 
related processes (Wishart et al., 2006). Tissue examination can help to identify 
pathological processes, also locating the site of the earliest visible alteration helps 
to establish the diagnosis. For example degeneration in the hippocampal and frontal 
lobe pyramidal neurons is associated with AD, degeneration in the dopaminergic 
neurons of the substantia nigra with PD, in the upper and lower motor neurons of the 
pyramidal system with ALS and in the medium-sized spiny GABAergic neurons of 
the striatum with Huntington’s. On the other hand, Dementia coupled with mainly 
limbic atrophy suggests Alzheimer’s, while mild atrophy implies Lewy body disease. 
Moderate cognition decline in the setting of asymmetric, motor and sensory 
impairment, with reduced metabolic activities, and atrophy prevailing around the 
central sulcus is indicative of corticobasal degeneration. To assign the most 
appropriate diagnosis to neurodegenerative diseases you need to identifying the 
sites or systems where tissue loss occurs, which may be revealed on neuroimaging 
during the disease progression, or on post-mortem examination; cataloguing the 
cells undergoing degeneration; identifying the abnormal aggregates, their cellular  
and topographic propensities (extracellular, cytoplasmic, or nuclear). Blood brain 
barrier dysfunction and hypertension may also contribute to the pathogenesis of 
neurodegenerative disease (Rao and Balachandran, 2002). This dysfunction is 
accompanied by the disruption of tight junctions, alterations in transport of molecules 
between blood and brain, and brain and blood, aberrant angiogenesis, vessel 
regression, brain hypo-perfusion and changes in inflammatory responses. All these 
processes leads to progressive synaptic loss and neurodegeneration (Zlokovic, 
2008).  
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  Genetics 
The high level of interplay between excitotoxicity, oxidative stress, and 
neuroinflammation in neurodegenerative diseases relies on specific genes. 
Neurodegenerative diseases have a small percentage of familial cases and a large 
percentage of apparently sporadic cases. Sporadic and familial cases are usually 
phenotypically and histologically indistinguishable, although the onset of familial 
cases tends be earlier. This suggests that genetic mutations accelerate the 
molecular processes that lead to late onset sporadic disease. A number of causative 
genes have been discovered for specific neurodegenerative disease, for example, 
mutations in amyloid precursor protein (APP), Presenilin 1, and Presenilin 2, which 
occur in early onset Alzheimer’s cause altered protein production and increased 
aggregation of β-amyloid protein (Herl et al., 2009). Similarly, PARK 1, the first gene 
to be identified in PD, alters the production of the protein α-synuclein. Mutations in 
genes associated with oxidative stress pathways, SOD1 and DJ1, have been 
implicated in familial amyotrophic lateral sclerosis ALS and PD, respectively 
(Hardiman and Doherty, 2011). 
  
Table 1.1 
Neurological diseases and selectively vulnerable cells (Hardiman and 
Doherty, 2011) 
 
Disease Vulnerable Neurons 
Parkinson’s disease (PD) Dopaminergic neurons 
Alzheimer’s disease (AD) Cholinergic neurons 
Amyotrophic lateral sclerosis (ALS) Upper and lower motor neurons 
Frontotemporal dementia Frontotemporal cortical neurons 
Huntington disease (HD) GABAergic neurons 
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  Protein Structures 
The formation of aberrant structures by more than 20 different proteins appears to 
underlie neurodegenerative diseases (Table 1.2). The mechanism by which the 
attainment of an aberrant protein structure causes disease is still unclear and may 
involve both the loss of a vital physiological function and/or the acquisition of toxic 
properties. An aberrant protein structure may bind to a specific receptor directly, 
causing an inappropriate activation of a cascade that initiates cellular changes, which 
leads to compromise of cellular function or it may acquire properties that allow them 
to interact with and destabilize cellular membranes or other proteins, thus causing a 
secondary toxicity. Moreover, accumulation of aberrant proteins may strain the 
normal mechanisms responsible for controlling protein folding and degradation, 
resulting in a generalised loss of protein homeostasis and consequent toxicity. 
Polymerization of aberrantly folded proteins is concentration dependent (Hardiman 
and Doherty, 2011). Changes in production, degradation, or clearance of native 
protein underlie the assembly of aberrantly folded protein and these structures are 
thought to be the primary event driving pathogenesis (Fig 1.4) (Hardiman and 
Doherty, 2011). Consequently, many of the therapies under development are 
designed either to remove or decrease the quantity of soluble native protein 
(Farooqui et al., 2007). 
 
Disease specific proteins (tau, Aβ, α-synuclein, huntingtin), which accumulate in 
neurodegenerative diseases, are substrates for transglutaminase-2, a calcium-
dependent cross-linking enzyme involved in the post translational modification of 
intra and extracellular proteins. It generates isopeptide bonds, which stabilise 
polymeric aggregates of accumulated proteins. This indicates the importance of 
transglutaminase 2-mediated cross-linking reactions (Harley et al., 2008, Wilhelmus 
et al., 2009, Caccamo et al., 2010). As abnormal protein aggregates cannot be 
degraded by cytosolic proteases, it accumulate in cells and extracellular 
compartments as residual debris. For example, in AD, misfolded Aβ peptide 
accumulates in the neuronal endoplasmic reticulum extracellularly as plaques. In 
contrast, in PD and dementia with Lewy bodies (DLB) abnormal accumulation of α-
synuclein occurs in neuronal cell bodies, axons, and synapses.   Intracellular or 
extracellular cerebral deposits of misfolded protein aggregates with a β-sheet 
Chapter 1 
9 
 
conformation, such as Aβ in AD, or α-synuclein in PD (Table 1.3) (Farooqui et al., 
2007) causing extensive neurodegeneration, synaptic dysfunction, and the 
accumulation of advanced glycation end products (Vicente et al., 2010). Glycation 
facilitate misfolding, aggregation and accumulation of Aβ, tau (τ), prions, and 
transthyretin proteins (Chen et al., 2009, Chen et al., 2010). Advanced Glycation end 
products Also may cause an increase in oxidative stress and inflammation by the 
formation of ROS and the induction of NF-κB through their receptor, RAGE, (Vicente 
et al., 2010). Interactions between fragments of α-synuclein and Aβ peptide promote 
the aggregation of α-synuclein. In addition, under pathological conditions, 
interactions between Aβ and α-synuclein may initiate the formation of toxic oligomers 
and nanopores that increase intracellular calcium leading to induction of oxidative 
stress, leakage of lysosomal membranes and mitochondrial dysfunction (Crews et 
al., 2009). 
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Table 1.2 
Neurological diseases associated with aberrant protein structure 
(Hardiman and Doherty, 2011) 
 
Disease Protein Site of deposition 
Parkinson disease -synuclein Intracellular (Lewy neuritis and 
Lewy bodies) 
Multiple systems 
atrophy 
-synuclein Intracellular argyrophilic 
inclusionsin both oligodendroglia 
and neurons 
Hereditary cerebral 
amyloid angiopathy 
Cystatin C Extracellular 
Congophilic amyloid 
angiopathy 
β-amyloid Extracellular 
Alzheimer’s disease β-amyloid Extracellular (amyloid plaques) 
Alzheimer’s disease Tau Intracellular (paired helical 
filaments) 
Frontotemporal 
dementia 
Tau Intracellular inclusions (paired 
helical filaments and Pick bodies) 
Familial British 
dementia 
ABri Extracellular (amyloid plaques) 
Familial British 
dementia 
ADan Extracellular (amyloid plaques) 
Transmissible 
spongiform 
encephalopathies 
Prion protein Extracellular amyloid plaques  
Amyotrophic lateral 
sclerosis 
TDP43-ubiquitin Cytoplasmic inclusions and 
ubiquitin-positive neuronal threads 
Huntington disease Mutant huntingtin Nuclear and cytoplasmic inclusions 
Inherited 
spinocerebellar 
ataxias 
Various proteins 
with polyglutamine 
expansions 
Nuclear and cytoplasmic inclusions 
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Table 1.3 
Accumulation of various types of protein aggregates and their location 
in neurodegenerative diseases (Farooqui et al., 2007) 
 
Disease Protein Type of 
aggregate 
Location References 
AD β-Amyloid Amyloid Extracellular (Haass and Selkoe, 
2007) 
PD α-
Synuclein 
Fibrillar 
non-amyloid 
Intracellular (Beyer, 2007) 
(Burke, 2004) 
HD Huntingtin Fibrillar 
non-amyloid 
Intracellular (Bonilla, 2000) 
(Gil and Rego, 
2008) 
ALS Superoxide 
dismutase I 
Fibrillar 
non-amyloid 
Intracellular (Jellinger, 2009) 
CJD Prion 
protein 
Amyloid Extracellular (DeArmond and 
Prusiner, 2003, 
Behrens, 2003) 
Other prion 
diseases 
Prion 
protein 
Amyloid Extracellular (DeArmond and 
Prusiner, 2003, 
Behrens, 2003) 
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  Oxidative Stress 
The Brain is the most metabolically active organ of the human body which consumes 
almost one-fifth of the total oxygen inspired by the individual (Cui et al., 2004) 
Neurons have high metabolic activity with a constant production and elimination of 
ROS making them more vulnerable to oxidative stress (Jenner, 2003, Emerit et al., 
2004). Loss of antioxidant protection or unusual increase in ROS can lead to 
proteins, lipids, and nucleic acids damage. Accumulation of unrepaired damaged 
molecules within the cellular compartments will results in disturbed homeostasis (Le 
Bourg, 2001). Widespread DNA damage is clearly apparent in ALS, PD, AD and HD 
(Jenner, 2003, Emerit et al., 2004). Increased presence of protein carboxyl moieties 
indicating protein damage has been also reported in all neurodegenerative disorders 
(Mariani et al., 2005).  
 
 
 
 
Fig 1.4 
Pathways to aberrant protein structure and aggregation in amyloid 
related diseases 
(Hardiman and Doherty, 2011) 
Chapter 1 
13 
 
In neurodegenerative diseases, oxidative stress initially occurs at the disease 
specific site, for example Aβ-mediated oxidative stress in the cerebral cortex and 
hippocampal region of AD patients, α-synuclein induced oxidative stress in the brain 
stem of PD patients and glutamate receptor-mediated oxidative stress in the motor 
system of ALS spinal cord. ROS also activate calcium channels and deactivate 
calcium pumps, this leads to abnormally high intracellular levels of calcium in 
neurons, which increase in cytosolic Ca2+ levels, resulting in activation of Ca2+-
dependent enzymes, including nicotinamide adenine dinucleotide phosphate 
(NADPH) oxidase, cytosolic phospholipase A2, xanthine oxidase, and neuronal nitric 
oxide synthase (NOS). This activation generates more ROS, nitric oxide, and 
peroxynitrite, which ultimately leads to nuclear damage, mitochondrial damage, 
proteasome inhibition, and endoplasmic reticulum (ER) stress (Shibata and 
Kobayashi, 2008). NO and peroxynitrite deplete glutathione,  and S-nitrosylation of 
many proteins, leading to more protein misfolding (Lipton et al., 2007).  
 
Oxidative stress also stimulates astrocytes and microglia to facilitate the generation 
and secretion of cytokines that cause neuronal caspase-8 activation and induce glial 
inflammatory response (Shibata, 2008, Farooqui, 2010). The release of these 
mediators continue the inflammatory cycle, activating additional microglia, promoting 
their proliferation, and resulting in further release of inflammatory factors. The 
accumulation of high concentrations of these metabolites will cause further neuronal 
injury (Dheen et al., 2007). Moreover, oxidative DNA damage mediates the release 
of mitochondrial apoptosis inducing kinase, which triggers apoptosis programmed 
cell death. 
 
Mitochondria are one of the major targets of ROS attacks and therefore, 
mitochondrial dysfunction is associated with progression of aging and manifestation 
of several neurodegenerative disorders (Sohal, 2002). Mitochondrial elements such 
as lipids, oxidative phosphorylation enzymes and mitochondrial DNA are particularly 
predisposed to attack by ROS due to their close proximity with the ROS production 
site (Pieczenik, 2007).  
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High concentrations of ROS generated by the oxidative phosphorylation pathway in 
mitochondria exposes the mitochondrial genome to oxidative stress leading to 
mitochondrial DNA injury. Mitochondrial dysfunction induces reduction in ATP and 
increased membrane permeability increasing the uptake of calcium ions, resulting in 
the release of cytochrome-C, which initiates the apoptotic cascade. Induction of 
apoptotic cell death with in vivo and in vitro studies have shown that NADPH oxidase 
derived from microglia play an important role in the generation of ROS. In PD, 
microglia-specific NADPH oxidases are involved in the production of ROS, which 
may contribute to the death of dopaminergic neurons. A similar process is seen in 
ALS, whereby oxygen radicals produced by microglial NADPH oxidase are believed 
to injure motor neurons. In addition, oxidation of K+ channels by ROS has been 
reported to be a major mechanism underlying the loss of neuronal function(Sesti et 
al., 2010). Redox-active transition metals contribute to oxidative stress (Bolognin et 
al., 2009) with increased localisation of redox-active transition metals (copper and 
iron) in the brain regions most affected by neurodegenerative diseases.  
 
  Excitotoxicity 
Glutamate is the major excitatory neurotransmitter in the CNS, with essential roles 
in synaptic transmission and plasticity, key to learning and memory processes, as 
well as sensory and motor functions. Transmission of glutamate is mediated through 
three major ionotropic receptors N-methyl-D-aspartate receptors (NMDA), -amino-
3-hydroxy-5-methyl-4-isoxazoleproprionic acid (AMPA) receptors, and kainate 
receptors, and a range of metabotropic glutamate receptors.  
 
The glutamate excitotoxicity hypothesis postulates that excessive synaptic 
glutamate causes over-activation of the postsynaptic NMDA and AMPA receptors 
resulting in neuronal death. High glutamate levels, which continuously activate 
postsynaptic receptors, may lead to increased intracellular calcium and catabolic 
enzyme activity. Downstream effects can include depolarization of mitochondrial 
membrane, activation of the caspase system, and production of ROS, all of which 
can culminate in cell death (Fig. 1.3). Excessive synaptic glutamate may also happen 
because of a fault in the cellular glutamate reuptake system. Excitatory amino-acid 
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transporter 2 (EAAT-2) is a glutamate transporter involved in cerebral glutamate 
transport. It has been postulated that some patients with ALS have decreased 
expression of this protein (Limpert, 2013). Patients with AD have also exhibited a 
reduction in EAAT-2 expression (Kong et al., 2014). It has been shown that GluA2, 
an AMPA glutamate receptor subunit responsible for calcium permeability into the 
postsynaptic cell, is not expressed in motor neurons affected by ALS patients 
because of a defect in the editing process for the messenger RNA encoding the 
GluA2 subunit (Brini et al., 2014). Absence of a functional GluA2 subunit allows 
calcium influx into the postsynaptic cell and results in cellular damage. Parkin, which 
is the gene product of PARK2, has regulatory effects on excitatory glutaminergic 
synapses (Dong et al., 2009). Abnormalities in parkin production can lead to 
enhanced synaptic activity and may even trigger an increase in the number of 
glutamate receptors (Dong et al., 2009). Riluzole which has a direct and indirect 
blocking effect on glutamate receptor activation has been proven to modestly 
slowdown the progression of ALS. Unfortunately, no other anti-glutamate agent has 
been successful thus far in disease treatment (Hardiman and Doherty, 2011). 
 
  Neuroinflammation 
Neuroinflammation plays a key a key feature shared by neurodegenerative 
disorders. Inflammatory responses in the brain have been associated with the 
pathogenesis of ALS, AD and PD (Andersen, 2004, Craft et al., 2005). Chronic 
neuroinflammation is characterized by long-standing activation of microglia and 
sustained release of inflammatory mediators. This sustained release of inflammatory 
mediators causes an imbalance in the inflammatory cycle homeostasis by activating 
additional microglia, promoting their proliferation, and leading to further release of 
inflammatory factors (Farooqui, 2010). Microglia are CNS-specific macrophages, 
and enter the CNS during embryogenesis. The primary function of this subset of 
immune cell is to protect the brain from extrinsic pathogens and processes. During 
the process of activation, microglia are highly plastic and differ in morphology and 
phenotype, depending on the nature of the insult. Activated microglia can cause 
irreversible damage to tissues of the CNS. A number of factors have been identified 
that prime microglia to the activated state, and they may remain in the activated state 
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for prolonged periods. However, it is unlikely that microglial activation is the primary 
cause of any neurodegenerative process. It is more likely that an initial challenge 
induces an inflammatory cascade, which in turn initiates maladaptive processes and 
positive feedback loops that cause further pathological inflammation (Farooqui, 
2010). Postmortem examination of brain tissue from PD patients has demonstrated 
activated microglia in the substantia nigra pars compacta. In AD, neuroinflammation 
is considered an effect of abnormal protein production. Aβ accumulation causes 
upregulation and activation of microglia leading to an inflammatory cascade. Also 
abnormal protein aggregates may trigger the expression of inflammatory mediator 
generating enzymes, such as phospholipase A2 (PLA2), cyclooxygenase-2 (COX-2) 
and lipoxygenase (LOX), which contributes to neurodegenerative process. 
Understanding the balance between protective and destructive capabilities of 
microglia may provide new ways of slowing neurodegeneration, by controlling 
neuroinflammatory processes. 
 Natural Products as Sources of Therapeutics for 
Neurodegenerative Diseases 
Natural products are a rich source of biologically active compounds that have arisen 
as a result of natural selection, over perhaps 300 million years. It has been well 
documented that natural products have played crucial roles in modern drug 
development, for instance of the 520 new pharmaceuticals approved between 1983 
and 1994, 39% were derived from natural products, Between 1990 and 2000, a total 
of 41 drugs derived from natural products were launched on the market by major 
pharmaceutical companies (Newman et al., 2003). 
 
Natural product research has been the single most successful strategy for 
discovering new pharmaceuticals. An interesting example is the alkaloid galantamine 
originally isolated from the bulbs of the Amaryllidaceae family (snowdrops, daffodils), 
used for symptomatic treatment of AD (Scott and Goa, 2000). It is a reversible 
competitive inhibitor of AChE and it also interacts allosterically with nicotinic 
acetylcholine receptors to potentiate its action. By acting to enhance the reduced 
central cholinergic function associated at the early stages of this disease, significant 
improvements in cognition and behavioural symptoms have been observed.  
Chapter 1 
17 
 
 
The popularity of natural products, particularly those from higher plants as leads for 
new pharmaceuticals declined as pharmaceutical companies focused on 
combinatorial chemistry, coupled with very high throughput screening. Following 
disappointing outcomes of combinatorial chemistry, natural products research has 
been revived using rapid progress in molecular biology, chemistry and high 
throughput screening technologies along with parallel synthesis, computations and 
many other new techniques in medicinal chemistry of natural products. 
 
Research of bioactive natural products spans a wide range of fields, including 
isolation and characterization of bioactive compounds from natural sources, 
structure modification for optimization of their activity and other physical properties, 
and total and semi-synthesis for a thorough scrutiny of structure activity relationship 
(SAR). In addition, synthesis of natural products also provides a powerful means of 
solving supply problems of natural products in bulk amounts.  Structural diversity of 
secondary metabolites makes them valuable sources of novel lead compounds 
against therapeutic targets that have been newly discovered by genomics, 
proteomics and high-throughput screening. 
 
Age-related loss of memory and cognitive decline has been documented for 
thousands of years in human history. Ancient writings which describe the cognitive 
decline symptoms also suggest remedies, based usually on plant extracts. For 
example Ashwagandha is mentioned in ancient Sanskrit writings from India as a 
promoter of learning and memory retrieval. Old European reference books (e.g. 
medical herbals) document a variety of other plants such as Salvia officinalis (sage) 
and M. officinalis (lemon balm) with memory improving properties. Some traditional 
herbs have anti-aging properties and they are potential candidates for the treatment 
neurodegenerative diseases (Luo et al., 2004, Wu et al., 2006, Chan et al., 2007, 
Heo et al., 2008, Zhou et al., 2008, Heo et al., 2011). Anti-aging herbs such as Panax 
(ginseng) and Lycium barbarum (wolfberry), are usually multi-functional and can 
work through different mechanisms. Increasing lines of evidence suggest that these 
herbs are potential candidates for the prevention or treatment of age-associated 
neurological disorders (Kim et al., 2007). Rosmarinus officinalis (Rosemary), for 
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example, is used by practising medical herbalists in the United Kingdom for memory 
problems (Moss et al., 2003). Ginkgo biloba is popular based on its perceived anti-
ageing properties, including enhancing cerebral activity (Kleijnen and Knipschild, 
1992, Perry et al., 1998, Perry et al., 1999). It has been reported to be of therapeutic 
value in mild to moderately affected patients with AD (Oken et al., 1998, DeKosky et 
al., 2008). 
 
Volatile oils have attracted interest in recent years. One of the first findings that 
monoterpenes had AChE inhibitory effects was made only in the mid-1990s, in 
studies investigating historical records that monoterpene containing plants were 
‘good for the memory’. An ethanol extract Salvia officinalis L. (Labiatae) and Salvia 
Lavandulaefolia (Labiatae) were investigated for AChE activity and it was found that 
both displayed AChE inhibitory properties at quite low concentrations (Perry et al., 
1996, Kennedy et al., 2005).  Since the effects of the oil were superior to those of 
individual monoterpenes, further in vivo and clinical studies were carried out on the 
essential oils, which consist of a mixture of monoterpenes. Oral administration of S. 
Lavandulaefolia essential oil in rats decreased striatal AChE activity in both the 
striatum and the hippocampus compared to the control rats. Thus, it appeared that 
constituents of the S. Lavandulaefolia oil, or their metabolites, reach the brain and 
inhibit AChE in select brain areas, consistent with evidence of inhibition of the brain 
enzyme previously decribribed in vitro (Perry et al., 1999). The essential oil of Salvia 
officinalis (Sage) was a potent inhibitor of human AChE and consisted almost 
exclusively of monoterpenoids. Oral consumption leads to improved performance of 
secondary memory and attention tasks (Kennedy et al., 2005, Kennedy et al., 2011). 
Melissa officinalis leaf is another species that contains monoterpenes in its essential 
oil. It has been used as a medicinal plant for more than 2000 years and has a 
reputation for promoting long life and for restoring memory (Man et al., 2012).  A 
recent randomised, placebo-controlled, double-blind, balanced crossover study 
showed an improvement in cognitive performance and mood in 20 healthy young 
participants, following treatment with dried leaf of Melissa officinalis. (Kennedy et al., 
2003). The extract was shown by previous in vitro tests to be cholinergically active 
(Kennedy et al., 2003). In another study, an extract of Melissa officinalis, 
administered to patients with mild to moderate AD for 4 months produced a 
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significantly better outcome in cognitive function than placebo, although the 
constituents present in the extract have not been investigated (Akhondzadeh et al., 
2003). 
 
Although natural products have a long history of use for neurological symptoms, the 
study of the mechanisms of action of neuroactive natural products has only began 
relatively recently. With new technologies, researchers are now able to take a closer 
look at the complex molecular events associated with the therapeutic actions of 
natural products in neurodegenerative diseases.  
 
A variety of natural products have been shown to have the desired effects in 
neurodegenerative diseases and some of these, or their derivatives, have been 
brought into clinical use. There are also many traditional medicinal plants used as 
crude extracts and mixtures with a reputation of alleviating or preventing symptoms 
of neurodegeneration (Bon et al., 1979, Bliss and Collingridge, 1993). In some cases, 
such extracts have been shown to relieve neurodegenerative symptoms in animal 
models or display relevant in vitro activity, but both the modes of action and identity 
of any compounds responsible have not been fully determined (Houghton et al., 
2007). Some natural plant products have been shown to exert anti-inflammatory 
and/or antioxidant effects in a variety of peripheral systems. As increasing evidence 
indicates that chronic inflammatory responses play a pathological role in the central 
nervous system, anti-inflammatory herbal medicine and constituents have been 
shown to be potent neuroprotectors in various brain pathologies (Sundaram and 
Gowtham, 2012).  
 
Treatment of neurodegenerative conditions presents some unique challenges as 
actives must penetrate into the brain either by active uptake mediated by transport 
proteins that bind the drug and facilitate the penetration across the blood-brain 
barrier, or by passive diffusion of lipophilic ones. Another concern with drugs adopted 
for use in neurodegenerative diseases is the potential interference of normal 
neurotransmission. The multifunctional properties of constituents of botanicals and 
their derivatives offer the possibilities for the development of effective multitarget 
therapeutics. The study of neuroactive natural products will indeed advance our 
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understanding of the nervous system, and open up exciting opportunities in drug 
discovery. 
 
Identification of natural product leads follow different strategies such as bioassay 
guided methods; for example by spraying thin layer chromatography plates with 
reactive media that respond by producing a colour change in the presence of an 
active compound. An alternative is to use an ethnobotanical or 
ethnopharmacological technique, whereby the accumulated knowledge of many 
generations of native plant users may be used in the search for better medicines. 
These two techniques may be combined. The problem with any bioassay-guided 
technique, however, is that the inactive constituents are not identified. This 
represents a considerable waste, given that the plant has had to be collected, 
preserved, and identified. An alternative view is that it is best to extract all the 
constituents, with a view to screening in whichever way is appropriate, at that time 
or in the future. With modern high-performance liquid chromatography, it is possible 
to reduce a plant to its secondary metabolites, as single compounds; the products 
are then able to be screened in a high throughput manner in an equally short time 
and the compounds can be re-evaluated when new screens become available. 
1.2 Aloysia citrodora Palau 
  Genus Aloysia 
The genus Aloysia (Verbenaceae) includes approximately 200 species of herbs, 
shrubs and small trees. The species are mainly distributed throughout the South and 
Central America countries, and Mediterranean  territories (Terblanché and Kornelius, 
1996). Most of them are traditionally utilized as gastrointestinal and respiratory 
remedies (Morton, 1981). Some Aloysia species have displayed anti-malarial 
(Traore‐Keita et al., 2000), antiviral and cytostatic activities (Lopez et al., 1979, 
Duscharzky et al., 2005, Reichling et al., 2009). Leaves from the majority of these 
species are utilized as seasoning for food preparations (Morton, 1981). The genus 
Lippia shows a rich genetic diversity, enabling it to synthesize a variety of essential 
oil constituents in plants grown in different parts of the world. However, the 
composition of the essential oil obtained from the same plant stock remains constant 
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under the same environmental conditions (Catalan and de Lampasona, 2002, 
Santos-Gomes et al., 2005). 
  Synonyms 
Aloysia triphylla (L'Hér.), Britton. Aloysia citriodora Paláu, Aloysia citriodora Paláu, 
Lippia citriodora Kunth, Lippia citriodora Kunth, Lippia triphylla (L'Hér.) Kuntze 
 Common Names 
Lemon-verbena (English), Verveine citronelle (French), Zitronenstrauch (German), 
Cidrão (Portuguese), Cedrón (Spanish), Melissa اسيلم  (Arabic). Herb Louisa, Hierba 
Luisa, Lemon-Scented Verbena, Verveine Citronnée, Verveine Citronnelle, Verveine 
des Indes, Verveine du Chili, Verveine du Pérou, Verveine Odorante, Zappania 
citrodora. 
  Taxonomic Hierarchy 
  Kingdom Plantae  – plants   
    Subkingdom Viridae plantae  – green plants   
       Infrakingdom Streptophyta  – land plants   
          Division Tracheophyta  – vascular plants, tracheophytes   
  
            Subdivision Spermatophytina  – spermatophytes, seed plants, 
phanérogames 
  
                Infradivision Angiospermae  – flowering plants,    
                   Class Magnoliopsida    
                      Superorder Asteranae     
                         Order Lamiales    
                            Family Verbenaceae  – verbenas, verbénacées   
                               Genus Aloysia    
                                  Species Aloysia citrodora Paláu   
  
Chapter 1 
22 
 
 
Fig 1.5 
Aloysia citrodora (Siedo and Botany, 2007) 
 
Fig 1.6 
Aloysia citrodora  leaf (Grasso, 2007) 
 
Fig 1.7  
Aloysia citrodora  dried leaf (Tucker, 2010) 
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 Description 
A. citrodora is a frost hardy perennial shrub  which grows to 2–3 meters high (Fig 
1.5).  It grows well in full sun in well-drained, dry soil, and is sensitive to cold, losing 
its leaves at temperatures below 0 °C. It has tiny lilac or white flowers which appear 
within Flowering period: July to August; leaves are lemon-scented, 8 cm long, 
glossy, pointed, and rough to the touch (Fig 1.6 & 1.7). Spanish explorers brought 
this plant to Spain in the 17th century at which point it was named after Princess 
Louisa of Parma (genus name is a version of Louisa and the common name is 
Herb Louisa).   
  Uses 
A. citrodora is a widely used herb for food and medicinal purposes and  has a long 
history of folk uses in treating asthma, spasms, cold, fever, flatulence, colic, diarrhea, 
indigestion, insomnia and anxiety (Carnat et al., 1999, Santos-Gomes et al., 2005). 
An ethnopharmacological survey in Brazil has shown that A. citrodora infusion was 
one of the most common remedies for insommnia and anxiety (Dellacassa and 
Bandoni, 2003). Some pharmacological properties have been attributed to the 
essential oil which is spasmolytic on the guinea pig ileum (Carnat et al., 1999) and 
an antimicrobial (Maruzzella and Sicurella, 1960, Maruzzella and Liguori, 1958, 
Abuhamdah et al., 2013).  Although A. citrodora has been approved as a herbal 
medicine and dietary supplement by many regulatory acts in many countries, the 
mechanisms of pharmacological actions of this herb are still unclear (Lai et al., 2006) 
 
  Composition 
Flavones, iridoids and phenylpropanoids represent the main class of compounds of 
this plant, with verbascoside being the most abundant one (Funeset al. 2009; 
Quirantes-Pine´ et al. 2009). The strong antioxidant properties of A. citrodora extract 
have been studied in detail (Valentao et al. 2002; Liu et al. 2003; Funes et al. 2009). 
In addition, A. citrodora extract has also shown anti-inflammatory activity through 
different in vitro assays and animal models (Dı´az et al. 2004, Lee et al. 2005, Lin et 
al. 2006, Hausmann et al. 2007, Korkina et al. 2007).  A. citrodora also have 
antispasmodic, antipyretic, sedative and digestive properties (Carnat et al., 1999, 
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Valentao et al., 1999, Pascual et al., 2001, Santos-Gomes et al., 2005). The essential 
oil from its leaves has been shown to exhibit antimicrobial activity (Duarte et al., 
2005, Duschatzky et al., 2004, Lo´pez et al., 2004, Ohno et al., 2003, Sartoratto et 
al., 2004). Activities attributed to A. citrodora, include anti-genotoxic and protection 
against genetic damage (Zamorano-Ponce et al., 2006), neuroprotective effects (Lai 
et al., 2006) and hypnotic effects of the aqueous extract. 
 
Analysis and identification of flavonoids and phenolic acids of the extracts of A. 
citrodora was performed in a number of studies (Tomaas-Barberan et al., 1987; 
Skaltsa and Shammas, 1988; Carnat et al., 1995, 1999; Nakamura et al., 1997; 
Valent et al., 1999). The leaf contains polyphenolic compounds: hydroxycinnamic 
derivatives with verbascoside (Lamaison et al., 1993), flavonoids, such as luteolin 7-
glucoside (Skaltsa and Shammas, 1988) and luteolin 7-diglucuronide (Carnat et al., 
1995). These compounds probably contribute to the antispasmodic activity. 
Iridoidglucosides were also reported. 
1.3 Objective 
In this thesis, the essential oil derived from the leaves of A. citrodora will be analysed 
and investigated for a range of pharmacological properties (focussed on receptor, 
AChE pharmacology, anti-oxidant and iron-chelation properties). The potential 
neuroprotective properties of this essential oil against oxidative stress and Aβ 
induced neurotoxicity was investigated using in vitro neuronal cell line system. A 
computer modelling approach was applied to identify constituents in the oil which 
endow AChE activity. Finally a new solid phase method was applied, as a first step, 
to fractionate the A. citrodora essential oil into its constituent neuroactive 
components. 
 
Overall Hypothesis of this thesis: Based on the common traditional uses of M. 
officinalis and A. citrodora essential oils in treating neurological disorders, we 
hypothesise that they share common pharmacological properties and neuroactive 
components. 
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Chapter 2 
Pharmacological Profile of Aloysia citrodora 
Palau Essential Oil: Radioligand Binding 
Properties 
1.1 Introduction 
 Neurotransmitters in Neurodegenerative Diseases 
Although the aetiology of neurodegenerative diseases is still largely unknown, for 
some neurodegenerative diseases there is a clear links between the disease and a 
deficiency of a neurotransmitters such as acetylcholine in AD, and dopamine in PD 
(Beal, 2005).  
 
The major excitatory neurotransmitter in the central nervous system (CNS) is 
glutamate (Fonnum, 1984). Glutamate is essential for learning and memory, synaptic 
plasticity, neuronal survival and in early development, proliferation, migration and 
differentiation of neuronal progenitors and immature neurons (Ikonomidou et al., 
2000). The glutamate neuronal pool is located in nerve endings. A separate pool is 
located in glia and serves to recycle the transmitter. Glutamate is also involved in the 
synthesis of the inhibitory neurotransmitter γ-aminobutyric acid (GABA). Glutamate 
is released from presynaptic terminals by a calcium dependent mechanism, then it 
is removed by uptake into the surrounding glial cells and aminated to glutamine. 
When released into the synaptic cleft, glutamate acts largely at postsynaptic 
receptors. These include the N-methyl-D-aspartate (NMDA), NMDA channel is 
normally blocked with a magnesium ion and requires depolarization of the neuron to 
remove the magnesium and allow the glutamate to open the channel, causing an 
influx of calcium, which then leads to subsequent depolarization. MK-801 an 
uncompetitive antagonist binds inside the ion channel of preventing the flow of ions, 
including an influx of calcium (Ca2+), through the channel (Foster, 1987). All receptor 
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subtypes for both ionotropic and metabotropic glutamate receptors have been cloned 
and characterized (Hollmann and Heinemann, 1994, Cao and Yao, 2013). Recently 
prevention of glutamate-mediated neurotoxicity has been utilised as a therapeutic 
mechanism in AD. Memantine, a moderate-affinity, voltage-dependent, 
uncompetitive antagonist of NMDA receptor, shows neuroprotective effects in 
patients with moderate-to-severe AD. Memantine has neuroprotective and cognition-
enhanced properties, which can be combined with other treatments for AD. The 
efficacy and safety profile of Memantine have been reported in several clinical trials 
for treatment of AD and vascular dementia (Tanovic and Alfaro, 2006, Kutzing et al., 
2012). 
 
 
 
Fig 2.1  
NMDA Receptor, Glycine and glutamate/N-methyl-D-aspartate (Glu/NMDA) are shown bound 
to their respective binding sites, and the binding site for Mg2+, MK-801 and memantine is 
within the ion channel pore region. The Zn2+-binding site is also highlighted. The location of 
the cysteine sulphydryl group (–SH) that reacts with nitric oxide (NO) species is labelled SNO. 
NR1, NMDA receptor subunit 1; NR2, NMDA receptor subunit 2A (Lipton, 2006). 
 
 
The predominant inhibitory neurotransmitter in the central nervous system is γ-
aminobutyric acid (GABA). GABA is essential for the overall balance between 
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neuronal excitation and inhibition. The inhibitory signal of GABA is transduced 
primarily by GABAA receptors. Activation of the GABAA receptor opens a Cl- anion 
channel, and the resulting influx of Cl- ions hyperpolarizes the neuron, decreasing 
neuronal activity. Dysfunction of GABAA receptors occurs in various neurological 
states, as epilepsy, PD and HD. Temporal lobe epilepsy seizures reflect excess 
excitation, which may result from local inhibitory circuit dysfunction. PD disrupts the 
input to striatal GABAergic neurons and HD destroys striatal GABAergic neurons.  
New drugs aimed at GABA synthesis, release and binding will offer novel and highly 
effective treatments for neurodegenerative diseases (Kleppner and Tobin, 2001). 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 2.2  
GABAA Receptor  
Top view of the extracellular domain of the pentameric α1β2γ2 GABAAR in ribbon mode. The 
benzodiazepine-binding site (BZ) and the two GABA-binding sites are indicated by arrows. 
Diazepam in the benzodiazepine-binding site is depicted in space-filling mode (Richter et al., 
2012). Chemical structure of GABA, TBPS and Flunitrazepam. 
 
GABA deficiency is associated with several psychiatric disorders, such as anxiety, 
depression, panic and mania (Marin, 2012). GABA agonists are active in animal 
models for dyskinesia, epilepsy and depression, amongst others (Lloyd et al., 1982). 
Animal studies have shown that increasing GABA can decrease aggression (Nelson, 
2007). Deficits in the central GABA system have been reported in the brains of 
patients with dementia (Ventriglia et al., 2013). Indirect supporting evidence for a role 
of GABA is provided by some of the drugs that are effective in the treatment of 
GABA 
TBPS
S 
Flunitrazepam 
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agitation such as benzodiazepines. Valproic acid, which is also effective in 
aggressive behaviours associated with dementia, is believed to increase levels of 
GABA (Chindo et al., 2008). Also GABA receptors have been implicated in learning 
and memory (Deng et al., 2010). The formation of memory seems to require the 
down regulation of GABAergic transmission in neural circuits such as the amygdala, 
and in the hippocampus (Makkar et al., 2010). A reduction in GABAergic inhibitory 
transmission would allow for the activation of various intracellular cascades that are 
essential for the stabilization and re-stabilization of memory (Bustos et al., 2009, Luft 
et al., 2004). Reduced GABA transmission facilitates memory storage by increasing 
the release of norepinephrine and enhancing activation of β-ARs within the 
amygdala (Hatfield et al., 1999).  
 
A large number of pharmacologically useful compounds interact with the GABAA 
receptors, including agonists and antagonists, barbiturates, neurosteroids, 
anesthetics and benzodiazepines. 
 
Benzodiazepines such as Flunitrazepam enhance the effect of GABA at the GABAA 
receptor, resulting in sedative, hypnotic, anxiolytic, anticonvulsant, and muscle 
relaxant properties. Benzodiazepines do not directly activate the GABAA receptor, 
but positively modulate GABAA receptor mediated Cl-  conductance (Mahadik et al., 
2012). The ability of benzodiazepine binding site agonists to potentiate or reduce, in 
the case of inverse agonists GABA-gated currents is highly correlated with the ability 
of GABA to increase or decrease the apparent affinity of these ligands for the 
benzodiazepine binding site. There appears to be a potential for new 
pharmacological agents for different neurodegenerative disorders based on agonist 
activity at inhibitory amino-acid receptors.  
 
Nicotine is reported to have cognition enhancing effects and these may be due to 
nicotinic receptor stimulation but also protection against AD by other mechanisms 
such as inhibition of β-amyloid formation (Salomon et al., 1996), inhibition of the 
neurotoxic effects of excitatory amino acids (e.g. glutamate) and enhancement of the 
effects of nerve growth factor (NGF) (Whitehouse and Kalaria, 1995). Cytisine, 
another Nicotine receptor agonist is only used as a pharmacological tool because of 
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its strong binding affinity to nicotinic receptors, but it does not have any 
pharmaceutical uses because of its toxicity. Postmortem studies have shown that in 
AD there also appears to be a depletion of nicotinic function. Attention deficit in AD 
is reversed with nicotine, which is reported to up-regulate nicotinic receptors and to 
increase ACh release, thus enhancing cholinergic neurotransmission. Also nicotinic 
acetylcholine receptor (nAChR)-mediated protection against neurotoxicity induced 
by β amyloid (Aβ) and glutamate. nAChR stimulation blocks glutamate neurotoxicity 
in spinal cord motor neurons. These findings suggest that nAChR-mediated 
neuroprotection is achieved through subtypes of nAChRs and common signal 
cascades. An early diagnosis and protective therapy with nAChR stimulation could 
be effective in delaying the progression of neurodegenerative diseases such as AD, 
PD and amyotrophic lateral sclerosis (Kawamata et al., 2011). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 2.3  
a) Schematic of a nAChR with one subunit removed to reveal the ion channel lumen. b) Agonist 
binding site loop model. c) The topography of a single subunit (Sharples and Wonnacott, 2001). 
 
 Radioligand Binding 
Radioligand receptor binding technology has been extensively used to identify lead 
compounds which interact with receptors likely to be involved in neuronal, 
functions/dysfunctions. The first rigorous study of drug binding to receptors was that 
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of Paton and Rang in 1965, who investigated H-atropine binding to muscarinic 
receptors in smooth muscle. The use of radiolabelled drugs in radioligand binding 
studies is common and for many pharmaceutical manufacturers forms an essential 
part of the screening process, providing a rapid means of determining the affinity of 
new drugs for a wide range of receptors. Labelling of drugs with radioisotopes is 
attractive because very small quantities, often as low as 1 fmol, can be readily and 
accurately measured in addition to several obvious advantages to using in vitro as a 
first-level screen when compared to in vivo screens. Structure–activity data 
generated in binding assays is a direct reflection of the ligand/receptor interaction 
minus the complications which result from secondary events indicating bioavailability 
issues (Misra, 1998). In order to use these assays for plant extracts, natural products 
should be soluble (DMSO–H2O) and free of salts as well as acids; otherwise false 
positives can be produced since the assay is pH dependent. Also, natural products 
must be free of proteins which may interfere with the assay. 
 
A pharmacological screen of A. citrodora essential oil was carried out using a range 
of radioligand binding assays targeting major ligand-gated ion channel receptors 
(NMDA, nicotinic and GABAARs), the rational for which is described in section 2.1.1. 
Four different oil concentrations [0.0001, 0.001, 0.01 and 0.1 mg/ml] of both dry and 
fresh essential oil were tested. 
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1.2 Materials and Methods 
 Chemical Materials  
[3H] Flunitrazepam (specific activity 91.0 Ci mmol-1), [3H] nicotine (specific activity 
77 Ci mmol-1) and [3H] MK-801 (specific activity 25 Ci mmol-1) were all provided by 
Amersham Biotech (Little Chalfont, UK). [35S]-t butylbicyclophosphorothionate 
(TBPS; specific activity 80 Ci mmol-1) was from Perkin Elmer Life Sciences 
(Waltham, USA). Dimethylsulphoxide (DMSO), GABA, glutamate, ketamine, and all 
other chemicals were purchased from Sigma (St. Louis, USA).  
 A. citrodora Essential Oil Protocol 
Fresh leaves of A. citrodora were collected from University of Jordan Faculty of 
Agriculture Botanic garden, spring 2011, when growth rate was maximal. The plant 
was authenticated by Prof. Suleiman Al-Olimat from the Faculty of Pharmacy, 
University of Jordan, where the voucher specimen (herbarium number AC-V1) is 
kept. Leaves were dried carefully in the shade at room temperature and then 
homogenized to fine powder and kept within tight bottles. 
 Rat Forebrain Membrane Protocol 
Wistar strain adult male rats (200–300 g) were maintained under a 12 h light, 12 h 
dark cycle at 23 °C and 65% humidity, with water and standard laboratory food 
available ad libitum. Animal treatment and husbandry were performed in accordance 
with approved use of animals in scientific procedures regulated by the Animals 
(Scientific Procedures) Act 1986, UK. Animals were sacrificed humanely using 
Schedule 1 procedures by stunning followed by decapitation. The head of the rat 
was removed and placed on ice. Excess tissue from neck, up to the base of the skull 
was trimmed with a pair of large scissors. Using a scalpel or blade, a midline skin 
incision was made along the top of the skull (from between the eyes to the base of 
the skull) and pulled back to expose the bone. With the points of the small scissors 
two lateral cuts in the bone at the base of the skull were made to enable this (flap) 
to be removed with the forceps. The small scissors were then used to carefully cut 
up the side of the skull, removing the one covering the top of the brain with forceps. 
Again, using the small scissors, a midline cut was made through the nasal sinuses 
and this bone was removed. With a small spatula, the brain was carefully scooped 
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out rinsed with physiological buffer, to remove any remaining blood, hair, meningeal 
or bone fragment, the required tissue (forebrain) dissected immediately and kept 
frozen at -20ºC until use. The tissue was then homogenized in ice-cold 
homogenisation buffer containing 320 mM sucrose, using a dounce glass/glass 
homogenizer. The homogenate was centrifuged at 1000 × g, 4 °C for 10 min, the 
supernatant was stored in ice, and the pellets was re-homogenized in ice-cold buffer 
again, re-centrifuged at 1000 × g, 4 °C for 10 min. The supernatant from the first and 
second centrifugation steps were pooled together and centrifuged at 12,000 × g, 4 
°C for 30 min. The supernatant was discarded and the pellet resuspended in 50 mM 
Tris containing 5 mM EDTA and 5 mM EGTA, pH 7.4 (5 ml/g of original tissue), and 
frozen at −20 °C until use. 
 Well-Washed Rat Membranes Freeze/thaw Protocol 
The GABAAR binding assays were performed with well-washed rat membranes 
prepared by a five-step freeze-thaw protocol (Enna, 1978, Rezai et al., 2003). Briefly 
the unwashed membranes, prepared as described above, were thawed, 
resuspended in 50 volumes of homogenization buffer (50 mM Tris–HCl, pH 7.4, 
containing 5 mM EDTA, 5 mM EGTA and 320 mM sucrose) and were snap frozen in 
liquid nitrogen, centrifuged 12,000 × g, 4 °C for 30 min. The pellets were washed 
four additional times by resuspension in 50 volumes of ice-cold homogenization 
buffer, snap frozen in liquid nitrogen followed by centrifugation at 12,000 × g, 4 °C 
for 30 min. Finally, the pellets were suspended in homogenization buffer (pH 7.4). 
The tissue was then homogenized using a dounce glass/glass homogenizer, aliquots 
into (1 ml) samples and were then frozen and stored at −20 °C. 
 Determination of Protein Concentration in Well-Washed Rat 
Membranes 
The protein concentration was determined using the method of Lowry (Lowry et al., 
1951) employing Bovine Serum Albumin (BSA) as the standard protein. A stock 
solution of BSA (1 mg/ml) was serially diluted in water, to give a range of standard 
BSA concentrations from 0 to 100 µg/ml.  Lowry reagent A (2% (w/v) sodium 
carbonate, 0.1M sodium hydroxide and 5% (w/v) SDS.), Lowry reagent B (2% (w/v) 
sodium potassium tartrate) and Lowry reagent C (1% (w/v) copper sulphate) were 
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mixed in a volume ratio of A (50): B (1): C (1). To both the BSA standards and the 
unknown protein samples (5 µl protein + 95 µl dH20, and 10µl protein + 90 µl dH20) 
0.5 ml of the mixture of reagent A, B and C was added, each sample was vortexed 
and incubated at room temperature for 10 minutes. All samples were assayed in 
triplicate. On the addition of 50 µl of Folin-Ciocalteau phenol reagent (1 M, 1:1 mix 
of Folin reagent and water) each sample was mixed and incubated at room 
temperature for 30 minutes.  The reaction was terminated by the addition of 500 µl 
of water.  The O.D. at λ = 750 nm was determined for each sample using a Jenway-
Genova spectrophotometer. A calibration curve was plotted of O.D. at λ = 750 nm 
for the BSA samples. This was then used to determine the unknown protein 
concentration for any prepared well washed rat membranes samples.  
 Binding Assay Protocol 
Each assay was performed in triplicate. All binding assays were carried out in 4 ml 
polystyrene tubes. Ligand stock was diluted in assay buffer to a concentration tenfold 
the desired final concentration. Solutions of test compounds were prepared at tenfold 
the desired final concentration. 80 μl assay buffer were added to the first three tube 
set (which represents total binding) and 60 μl assay buffer for all other tubes in the 
experiment.20 μl of the 10 x test compound were added to the tubes, except the total 
and non-specific binding sets. 20 μl of the 10x non-specific agent were added to the 
second three set of tubes for determination of non-specific binding. 100 μl of 
membrane preparation or cell homogenate were added to all the tubes. 20 μl of the 
10x [3H] or [35S] ligand were added to all the tube. The samples were vortex-mixed 
and incubated until binding equilibrium was achieved. For many ligands, 1 hr at room 
temperature is sufficient to reach equilibrium. At the end of the incubation, the assay 
mixtures were harvested onto pre-soaked (0.2% polyethyleneimine) GF/B filters 
using Brandel cell harvester and wash subjected to three quick washes with ice-cold 
10 mM sodium phosphaste buffer pH 7.4. The filters were transfered into 3 ml 
scintillation vials, each incubated with 1 ml scintillation cocktail, left for 16-24 hr at 
room temperature. Membrane bound readioactivity was determined by liquid 
scintillation counter (Beckman LS 500 CE). All   tested compounds were dissolved 
at 100 mM in DMSO and serial dilutions were made with respective assay buffer. 
GABA, (-)-Nicotine hydrogen tartrate salt, and Ketamine stocks (10−2 M) were made 
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in assay buffer. Diazepam stocks (10−2 M) were prepared in absolute ethanol. 
Picrotoxinin stocks (10−2 M) were prepared in DMSO.  No effect of solvents on 
radioligand binding assays was seen at concentrations below 0.1% (v/v) DMSO or 
0.1% (v/v) ethanol. 
 [3H] Flunitrazepam Binding Assay 
[3H] flunitrazepam binding assays were performed as previously described (Rezai et 
al., 2003).  Briefly, well-washed rat forebrain membranes prepared by five-step 
freeze-thaw protocol were thawed, centrifuged and the supernatant was discarded. 
The pellets were resuspended again in fresh buffer (50 mM Tris-HCl, 5 mM EDTA, 
5 mM EGTA, pH 7.4) to yield a final protein concentration in the assay of 1 mg/ml. 
An amount of 100 μg membrane protein was incubated with [3H] flunitrazepam 
(approximately 1 nM) for 1 h at 4 °C with a range of test concentrations (10−11 to 10−4 
M). Non-specific binding was defined in the presence of 100 μM diazepam.  
 [3H] Muscimol Binding Assay 
[3H] muscimol binding assays were performed as previously described in Bohme et 
al., (2004). Briefly, well-washed rat forebrain membranes prepared by five-step 
freeze-thaw protocol were thawed, centrifuged and the supernatant was discarded. 
The pellets were resuspended again in fresh buffer (50 mM Tris-HCl, pH 7.4) to yield 
a final protein concentration in the assay of 1 mg/ml. An amount of 100 μg membrane 
protein was incubated with [3H] muscimol (approximately 10 nM) for 1 h at 4 °C with 
a range of test concentrations (10−11 to 10−4 M). Non-specific binding was defined in 
the presence of 100 μM GABA.  
 [35S]-t-butylbicyclophosphorothionate (TBPS) Binding Assay 
[35S] TBPS binding was performed essentially as described in Im et al., (1994). 
Briefly, well-washed rat membranes prepared by a five-step freeze-thaw protocol 
were, on the day of experiment, centrifuged and the supernatant was discarded. The 
pellets were resuspended in fresh buffer (50 mM Tris-HCl, containing 0.2 M NaCl, 
pH 7.4) to yield a final protein concentration in the assay of 1 mg/ml. An amount of 
100 μg membrane protein was incubated with [35S] TBPS (approximately 20 nM) for 
90 min at 25 °C with a range of test concentrations (10−11 to 10−4 M). Non-specific 
binding was defined in the presence of 100 μM picrotoxinin. 
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 [3H] MK-801 Binding Assay 
[3H] MK-801 binding assays were performed as previously described (Chazot et al., 
1993).  Briefly, well-washed rat forebrain membranes prepared by five-step freeze-
thaw protocol were thawed, centrifuged and the supernatant was discarded. The 
pellets were resuspended again in fresh buffer (25 mM sodium phosphate buffer pH 
7.4) to yield a final protein concentration in the assay of 1 mg/ml. An amount of 100 
μg membrane protein was incubated with [3H] MK-801 (approximately 1 nM) and 10 
μM glutamate for 2h at 22 °C with a range of test concentrations (10−11 to 10−4 M). 
Non-specific binding was defined in the presence of 10 mM ketamine.  
 [3H] Nicotine Binding Assay 
[3H] Nicotine binding assays were performed as previously described in Wake et al., 
(2000). Briefly, well-washed rat forebrain membranes prepared by five-step freeze-
thaw protocol were thawed, centrifuged and the supernatant was discarded. The 
pellets were resuspended again in fresh buffer (50 mM Tris buffer containing 8 mM 
CaCl2 pH 7.4) to yield a final protein concentration in the assay of 1 mg/ml. An 
amount of 150 μg membrane protein was incubated with [3H] Nicotine (approximately 
4 nM) for 1 h at 25 °C with a range of test concentrations (10−11 to 10−4 M). Non-
specific binding was defined in the presence of 100 μM (-)-Nicotine hydrogen tartrate 
salt.  
 Radio Ligand Binding Assay Analysis 
Results from the radioligand binding assays were analysed using GraphPad Prism 
5 Software program (GraphPad Software, San Diego, CA). For competition assays 
non-linear least squares regression was used, curves were best fitted to a one- or 
two-site binding model.  The EC50 and IC50 values are the concentrations for half-
maximal enhancement and displacement, respectively. Data were analysed using a 
Student's unpaired t-test, with levels of significance set at p < 0.05. 
The IC50 values for competition curves fitted to a one-site competition model, were 
calculated from the following equation:   
 
 50log101
ICx
ABA
y


  
Where:  
A and B = the minimum and maximum percentage specific binding respectively. 
          Y = specific binding at a fixed concentration of displacing drug 
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          X = log10 concentration of the displacer 
       IC50 = concentration of the displacer which inhibits 50% of the specific binding 
of the radioligand. 
The IC50 values for competition curves fitted to a two-site competition model were 
calculated from,  
 
    
















 2log1log 5050 101
11
101
1
ICxICx
FractionFraction
ABA
Y  
 
Where: A, B, X and Y are as above, (1) and (2) = the high and low affinity sites for 
the one-site and two-site binding models, the apparent inhibition constants (KI) were 
calculated using the Cheng-Prusoff equation (Yung-Chi and Prusoff, 1973),            
Where: 
IC50 = concentration of ligand giving 50% of the specific binding. 
[L] = [3H] Radioligand concentration. 
KD = dissociation constant from saturation binding of [3H] radioligand to the 
respective receptor. 
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1.3 Results 
 Effects of A. citrodora Essential Oils on the Benzodiazepine 
Binding Site of the GABAA labelled by [3H] Flunitrazepam in rat 
forebrain membranes 
To validate the [3H] flunitrazepam binding assay, two control compounds were used, 
GABA & diazepam.  It is known that the binding sites for GABA and benzodiazepines 
are allosterically coupled; this is demonstrated by the ability of GABA to enhance the 
binding of [3H] flunitrazepam as shown in Fig 2.4.  GABA significantly enhanced 
specific binding of [3H] flunitrazepam to native forebrain preparation in a 
concentration-dependent manner, yielding a mean Emax = 153 ± 4% and apparent 
EC50 = 31 ± 2 nM, respectively. GABA enhancement of [3H] flunitrazepam observed 
in our study was in the range of that observed for well-washed rat cerebral cortical 
membranes by (Ghiani et al., 1996). Diazepam significantly displaced specific 
binding of [3H] flunitrazepam in a concentration-dependent manner. Data were best 
fit to sigmoidal model yielding a mean apparent IC50 = 19.4 ± 1.5 nM. (Fig 2.5) shows 
the results from three independent experiments, each performed in triplicate for each 
membrane preparation. The potency of diazepam to displace [3H] flunitrazepam is in 
good agreement with the literature data obtained for the displacement of the same 
radioligand from brain membranes (Massotti et al., 1991). 
 
The effects of A. citrodora essential oil on radioligand binding to benzodiazepine site 
of GABAA were studied using [3H] flunitrazepam binding assay with four different oil 
concentrations [0.0001, 0.001, 0.01 and  0.1 mg/ml] of both dry and fresh extract. 
Specific [3H] flunitrazepam binding was defined using diazepam (100 μM). A. 
citrodora essential oil (both fresh and dry) did not alter the equilibrium binding of [3H] 
flunitrazepam to GABAA receptors in adult rat forebrain membranes as shown in 
figures 2.6 and 2.7  
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Figure 2.4  
Effect of GABA upon [3H] Flunitrazepam binding to adult rat forebrain membranes. Results are 
mean ± SD for three independent experiments each performed in triplicate. 
 
Figure 2.5  
Effect of diazepam upon [3H] flunitrazepam binding to adult rat forebrain membranes. Results 
are mean ± SD for three independent experiments each performed in triplicate. 
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Fig 2.6 
Effect of Fresh A. citrodora essential oil upon [3H] flunitrazepam binding to adult rat forebrain 
membranes. Results are mean ± S.D for three independent experiments each performed in 
triplicate. 
 
 
Fig 2.7 
Effect of Dry A. citrodora essential oil upon [3H] flunitrazepam binding to adult rat forebrain 
membranes. Results are mean ± S.D for three independent experiments each performed in 
triplicate. 
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 Effects of A. citrodora EO on the Agonist Binding Site of the 
GABAAR labelled by [3H] Muscimol in rat forebrain membranes. 
A control experiment of [3H] muscimol binding to well washed rat forebrain in the 
presence of different concentrations of GABA was carried out to validate the assay. 
GABA significantly displaced specific binding of [3H] muscimol in a concentration-
dependent manner. Data were best fit to sigmodial model variable slope with a 
pseudo-Hill coefficient, close to unity (nH = 0.72 ± 0.06) with an apparent IC50 = 106 
± 1 nM. (Fig 2.8) shows the results from three independent experiments, each 
performed in triplicate for each membrane preparation. The observed potency of 
GABA for inhibiting [3H] muscimol binding is also in good agreement with the binding 
affinity of this drug for recombinant α1β2γ2 GABAAR reported by (Baur and Sigel, 
2003). 
 
 
Fig 2.8  
Effect of GABA upon [3H] muscimol binding to adult rat forebrain membranes. Results are 
mean ± SD for three independent experiments each performed in triplicate. 
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The effects of A. citrodora essential oils on radioligand binding of GABAAR were 
studied using [3H] muscimol binding assay with concentrations [0.0001, 0.001, 0.01 
and  0.1 mg/ml] of both dry and fresh extract. Specific binding was defined using 100 
μM GABA. A. citrodora essential oil did not alter the equilibrium binding of [3H] 
muscimol to GABAA receptors in adult rat forebrain membranes as shown in figures 
2.9 and 2.10.  
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Fig 2.9  
Effect of fresh A. citrodora upon [3H] muscimol binding to adult rat forebrain membranes. Results 
are mean ± SD for three independent experiments each performed in triplicate. 
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Fig 2.10   Effect of dry A. citrodora upon [3H] muscimol binding to adult rat forebrain membranes. 
Results are mean ± SD for three independent experiments each performed in triplicate. 
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 Effects of A. citrodora EO on the Channel Binding Site of the 
GABAAR Labelled by [35S] TBPS in Rat Forebrain Membranes 
Two control compounds were used to validate [35S] TBPS (t- 
butylbicyclophosphorothionate) binding assay, picrotoxinin and diazepam. 
Picrotoxinin displayed a steep monophasic inhibition of [35S] TBPS binding with Hill 
slope close to unity nH = 1.3 ± 0.2 with an apparent IC50 = 309 ± 1 nM. Fig 2.11 
shows the results.  The observed IC50 appears to be in close agreement with the 
published literature (257 ± 12 nM) (Wang et al., 1999). Consistent with pervious 
published data (Ghiani et al., 1996), diazepam significantly enhanced specific 
binding of [35S] TBPS in a concentration-dependent manner, data were best fit to 
sigmoidal model, yielding a mean Emax = 157 ± 3% and apparent 
EC50 = 4.3 ± 0.5 nM, respectively. Fig 2.12 shows the results from three independent 
experiments, each performed in triplicate. However, it is known from the literature 
that diazepam had a bidirectional modulatory effect on [35S] TBPS binding.  At low 
concentrations diazepam enhanced the specific binding of [35S] TBPS whereas, at 
high concentrations it elicited an inhibitory effect. The observed apparent EC50 
values obtained are similar to the literature (Ghiani et al., 1996).  
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Fig 2.11 
[35S] TBPS competition binding to well-washed adult rat forebrain membranes in the presence 
of picrotoxinin. Results are mean ± SD for three independent experiments each performed in 
triplicate. 
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Fig 2.12  
[35S] TBPS competition binding to well-washed adult rat forebrain membranes in the presence 
of diazepam. Results are mean ± SD for three independent experiments each performed in 
triplicate. 
 
 
To investigate the effect of A. citrodora essential oils on the channel site of GABAA 
receptor  [35S] TBPS binding activity was carried to well-washed to adult rat forebrain, 
using four different oil concentrations [0.0001, 0.001, 0.01 and  0.1 mg/ml] of both 
dry and fresh oil extract. Specific binding was defined using 100 μM picrotoxinin. A. 
citrodora essential oil both fresh and dry did not alter the equilibrium binding of [35S] 
TBPS to GABAA receptors in adult rat forebrain membranes as shown in  figures 
2.13 and 2.14. 
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Figure 2.13  
[35S] TBPS competition binding to well-washed adult rat forebrain membranes in the presence 
of fresh A. citrodora oil. Results are mean ± SD for three independent experiments each 
performed in triplicate. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.14 
[35S] TBPS competition binding to well-washed adult rat forebrain membranes in the presence 
of dried A. citrodora essential oil. Results are mean ± SD for three independent experiments 
each performed in triplicate. 
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 Effects of A. citrodora EO on the [3H] MK-801 Binding to Rat 
Forebrain Membranes 
A control experiment of [3H] MK-801 (uncompetitive antagonist of the NMDA 
receptor) binding to adult rat forebrain in the presence of different concentrations of 
ketamine was carried out to validate the assay. Ketamine significantly displaced 
specific binding of [3H] MK-801 in a concentration-dependent manner in native 
preparation.  Data were best fit to one site model yielding a mean of apparent IC50 = 
2 ± 1 mM. Fig 2.15 shows the results. The observed IC50 value appears to be similar 
to the literature value (Wang et al., 1999).   
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Fig 2.15 [3H] MK-801 competition binding to adult rat forebrain membranes in the presence of 
ketamine. Results are mean ± SD for three independent experiments each performed in 
triplicate. 
 
The effects of A. citrodora Essential Oils on radioligand binding was assayed at the 
excitatory ligand gated ion channels gated by NMDA using [3H] MK-801 binding 
assay with four different oil concentrations [0.0001, 0.001, 0.01 and  0.1 mg/ml] of 
both dry and fresh extract. Non-specific binding was defined in the presence of 10 
mM ketamine. A. citrodora Essential Oils both fresh and dry did not alter the 
equilibrium binding of [3H] MK-801 binding to rat forebrain membranes. (Fig 2.16 and 
2.17) show the results. 
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Fig 2.16 [3H] MK-801 competition binding to adult rat forebrain membranes in the presence of 
fresh A. citrodora essential oil. Results are mean ± SD for three independent experiments each 
performed in triplicate. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 2.17 [3H] MK-801 competition binding to adult rat forebrain membranes in the presence of 
dried A. citrodora essential oil. Results are mean ± SD for three independent experiments each 
performed in triplicate. 
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 Effects of A. citrodora EO on [3H] Nicotine Binding to Rat 
Forebrain Membranes 
A control experiment of [3H] nicotine binding to adult rat forebrain, in the presence of 
different concentrations of nicotine, was carried out to validate the assay. Fig 2.18 
shows the results.  Nicotine produced a  concentration dependent inhibition of [3H] 
nicotine binding, data was best fit to two site competition model, comprising high and 
low affinity binding sites in the ratio 74: 26 ( high: Low % , SD ± 6). Site one apparent 
IC50 4.5 nM, site two apparent IC50= 3.5 µM. Nicotine binds to the α4β2 nAChR with 
high affinity (4.5 nM) whereas the α7 is 1000-fold less sensitive (3.5 µM). This 
selectivity profile is consistent with the published literature (Xiao et al., 1998). 
 
 
 
 
Fig 2.18 [3H] nicotine competition binding to adult rat forebrain membranes in [3H] nicotine 
competition binding to adult rat forebrain membranes in the presence of nicotine. Results are 
mean  of three independent experiments each performed in triplicate. 
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The effects of A. citrodora essential oils on neuronal nicotinic receptors using [3H] 
nicotine binding assay with four different oil concentrations [0.0001, 0.001, 0.01 and 
0.1 mg/ml] of both fresh and dried extract. Only fresh extract inhibited from  [3H] 
nicotine binding to well washed rat forebrain membranes at concentrations of 
0.001mg/ml and above, with mean apparent IC50 of 0.0018 ± 0.0008 mg/ml (Fig 
2.19). 
 
 
Fig 2.19 
[3H] Nicotine competition binding to well-washed adult rat forebrain membranes. Results are 
expressed as mean % specific [3H] nicotine binding ± S.D. for three independent experiments 
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1.4 Discussion 
In this chapter, we have characterized the radioligand binding profile for the essential 
oils (EO) derived from freshly prepared and dried A. citrodora focussing on the 
binding sites of major CNS ligand gated ion channel GABAA, NMDA and nicotinic 
receptors. A series of control experiments were initially performed to validate the 
assays employed. 
 
The major finding was that fresh A. citrodora essential oil inhibited [3H] nicotine 
binding in a concentration-dependent manner (IC50 = 0.0018 mg/ml) with no 
significant effects on the other major ligand gated ion channels (up to 0.1 mg/ml) 
which were tested. This is in marked contrast to our previous published findings with 
the essential oils derived from the European Melissa (M. officianalis) essential oil in 
which displayed no apparent effects upon nicotinic receptors, but showed a dose 
dependent inhibition of [35S] TBPS binding to GABAA receptor with apparent IC50  
0.040 mg/ml (Huang et al., 2008) 
 
Many medicinal plants have nicotinic agonist activity (Polya, 2003). For instance 
Lobeline from Lobelia inflate interacts with the nicotinic receptor (Decker et al., 1993) 
and could also be exploited to influence cholinergic function in AD. Other alkaloids 
such as sophoramine and cytisine, found in members of the Leguminosae, have 
nicotinic actions (Brahmachari 2012).  Cytisine is only used as a pharmacological 
tool because of its strong binding affinity for nicotinic receptors, but not used for any 
pharmaceutical purposes because of its toxicity (Brahmachari 2012).  The root of 
Withania somnifera is one of the most highly regarded herbs in Ayurvedic medicine 
and has cognitive enhancing properties, by augmenting learning acquisition and 
memory in both young and old rats (Ghosal et al., 1989). The mechanisms to explain 
this effect involve the modulation of cholinergic neurotransmission. The root extract 
enhanced AChE activity in the lateral septum and globus pallidus areas of the brain 
and also enhanced muscarinic M1 receptor binding in cortical regions, but as with A. 
citrodora  essential oil it did not affect GABAA, benzodiazepine receptor binding, nor 
NMDA or AMPA glutamate receptor subtypes (Schliebs et al., 1997).  
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Neuronal nicotinic acetylcholine receptors represent novel targets for CNS 
therapeutics, and may have substantial roles in mediating antinociception, as well as 
modulating cognitive performance. Much of the current pharmacological approaches 
for treating neurodegenerative disorders are mainly directed at correcting 
neurotransmitter specific deficiencies. This significantly contributes to the 
deterioration in cognitive function seen in AD patients (Birks, 2006). Furthermore, 
the reduced number of nicotinic acetylcholine receptors in the hippocampus and 
cortex of AD patients, as compared to age-matched controls, results in reduced 
nicotinic cholinergic excitation which may not only impair postsynaptic depolarization 
but also presynaptic neurotransmitter release and Ca2+ dependent intracellular 
signalling, including transcriptional activity. The most common approach to correct 
the nicotinic cholinergic deficit in AD is the application of cholinesterase inhibitors. 
The use of nicotinic acetylcholine receptors agonists may represent another means 
for activating viable cholinergic receptors in the AD brain. (Maelicke and 
Albuquerque, 2000).  
 
Nicotinic agonists can increase tau immune reactivity and alter its phosphorylation 
state (e.g., increased both tau phosphorylated and dephosphorylated levels probably 
via activation of nicotinic acetylcholine receptors (Rubio et al., 2006). Chronic 
nicotine treatment results in decreased plaque load and reductions in cortical β-
amyloid concentrations in the Tg mice carrying the Swedish mutation of human APP 
(Hellstrom-Lindahl et al., 2004), but not in 3xTg-AD mice (Oddo et al., 2005). 
 
Approximately half of the cortical tyrosine kinase receptor A (TRkA) is lost in the early 
stages of AD progression (Counts et al., 2004). Nicotine treatment of Wistar rats 
increased the expression of TrkA in the hippocampus (Jonnala et al., 2002). In the 
cholinergic neurons of the basal forebrain from AD patients, TrkA was found to serve 
as a receptor for the NGF a critical trophic factor for the survival of neurons. 
 
New evidence that the cholinergic system has a specific pathogenic role in the 
neurodegenerative alterations of aged and, especially, demented patients is fast 
accumulating. Both in vivo and in culture, nicotine protects striatal, hippocampal and 
cortical neurons against the neurotoxicity induced by excitotoxic amino acids as well 
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as the toxicity caused by β-amyloid, the major component of senile plaques. Further 
support for the implication of nicotinic receptors in brain ageing has arisen from 
recent studies on transgenic animals lacking nicotinic receptor subtypes, which has 
shed light on the mechanisms of nicotine neuroprotection and neurotoxicity (Zanardi 
et al., 2002).  
 
A. citrodora essential oil constituent(s) responsible for this activity needs to be 
identified. An initial attempt will be described later in Chapter 5. The next two 
chapters will investigate whether the A. citrodora essential oils display any anti-
cholinesterase, or anti-oxidant or neuroprotective properties along with its nicotinic 
binding profile. 
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Chapter 3 
Pharmacological Profile of Aloysia citrodora 
Palau Essential Oil: Cholinergic, Anti-Oxidant 
and Iron Chelation Properties 
  
3.1 Introduction 
3.1.1 Acetylcholinesterase Inhibitors in Neurodegenerative Diseases 
According to the cholinergic hypothesis, AD is caused by reduction in the synthesis 
of acetylcholine in cholinergic neurons of basal forebrain and loss of cholinergic 
neurotransmission in the cerebral cortex. The decrease in acetylcholine 
significantly contributes to the deterioration in cognitive function seen in AD 
patients (Birks, 2006). Cholinesterase enzymes hydrolyze acetylcholine. The 
selective inhibition of AChE reduces the breakdown of acetylcholine and increases 
availability of acetylcholine at the synapse resulting in restoration of cognitive and 
memory function. AChE inhibitors are currently the pharmacological mainstay 
therapy for AD. They include donepezil, galantamine, and rivastigmine (Bond et al., 
2012). 
3.1.2 Oxidative Stress in Neurodegenerative Diseases 
Oxidative stress results from excessive levels of ROS generated through 
imbalance of normal biochemical processes. These oxygen radicals can then 
damage all types of macromolecules, disrupting normal cellular functions and, 
ultimately, cause cell death. The brain has the highest metabolic rate of any tissue 
and has an obligate requirement for aerobic metabolism. This, combined with 
endogenously high concentrations of Cu+ and Fe+ metal ions increase the 
vulnerability of brain to oxidative stress. The vast majority of biochemical radicals 
and ROS arise from the redox chemistry of metals. Redox-active metals become 
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available for ROS and radical generation when they either escape their chaperones 
(usually because the concentration of metal is too high to be completely 
chaperoned), or because of an accumulation of a damaged metalloprotein that 
inappropriately permits reaction of the metal with oxygen. The hydroxyl radical 
generates a variety of oxidative damage observed often in neurodegenerative 
disorders, including AD and PD.  
 
The primary ROS implicated in oxidative stress is the hydroxyl radical, whose 
damage is dependent upon its diffusion capacity over nanometre distances from its 
generation site. Although peroxynitrite also appears capable of hydroxyl-like 
activity, most hydroxyl radicals reflect the Fenton reaction between reduced 
transition metals (usually iron II or copper I) and H202. Re-reduction of iron III and 
copper II can be performed by superoxide or other cellular reductants such as 
ascorbate.  
 
In addition to their role in redox processes, transition metals may contribute to 
neurodegeneration, along with redox-inactive metal ions, through their deleterious 
effects on protein and peptide structure, such as a pathological aggregation 
phenomenon. In such cases, transition metals can sometimes exert dual neurotoxic 
effects. In contrast, there are also a number of normal antioxidant defence 
mechanisms to combat the effects of ROS through both enzymatic and none 
enzymatic pathways in mammalian cells. Cytosolic copper-zinc superoxide 
dismutase (CuZnSOD) and mitochondrial manganese superoxide dismutase 
(MnSOD) are two such important players in the antioxidant defense system. These 
enzymes convert reactive superoxide to harmless O2 and H2O2. The latter is then 
removed by catalase and peroxidases, which are abundant throughout tissues. In 
addition, there are a number of proteins closely tied to metal induced redox activity. 
These include proteins involved in metal transport and those which do not normally 
have a metal-binding function, but are able to bind metals for neuroprotection 
(Zatta, 2003). 
Chapter 3 
 
54 
 
3.1.3 Iron in Neurodegenerative Diseases 
Free iron has long been implicated in neurodegenerative disease through its redox 
transitions in vivo. The consequential generation of oxygen free radicals can further 
induce oxidative stress in tissues. Abnormally high levels of iron and oxidative 
stress have been found in most neurodegenerative disorders (Sayre et al., 2000, 
Smith et al., 2010). Oxidative stress, under these conditions, has been associated 
with levels of free iron. An increased level of total iron does not necessarily signify 
increased oxidative stress if it is accompanied by a concomitant increase in iron 
storage proteins, which keep iron in a redox-inert state. Two classes of iron-related 
neurodegenerative disorders can be distinguished; the first due to iron 
accumulation in specific brain regions, and the second resulting from defective iron 
metabolism and perturbation of iron homeostasis (Zecca et al., 2004). As life 
expectancy increases and, as a consequence, brain iron accumulates, we would 
expect the occurrence of iron-related neurodegenerative diseases to inexorably 
increase (Robert Crichton, 2013).  
 
The aim of this chapter is to screen the essential oil derived from the leaves A. 
citrodora for potential anti-oxidant and iron chelation properties, in addition to AChE 
inhibitory activity.  
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3.2 Materials and Methods 
3.2.1 Acetylcholinesterase Inhibitory Assay in 96-well Plate 
AChE inhibitory activity was determined using a 96-well plate format Ellman’s 
colorimetric method (Ellman et al., 1961) with slight modification as previously 
described by (Oinonen et al., 2006). 25 µl of plant extract dissolved in 50 mM Tris 
buffer (pH 8), was added to the wells in a 96-well plate, followed by 25 µl of 15 mM 
acetylthiocholine iodide in H2O, 125 µl of 3 mM 5,50-dithiobis (2-nitrobenzoic acid) 
in 50 mM Tris buffer containing 0.1 M NaCl and 0.02 M MgCl2 (pH 8) and 50 µL of 
50 mM Tris buffer containing 0.1% (w/v) bovine serum albumin (BSA). The 
absorbance at 412 nm was measured on 15 occasions over a 15 min period 
(spontaneous hydrolysis) using BioTek ELx800 microplate reader, USA. Then, 25 
µL of 0.22 U/ml AChE in 50 mM Tris buffer containing 0.1% (w/v) BSA was added 
to initiate the reaction and the measurement was repeated. The absorbance 
readings were corrected by subtracting the spontaneous hydrolysis values. AChE 
inhibitory effect of the sample was estimated in terms of percentage change in 
average absorbance compared to the blank, which is referred to as percentage 
inhibition. Galantamine hydrobromide (0.67 μM) was used as the reference 
standard. 
3.2.2 DPPH ( 2,2-diphenyl-1-picrylhydrazyl) Assay 
Radical scavenging capacity was determined according to the technique reported 
by (Loizzo et al., 2009). An aliquot of 1.5 ml of 0.25 mM 2,2-diphenyl-1-
picrylhydrazyl (DPPH) solution in methanol and 12 μl of essential oil at 
concentrations ranging  from 0.0001 to 1 mg/ml were mixed. The mixture was 
shaken vigorously and allowed to reach a steady state at room temperature for 30 
min. Decolourization of DPPH was determined by measuring the absorbance at  
λ=517 nm with a SpectroScan80D spectrophotometer. The DPPH radicals 
scavenging activity was calculated according to the following equation: Scavenging 
activity % = [(A0 - A1) /A0] X100. Where A0 is the absorbance of the control (blank, 
without extract) and A1 is the absorbance in the presence of the extract. The results 
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were compared to that of butylated hydroxyanisole (BHA) employed as the 
standard control. 
3.2.3 Ferrous Ion-Chelating Effect 
The ferrous ion chelating activity of EOs was assessed by the ferrozine assay as 
described by (Yamaguchi et al., 2000).  Briefly, 200 μl of different concentrations of 
EOs prepared in methanol were added to 740 μl methanol and 20 μl of FeCl2.4H2O 
solution (2 mM) and left for incubation at room temperature for 5 min. The reaction 
was initiated by adding 40 μl of ferrozine (5 mM), into the mixture which was then; 
shaken vigorously and left to stand at room temperature for 10 min. Absorbance of 
the solution was then measured spectrophotometrically at 562 nm. The percentage 
inhibition of ferrozine Fe2+ complex formation was calculated using the formula: (%) 
= [A0 - A1) /A0] X 100. Where A0 is the absorbance of the ferrozine–Fe2+ complex 
and A1 is the absorbance of the test compound. EDTA (0.1%) was used as a 
positive control. 
3.2.4 Materials 
Ethylenediaminetetraacetic acid (EDTA), AChE (Type-VI-S, EC 3.1.1.7), 
acetylthiocholine iodide, 5,5′-dithiobis-2-nitrobenzoic acid (DTNB), Tris-HCl, bovine 
serum albumin, galantamine, Ferrozine , iron (II) chloride tetrahydrate. 
3.2.5 Statistical Analysis 
All the experiments were performed in triplicate and statistical analysis of the data 
were performed using GraphPad Prism 5.0 program. A probability value of p<0.05 
was considered statistically significant.  
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3.3 Results 
3.3.1 Anti-cholinesterase Activity 
Both EOs from dried and fresh leaves elicited as effective AChE inhibitory activity 
as the positive control galantamine, but with higher potency for the dried leaf oil 
compared to fresh leaf oil. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 3.1  
Percentage inhibition of AChE by fresh A. citrodora essential oil compared to standard, 
galantamine (1.93e-4 mg/ml).  Values are means ± SD, from at least three separate 
experiments. All concentrations of oil displayed significant activity Vs baseline, p < 0.001. 
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Fig 3.2  
Percentage inhibition of AChE by A. citrodora dry essential oil compared to standard, 
galantamine (1.93e-4 mg/ml).  Values are means ± SD, from at least three separate 
experiments. All concentrations of oil displayed significant activity Vs baseline, p < 0.001.  
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3.3.2 Anti-oxidant Properties 
The 2,2-diphenylpicrylhydrazyl (DPPH) assay is widely used to evaluate the 
properties of plant constituents for scavenging free radicals. DPPH is a stable free 
radical and accepts an electron or hydrogen radical to become a stable 
diamagnetic molecule (Aazza et al., 2011). The method is based on the 
spectrophotometric measurement of the DPPH concentration change resulting from 
the reaction with an antioxidant. Essential oil of A. citrodora from dried & fresh 
leaves exhibited a comparable radical scavenging activity against DPPH radical in 
comparison to 0.1 % Butylated hydroxyanisole (BHA) as reference standard (Fig 
3.3 and Fig 3.4). 
 
 
   A. citrodora essential oil conc. (mg/ml) 
 
Fig 3.3  
Antioxidant activity of A. citrodora fresh essential oil using DPPH Assay. Values are mean ± 
SEM, n=3, All concentrations of oil displayed significant activity Vs baseline, p < 0.001. 
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A. citrodora essential oil conc. (mg/ml) 
 
Fig 3.4  
Antioxidant activity of A. citrodora dried essential oil using DPPH Assay. Values are mean ± 
SEM, n=3, All concentrations of oil displayed significant activity Vs baseline, p < 0.001. 
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3.3.3 Iron Chelation Properties 
A robust antioxidant capacity was observed with the A. citrodora EO using the iron 
chelating test system. A. citrodora EOs derived from the fresh leaf displayed a 
significant dose-dependent iron-chelating property (between 0.001-1 mg/ml), while 
the dried leaf oil displayed a limited effect, only at 1 mg/ml and above, compared to 
0.1 % EDTA as positive control. 
 
Fig 3.5  
Antioxidant activity of A. citrodora (Dry) essential oils using Metal Iron chelating assay. Data 
are compared to standard, EDTA (0.1%). Values are means ± SD, from at least three 
separate experiments. All concentrations of oil displayed significant activity Vs baseline, p < 
0.001. 
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Fig 3.6  
Antioxidant activity of A. citrodora (Fresh) essential oils using Metal Iron chelating assay. 
Data are compared to standard, EDTA (0.1%). Values are means ± SD, from at least three 
separate experiments. All concentrations of oil displayed significant activity Vs baseline, p < 
0.001.  
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3.4 Discussion 
The goal of this chapter was the biological evaluation of a traditionally used 
Jordanian medicinal plant, A. citrodora (which is accessible, abundant and has 
been subjected to limited neurological assessment) as a potential source of novel 
neuroactive compounds. Lemon verbena leaves were harvested in Amman area of 
Jordan and a portion was air-dried and a second portion used fresh, to obtain the 
EOs utilized in this present study. 
 
The potential of the EOs of A. citrodora species in the treatment of early stages of 
AD was evaluated utilising the AChE inhibition assays. A. citrodora EOs derived 
from dried and fresh leaves displayed AChE inhibitory activity in our study 
compared with a standard galantamine, an activity that has not previously been 
reported for this plant species. The high content of monoterpenes may underpin 
this activity (Howes et al., 2003, Savelev et al., 2004) The anti-AChE activity of the 
oil could be attributed to Limonene, Caryophyllene oxide and/or 1,8-Cineole, which 
are major components found in the A. citrodora EO. Dried leaves oil showed a 
more clear AChE inhibitory activity than fresh oil, which could be related to higher 
respective levels of Limonene and Caryophyllene oxide (see Chapter 5).  Recent 
studies have indicated that the constituents combined in a naturally occurring ratio 
are different than that of the whole natural oil. This has led to the suggestion that 
the bioactivity exhibited by the essential oil is probably due to synergetic activities 
of several components (Savelev et al., 2003, AH et al., 2008). For instance it is 
been reported that 1,8-cineole/α-pinene and 1,8-cineole/caryophyllene oxide 
combinations (both found in A. citrodora) have minor synergy (Savelev et al., 2003, 
AH et al., 2008). 
 
In chapter 5, a docking model will be utilised in attempt to identify potential anti-
cholinesterase components of the oils. Natural antioxidants that are present in 
medicinal plants are responsible for inhibiting or preventing the deleterious 
consequences of oxidative stress. These comprise free radical scavengers, 
including polyphenols, flavonoids and phenolic compounds. The A. citrodora oil 
exhibited a clear radical scavenging activity at all tested concentrations. This 
activity has been reported earlier in several studies for related plants (AH et al., 
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2008, Ono et al., 2008, Quirantes-Piné et al., 2009) For example the aqueous 
extract of Aloysia gratissima  (Verbenaceae) native to South America showed 
higher antioxidant activity than BHT, but lower than ferulic acid, (Maraschin, 2013), 
and the methanol extract of Lippia schomburgkiana (Verbenaceae) has been 
reported to display an EC50 value only three times lower than that of trolox in the 
DPPH test (da Silva et al., 2009) 
 
Furthermore, A. citrodora infusion was evaluated by the DPPH test using Trolox as 
the reference compound and showed a high radical scavenging activity of 
superoxide, hydroxyl radical and hypochlorous acid (Valentão et al., 2002, Bilia et 
al., 2006, Bilia et al., 2008). Oxidative cellular damage is a multiphase process 
involving free-radical chain initiation and propagation steps. An important 
mechanism of anti-oxidative action is the chelation of transition metals, thus 
preventing catalysis of hydrogen peroxide decomposition via the Fenton-type 
reaction (Bush, 2003). A line of treatment for neurodegenerative treatments 
currently under investigation is through selective low affinity binding of transition 
metals. (Allan Butterfield et al., 2002, Bush, 2003). Therefore, herein, the ability of 
A. citriodora essential oil to chelate iron (II) was investigated.  As can be seen, the 
oil derived from fresh leaves was effectively capable of chelating iron (II) and did so 
in a concentration-dependent manner to approx. 70% of the level of EDTA. Oil 
derived from dry leaves was of capable of chelating iron (II) to a lesser extent, up to 
approx. 50% of that of EDTA. The anti-oxidant and iron-chelation properties 
displayed by A. citrodora in this chapter suggest that this may have potential for a 
neuroprotective capability which will be investigated in the next chapter, using in 
vitro cell culture models of oxidative stress- and β-amyloid-induced neurotoxicity. 
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Chapter 4 
Pharmacological Profile of Aloysia citrodora 
Palau Essential Oil: Neuroprotective Properties 
 
4.1 Introduction 
Due to premature and slow death of specific neuronal populations, 
neurodegenerative diseases are accompanied by the loss of structural organization 
and functioning of the brain tissue. Despite the important differences in clinical 
manifestation and progressive cell loss of specific neuronal populations in a 
specific region, neurodegenerative diseases share some common features such as 
the appearance of aged brain, the extensive neurodegeneration, synaptic 
dysfunction, and the accumulation of intracellular or extracellular deposits of 
misfolded protein aggregates with a β-sheet conformation, such as β-amyloid (Aβ) 
in AD, α-synuclein in PD, mutated huntingtin in HD, resulting in respective 
behavioural deficits. (Farooqui, 2010). 
 
In the previous chapter, A. citrodora EO was shown to display a range of anti-
oxidant and metal-chelation properties which indicate that this natural product may 
have utilities in neuroprotection. A neuroprotectant is generally defined as an agent 
that prevents neuronal death by inhibiting one or more of the pathophysiological 
steps in the processes that follow injury to the nervous system, ischemia or 
application of neurotoxins. The definition includes interventions that slow or halt the 
progression of neuronal degeneration. The mechanisms involved in 
neurodegeneration are multifactorial, including a complex set of phenomena, 
including inflammation, glutamatergic neurotoxicity, increases in iron, nitric oxide 
and ROS, and depletion of endogenous antioxidants. Generally speaking, ROS 
can exert multiple damaging reactions to proteins, lipids, carbohydrates and nucleic 
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acids, disrupting cellular functions. The increased production of ROS is therefore a 
potential threat to cellular homeostasis and neuronal survival if production is not 
balanced by the capacity of endogenous antioxidant mechanisms (Jain, 2011).  
 
Mouse catecholaminergic neuronal tumour, CAD cells (Cath.-a-differentiated) are a 
variant of a CNS catecholaminergic cell line established from a brain tumour in a 
transgenic mouse carrying wild-type SV40 T antigen under transcriptional control of 
rat tyrosine hydroxylase promoter. CAD has lost the immortalising oncogene and 
expresses neuron-specific proteins and synaptic vesicle proteins. CAD cells 
differentiate to form neuronal processes in serum free conditions (Qi et al., 1997). 
In this chapter, the preconditioning and neuroprotective properties of A. citrodora 
EO will be assessed using H2O2 and amyloid-induced toxicity in the CAD neuronal 
cell line grown in culture. Morphological differentiation can be induces in CAD by 
growing them in serum free media (fig 4.1 and 4.2). 
 
 
Fig 4.1 Undifferentiated CAD cell line in 
serum containing media 
Phase contrast image                
Fig 4.2 Differentiated CAD cell line in 
serum free showing long axons   
Phase contrast image                
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4.2 Materials and Methods 
4.2.1 CAD cell culture 
(Cath.-a-differentiated) cultures and experiments were performed in CL1 facilities 
under sterile conditions. CAD cells were grown at 37°C and in 5% CO2 on 75 cm2 
tissue culture flasks (Sarstedt, Newton, NC) in  Dulbecco's modified eagles' 
medium DMEM / F-12 Media - GlutaMAX™-I (GIBCO, Grand Island, NY), 
supplemented with 10% foetal bovine serum (FBS; Sigma, St. Louis, MO) Cells 
were passaged every 6–7 days at a 1:4 dilution. CAD differentiate to form neuronal 
processes in serum free conditions. To induce morphological differentiation, cells 
were switched to the same medium without serum supplementation after 12–24 h.  
 
4.2.2 CAD cell line subculturing 
Original medium from the T75 flask, were removed, rinsed once with 10 ml PBS, 
then 4 ml Accutase (Innovative Cell Techonologies, Cat#AT104) added to lift the 
cells. 4 ml complete medium were then added to neutralize. 8ml cell mixtures were 
added to a15 ml sterile centrifuge tube and centrifuged at 1000 rpm for 5 min. The 
superatant was removed and 5 ml complete medium added to resuspend the 
pellet. The cells were divided 1:3-4 into 75 cm2 flasks, with 20 ml total medium in 
each flask. 
 
4.2.3 Cryopreservation and storage of CAD Cell line 
Sub-confluent cultures (70-80%) was dislodged by gentle pipetting; transferred to 
15 ml falcon tube and centrifuged at 200xg for 5 minutes at 4 ºC. The pellet was 
resuspended in DMEM ⁄ F-12 Media - GlutaMAX™-I supplemented with 10% FBS 
and 10% DMSO. The cell suspension was immediately divided into and stored at –
80 ºC for 24 hours and then transferred to liquid nitrogen. 
 
4.2.4 Resuscitation of frozen CAD Cell Line 
A cryogenic vial of cells from liquid nitrogen storage is collected wearing 
appropriate personal protective equipment. The vial was then quickly transferred to 
a 37°C water bath. It is important to thaw rapidly to minimise any damage to the 
cell membranes. The ampoule then was wiped out with a tissue soaked in 70% 
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alcohol prior to opening. The whole content of the ampoule is pipetted into 15 ml 
sterile falcon tube. Pre-warmed medium was added to reach a total volume of 10 
ml, the tube then centrifuged at 1000 rpm for 5 min. supernatant was removed and 
the pellet was resuspended inDMEM⁄F-12 Media - GlutaMAX™-I supplemented 
with 10% FBS. The resuspended cells were grown at 37°C with 5% CO2 in 75 cm2 
tissue culture flasks. 
 
4.2.5 Treatment of cell cultures with H2O2 
Hydrogen peroxide (H2O2)-induced insult with a series of increasing concentrations 
was performed to determine the dose-dependent effects on CAD cell survival. A 
stock solution of H2O2 (2500 µM) in PBS was freshly prepared. A series of 
concentrations were then prepared using Dulbecco's modified eagles' medium 
DMEM⁄F-12 Media - GlutaMAX™-I supplemented with 10% FBS to achieve final 
concentrations of 250 µM, 200 µM, 150 µM, 100 µM and 50 µM. Sub-confluent 
cultures (70-80%) was dislodged by gentle pipetting; transferred to a 15 ml falcon 
tube and centrifuged at 200xg for 5 minutes at 4 ºC. The pellet was resuspended in 
DMEM⁄F-12 Media GlutaMAX™-I supplemented with 10% FBS. The cell 
suspension was immediately plated in 24-well plates and incubated at 37°C and 
5% CO2. After 24 hours the media was replaced with the different H202 
concentrations prepared earlier and grown in culture for further 24 hours after 
which an MTT assay was performed (section 4.2.8). 
 
The choice of essential oil concentrations was initially investigated by applying 
different concentrations of the oil (0.0001, 0.001, 0.01, 0.1mg/ml) for 24h to CAD 
cell cultures. Viability of neurons was assayed using a standard MTT assay 
(Freshney, Culture of Animal Cells 6th ed: 373, 2011).  Survival of CAD cells was 
assessed by the MTT assay, after 24 hr pre-treatment with A. citrodora EO (0.001 
and 0.01 mg/ml (w/v)) followed by 24 hr post-treatment with 250 µM H2O2 (i.e. A. 
citrodora containing media removed before addition of H2O2 - preconditioning 
method). A second set of experiments were performed when the A. citrodora 
containing media was not removed prior to exposure to the H2O2 - Neuroprotection 
method). N=12 well replicates from 3 independent cultures were carried out (* p < 
0.05; ** p < 0.01; *** p < 0.001). 
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4.2.6 MTT cell proliferation assay 
50 µl Phosphate Buffered Saline (PBS) (136.9 mM 2.68 mM KCl, 4.3 mM Na2HP04, 
1.4 mM KH2P04, pH 7.4) containing 5 mg/ ml MTT was added to the cultures and 
incubated at 37°C and in 5% CO2 for  2.5 hours. Then MTT- containing medium 
was removed, the surface of the wells was rinsed with 300 µl PBS before the 
application of 250 µl isopropanol. After the purple crystals dissolved, the optical 
density of 100 µl sample was spectrophotometrically read at 595 nm (Thermo 
Labsystems Multiskan Ascent, V1.3). 
 
4.2.7 Treatment of cell cultures with β-Amyloid 
Human β-amyloid peptide, Ascent Scientific, UK, was dissolved in DMSO (dimethyl 
sulphoxide) at 1 mg/ml and stored at -80°C until use. Prior to use, the molar 
concentration of the peptide was calculated and diluted to 200 μM using sterile 
PBS. The peptide was then incubated for 72 hours at 37°C, 5% CO2, without 
agitation. The peptide was then diluted to the required concentration using 
DMEM/F12 plus GlutaMAX® +10% FCS, inverted and gently added to neuronal 
cultures, with DMSO in DMEM/F12 plus GlutaMAX® +10% FCS as a control 
volume in control neuronal cultures. 
 
4.2.8 CytoTox 96 non-radioactive assay (Promega, UK) 
CytoTox 96 assay kit quantifies LDH (lactate dehydrogenase) levels as a measure 
of cell lysis (necrosis). Media was removed from cells and centrifuged at 13,000 
rpm for two minutes. The supernatant containing the LDH was retained and the 
pellet resuspended in PBS, using the same volume removed from the cells, and 
placed back into the respective well of the 24 well plate. The 24 well plate was then 
frozen for two hours at -20°C to lyse all remaining cells. Cells were subsequently 
thawed and centrifuged at 13,000 rpm for two minutes; again the supernatant was 
retained as a measure of total remaining LDH. Dilutions; 1:10 and 1:20, were made 
of each supernatant using PBS as the diluent with DMEM/F12 plus 10% FCS used 
to calibrate the assay. 50 μl of substrate mix was added to 50 μl of each dilution 
prior to incubation for 30 minutes at room temperature in the dark. Neat, 1:10 and 
1:20 dilutions were all completed in triplicate. Following this, 50 μl of stop solution 
was added to each well and the absorbance measured at 490 nm on a Multiskan 
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Ascent Plate Reader, Version 2.6. Cell lysis, via LDH release in the media 
supernatant, was calculated as a percentage of the sum of total LDH absorbance, 
combining the absorbance of positive control freeze-thawed cells and absorbance 
of media containing LDH. 
 
4.2.9 Statistical analysis 
All the experiments were performed in triplicate and statistical analysis of the data 
were performed using GraphPad Prism 5.0 program. A probability value 
Convention: (* p < 0.05; ** p < 0.01; *** p < 0.001). 
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4.3 Results 
4.3.1 Treatment of CAD Cell Cultures with Aloysia citrodora 
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Fig  4.3 
24 hours Treatment of CAD cell cultures with (Dry) A. citrodora. Concentrations 0.001, 0.01 
and 0.05 mg/ml elicited no neurotoxic effect upon CAD cells. *** p < 0.001 compared to 
control.  
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4.3.2 Hydrogen peroxide insult: concentration-dependent effects 
of Hydrogen peroxide (24 hours) 
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Fig 4.4 
24 hours insult of CAD Cell Cultures with Hydrogen peroxide. 200 µM and 250 µM H2O2 
elicited a significant neurotoxic effect up to 62% loss of cell viability. *** p < 0.001 compared 
to control. 
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4.3.3 Preconditioning of CAD cultures with Aloysia citrodora 
before 24 hours insult with 250 µM hydrogen peroxide 
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Fig 4.5 
Preconditioning of CAD Cell Cultures with A. citrodora before 24 hours insult with 250 µM 
Hydrogen peroxide.  No significant difference in comparison to 250 µM H2O2 treated cells.   
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4.3.4 Protection of CAD cells with Aloysia citrodora from 24 hours 
250 µM hydrogen Peroxide insult 
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Fig 4.6 
Protection of CAD neuronal cells with A. citrodora from 24 hours 250 µM Hydrogen 
peroxide insult. (*** p < 0.001 compared to 250 µM H2O2 treated cells). 
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4.3.5 CAD cell cultures insult with β-amyloid 
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Fig 4.7 
24 hours insult of CAD Cell Cultures with β-amyloid (*** p < 0.001 compared to PBS 
control) 
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4.3.6 Protection of CAD cells with Aloysia citrodora from 10 µMβ-
amyloid insult 
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Fig 4.8 
Protection of CAD cells with A. citrodora from 10 µM β-amyloid insult. N = 6 independent 
experiments. (*** p < 0.001 compared to 10 µM Aβ treated cells). 
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4.3.7 Protection of CAD cells with Aloysia citrodora from 15 µM β-
amyloid insult 
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Fig 4.9 
Protection of CAD cells with A. citrodora from 15 µM β-amyloid insult  
N = 6 independent experiments. (*** p < 0.001) 
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4.4 Discussion 
Oxidative stress resulting from increased formation of hydrogen peroxide and 
oxygen-derived free radicals, can damage biological molecules and initiate a 
cascade of events, including dysfunction of mitochondrial respiration, excitotoxicity, 
and a fatal rise in cytosolic calcium, and cause the cells to undergo necrosis or 
apoptosis (Van Houten et al., 2006). Among the various free radicals generated in 
the cell, hydroxyl radical and peroxynitrite are the most potent, and can damage 
cells via non-selective oxidation of proteins, lipids, fatty acids, and nucleic acid 
(Sayre et al., 2001, Barnham et al., 2004, Mariani et al., 2005). Proteins are initial 
targets of ROS, for instance, in AD, aberrant metal homeostasis may contribute to 
the formation of ROS and toxic Aβ oligomers, thus, facilitating the formation of 
amyloid plaques (Maynard et al., 2005).  Also hydrogen peroxide accumulates 
during the incubation of β-amyloid or α-synuclein and hyperphosphorylated tau that 
show a close interrelationship (Geddes, 2005) and synergistic action (Wenning and 
Jellinger, 2005, Mamah et al., 2005).  
 
In order to select an appropriate concentration of the essential oil to test for 
neuroprotection properties, 24 hr treatment of CAD cells with a range of 
concentrations (0.001, 0.01, 0.05, 0.1 and 0.5 mg/ml) was performed. Results are 
shown in Fig 4.3. Concentrations 0.001 and 0.01 mg/ml of A. citrodora did not elicit 
a neurotoxic effect, therefore were selected for neuroprotection tests. Interestingly, 
at concentrations 0.1 mg/ml and above, the oil elicited a neurotoxic effect itself, 
indicating the presence of a low affinity neurotoxin, possibly through GABAAR 
inhibition or glutamate receptor activation. 
 
Hydrogen peroxide is a commonly used insult to elicit oxidative stress in cells. The 
effects of hydrogen peroxide upon CAD cells were investigated using a 24 hr 
incubation period. Results shown in Fig 4.4 show H2O2 significantly reduced cell 
survival in a dose-dependent manner relative to the control condition. The highest 
concentration of 250 µM H202 was chosen to investigate the potential 
preconditioning and neuroprotective properties of A. citrodora. Utilising the 
preconditioning protocol (section 4.2.7), no protective effect was evident with either 
oil concentration tested versus 250 µM H2O2 (Fig 4.5). However, when cells were 
Chapter 4 
 
79 
 
pre-treated with oil and remained in the cultures when peroxide insults were 
applied, a clear neuroprotective effect was observed with both oil concentrations 
tested (Fig 4.6). This is consistent with the anti-oxidant and free radical chelating 
properties displayed by the oil as described in chapter 3. 
 
This study provided new evidence that the A. citrodora EO essential oil (at the 
same concentrations shown to be neuroprotective against a H2O2 insult) displays 
significant neuroprotective properties versus β-amyloid-induced toxicity particularly 
at a concentration of 0.01 mg/ml. A further point to make is that the oil proves to 
afford higher protection against the lower concentration of 10 µM β-amyloid (Fig 
4.9) than the higher concentration of 15 µM, which is unsurprising.  
 
Therefore, in this present chapter, we demonstrated that the A. citrodora EO 
endows neuroprotective characteristics against the toxic effects of oxidative stress 
and β-amyloid in CAD neuronal cell culture. These results were consistent with the 
results reported in the previous chapters showing that A. citrodora EO has effective 
in vitro free-radical-scavenging effects and capability of chelating iron (II).  A. 
citrodora share these properties with some of the best known neuroprotective 
plants such as Ginkgo biloba, Ginseng, and Curcuma. For instance Bastianetto et 
al., (2000) showed that Ginkgo biloba extract protects hippocampal primary 
cultured cells from H2O2 and β-amyloid induced toxicity. While Ginseng protected 
rat pheochromocytoma PC12 cells from H2O2 and β-amyloid induced toxicity in 
different experimental models of AD, (Chen et al., 2006). Also, Curcuminoids from 
Curcuma longa L. (Zingiberaceae) protected PC12 from β-amyloid and H2O2 insult 
(Kim et al., 2001). 
 
This encouraging profile warrants further investigation by attempting to identify the 
A. citrodora EO constituents responsible for this activity, which will be discussed in 
Chapter 5.  
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Chapter 5 
Pharmacological profile of Aloysia citrodora 
Palau essential Oil: Analysis and solid Phase 
Fractionation 
5.1 Introduction 
5.1.1 GC/MS analysis of A. citrodora EO 
GC/MS has been widely used for the investigation of the chemical composition of 
essential oils. It has been effectively used for the identification of the main 
compounds in the isolated essential oils and for the distinction between different 
species of various spice plants (Daferera et al., 2000).  
 
The chemical composition of A. citrodora phenolic compounds (flavonoids and 
phenolic acids) of the leaves of A. citrodora have been reviewed (Tomás-Barberán 
et al., 1987, Skaltsa and Shammas, 1988, Carnat et al., 1995, Nakamura et al., 
1997, Carnat et al., 1999, Valentão et al., 1999, Argyropoulou et al., 2007). The 
chemical composition of A. citrodora extract has also been studied and reviewed 
(Montes et al., 1973, Kaiser and Lamparsky, 1976, Velasco-Negueruela et al., 
1993, Bellakhdar et al., 1994, Zygadlo et al., 1994, Özek et al., 1996, Terblanché 
and Kornelius, 1996, Carnat et al., 1999, Pascual et al., 2001, Crabas et al., 2003, 
Kim and Lee, 2004, Sartoratto et al., 2004, Santos-Gomes et al., 2005, 
Argyropoulou et al., 2007). Genus Lippia shows rich genetic diversity, enabling it to 
synthesize a variety of essential oil constituents if grown in different parts of the 
world. However, the composition of the essential oil obtained from the same plant 
stock remains constant under the same environmental conditions (Catalan and de 
Lampasona, 2002, Santos-Gomes et al., 2005). 
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5.1.2 Solid phase extraction of A. citrodora EO 
5.1.2.1 A brief history 
Solid phase extraction (SPE) is a popular sample preparation method used for 
isolation, enrichment and/or clean-up of components of interest. SPE normally 
involves bringing an aqueous sample into contact with a solid phase or sorbent 
where the compound is selectively adsorbed on to the surface of the solid phase 
prior to elution (Dean, 2010). According to (Walton, 1970) the first literature 
reference for the use of Solid-phase extraction is to be found in the Bible even if 
the users were unaware of the science behind it.  However the first modern use of 
SPE probably employed animal charcoal to remove pigments from chemical 
reaction mixtures. In such cases the charcoal was filtered out of the mixture and 
discarded along with the compounds it had absorbed, Our goal, however, is not to 
discard compounds of interest but to collect them  preferably by concentrating them 
from a  sample and removing those compounds we do not wish to analyse.  In this 
sense SPE did not really become a scientific technique until the 1970s. Recently 
many developments in SPE technology have taken place including new formats 
(e.g. discs, pipette tips and 96-well plates), new sorbents (e.g. silica or polymer-
based media and mixed-mode (Dean, 2010), and the development of automated 
and on-line systems (Mondello et al., 2002). Growth of SPE applications is directly 
attributable to the automation, high-throughput capability and the ease of use of 
SPE products.  
5.1.2.2 Definition 
Solid phase extraction is a physical extraction process that involves a liquid and a 
solid phase. The solid phase has a greater attraction for the isolate than the solvent 
in which the isolate is dissolved. As the sample solution passes through the 
sorbent bed, the isolate concentrates on this surface, while the other sample 
components pass through the bed (Camel, 2003). The selection of an appropriate 
SPE extraction sorbent depends on understanding the mechanism(s) of interaction 
between the sorbent and analyte of interest. That understanding in turn depends 
on knowledge of the hydrophobic, polar and ionogenic properties of both the solute 
and the sorbent. The most common retention mechanisms in SPE are based on 
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van der Waals forces, hydrogen bonding, dipole-dipole forces and cation-anion 
interactions (Żwir-Ferenc and Biziuk, 2006). Very selective extractions resulting in 
highly purified and concentrated isolates can be achieved by choosing sorbents 
with an attraction for the isolate but not for the other sample components. 
Generally SPE sorbents can be divided into three classes, i.e. normal phase, 
reversed phase and ion exchange. The most common sorbents are based on silica 
particles (irregular shaped particles with a particle diameter between 30 and 60 
µm) to which functional groups are bonded to surface silanol groups to alter their 
retentive properties. A variety of different bonded silica are commercially available, 
offering a wide range of selective properties for extraction. In addition to silica some 
other common sorbents are based on florisil, alumina and macroreticular polymers. 
 
Normal phase sorbents have polar functional groups e.g. unmodified silica cyano, 
amino and diol. The polar nature of these sorbents means that it is more likely that 
polar compounds, e.g. phenol, will be retained. In contrast, reversed phase 
sorbents have non-polar functional groups, e.g. octadecyl, octyl and methyl, and 
conversely are more likely to retain non-polar compounds, e.g. polycyclic aromatic 
hydrocarbons. Ion exchange sorbents have either cationic or anionic functional 
groups and when in the ionized form attract compounds of the opposite charge.  
 
5.1.2.3 Basic Steps 
Each of the steps shown can be controlled: the sorbent type can be selected; the 
sample can be manipulated to enhance retention of one chemical species over 
another; an elution liquid that has properties that are not just desirable to the 
compound of interest, but which may be convenient for your method of analysis or 
for subsequent sample handling can be selected; any number of wash steps can 
be used.  
 
Pretreatment 
Some samples require initial pretreatment to obtain the optimal extraction. This 
pretreatment can include homogenization of solid samples, adjustment of the 
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matrix to the proper ionic strength and pH, and removal of particulates via filtration 
or centrifugation. This step may also include addition of an internal standard. 
 
Column Conditioning 
Sorbent activation and functional group activation are achieved by passing a 
volume of an appropriate solvent or a mixture of solvent, through the column. 
Methanol or acetonitrile are commonly used for activating hydrophobic sorbents, 
while hexane or dichloromethane activate hydrophilic sorbents.  
 
Sample Loading 
To get a maximum purification efficiency, the sample flow needs to be controlled 
via vacuum or pressure. To achieve faster flow of viscous sample through a 
column, larger particle size can be used. The exchange capacity and selectivity are 
unaffected. 
 
Retention 
When the compound of interest distributes between the liquid sample and the solid 
surface, either by simple adsorption to the surface or through penetration of the 
outer layer of molecules on that surface, an equilibrium is set up.  We can define 
that distribution by a coefficient, K, which indicates what fraction of the analyte has 
remained in solution and what fraction has adsorbed on or entered the solid phase. 
This distribution coefficient should be defined in terms of activities of the analyte in 
either phase. However, for convenience concentrations are used and therefore If 
this process occurs in a column packed with a sorbent into whose outer layer the 
compound distributes, then we are dealing with a system that is no longer a "batch" 
partition such as liquid-liquid extraction LLE. Instead the process more closely 
parallels distillation as the compound is entirely trapped on this solid surface and 
therefore, the distribution coefficient will be very large (Żwir-Ferenc and Biziuk, 
2006).  
 
Elution 
When a liquid provides a more desirable environment for the analyte than the solid 
phase does, then the compound of interest is desorbed and can be collected in the 
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liquid as it exits the SPE device. This is called “elution”. It is characterized by a 
distribution coefficient, K value that is very small. One way to view the solid phase 
is as an intermediary between the sample and the elution solvent and this 
highlights a very important difference between LLE and SPE. An elution solvent 
may be used which is miscible with the sample in a solid-phase extraction, because 
the elution solvent and the sample never come into direct contact. Thus, our 
sample may be aqueous but our SPE elution solvent may be methanol, which is 
miscible in all proportions with water. Such a scheme is not possible in a LLE (Żwir-
Ferenc and Biziuk, 2006). 
 
The choice of solvent directly influences the retention of the compound on the 
sorbent and its subsequent elution, whereas the solvent polarity determines the 
solvent strength (or ability to elute the compound from the sorbent in a smaller 
volume than a weaker solvent). The solvent strengths for normal phase and 
reversed phase sorbents are shown in Table (5.1). Obviously this is the ideal. In 
some situations it may be that no individual solvent will perform its function 
adequately and so it is necessary to resort to mixed solvent systems. It should also 
be noted that for a normal phase solvent, both solvent polarity and solvent strength 
are coincident whereas this is not the case for a reversed phase sorbent. In 
practice, however, the solvents normally used for reversed phase sorbents are 
restricted to water, methanol, isopropyl alcohol and acetonitrile. For ion exchange 
sorbents, solvent strength is not the main effect (Dean, 2010). 
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Table 5.1 
Solvent strengths for normal and reversed phase sorbents (Dean, 1998). 
Solvent strength 
normal  phase 
 Solvent strength 
Reversed phase 
Weakest 
 
 
 
 
 
 
 
 
 
 
 
Strongest 
Hexane 
Iso-octane 
Toluene 
Chloroform 
Dichloromethane 
Tetrahydrofuran 
Ethyl ether 
Ethyl acetate 
Acetone 
Acetonitrile 
Isopropyl alcohol 
Methanol 
Water 
Strongest 
 
 
 
 
 
 
 
 
 
 
 
Weakest 
 
 
Rinsing or Washing 
During the retention step, many compounds in our complex sample may have been 
retained on the solid surface at the same time as our compound of interest. 
Likewise, at elution it is likely that some of these co-retained compounds will be 
eluted with our compound of interest. To minimize the interferences these 
undesirable compounds will create during the analysis stage, we may add one or 
more wash steps between retention and elution, to attempt to remove or rinse them 
out. Each wash step involves another distribution between the analyte and the co-
retained species, the solid surface and the liquid that is passing over it. Each step 
can be controlled by careful selection of the sample loading, wash, and elution 
conditions. 
5.1.2.4 Solid phase extraction objectives 
Concentration 
In order to be able to measure the quantity of a compound accurately it must be 
concentrated as much as possible. This will ensure the largest response from our 
detection system and will minimize errors in precision caused by background noise.  
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Clean-Up  
Components of the sample that mask the analyte during the analysis (for example, 
when two or more compounds co-elute in a chromatographic experiment such as 
gas or liquid chromatography), sample preparation permits removal of such 
interferences before the analytical separation The cleaned-up extract gives clearly 
identifiable signals from the extracted components in the sample. Such a 
chromatogram is readily interpreted and the quantities of desired analytes present 
in that sample are easily measured.  
 
Sample matrix removal/solvent exchange 
Many analytical instruments (e.g. gas or liquid chromatographs, nuclear magnetic 
resonance or infrared spectrometers) require that the sample to be analyzed is in a 
specific environment. In such cases, you will need to remove the sample matrix, 
and convert your sample into a form compatible with the instrument to be used. A 
significant advantage of SPE over LLE is that solvents that are miscible with the 
sample matrix, may be used to elute the analytes. The corresponding LLE 
commonly leaves the analytes in a water-immiscible solvent that must be dried 
down and the residue reconstituted in a suitable solvent before analysis may begin. 
 
5.1.2.5 SPE and essential oils 
Essential oils are characterized by a very complex mixture (Lawrence, 1997)  
whose components belong to different classes of compounds, including 
hydrocarbons, aldehydes, ketones, esters, alcohols, that range widely in 
concentration and variability among different plant species. They contain a variety 
of volatile molecules such as terpenes and terpenoids, phenol-derived aromatic 
components and aliphatic components (Bakkali et al., 2008). Several techniques 
can be used to extract essential oils from different parts of the aromatic plant, 
including water or steam distillation, solvent extraction, expression under pressure, 
supercritical fluid and subcritical water extractions (Edris, 2007).  
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5.1.2.6 SPE of A. citrodora EO 
Many methods of essential oil fractionation have been reported in literature. Some 
of them are time and solvent consuming since they use large volumes of solvents 
(David 1987). Others are very attractive, but need a highly technological approach 
such as multidimensional gas chromatography (Mazza 1986). 
 
This project approach is to fractionate the essential oil prior to analysis. The 
fractionation process will increase the concentration of the components and 
consequently ease the analysis. This Chapter reports a simple, inexpensive 
method that uses silica SPE to carry out a fractionation. Two different essential oils 
will be analysed, validated and fractionated. 
 
5.1.3 Structure based Virtual Screening of A. citrodora EO 
constituents for anticholinesterase inhibitors 
5.1.3.1 Introduction 
The need for a rapid search for small molecules that may bind to targets of 
biological interest is of crucial importance in the drug discovery process. One way 
of achieving this is the in silico or virtual screening of large compound databases to 
identify a set of compounds that contain relatively many hits against the target, if a 
three-dimensional (3D) model of the target is available, then structure-based virtual 
screening can be done, utilizing a docking program. The docking program places a 
3D structure in all available positions, conformations and orientations of each 
molecule from the screened data set into the target structure (the active site of an 
enzyme for instance).  Each such docking mode is called a ‘pose’.  In order to 
identify the most energetically favourable pose, a good score for a molecule 
indicates potentially a good binding between the molecule and the target. All 
molecules in the data set are ranked according by their scores; top ranking 
molecules then can undergo further testing as they are predicted to be most active 
(Schneider et al., 2000). High-throughput virtual screening has become 
increasingly important in the context of drug discovery (Schneider and Böhm, 
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2002). Despite its many challenges the use of virtual screening has produced 
higher hit rates compared to random screening (Trosset et al., 2006).  
 
5.1.3.2 Receptor modelling 
To perform a structure-based virtual screening it is necessary to have the structure 
of the receptor of interest. Usually this structure is determined by experimental 
techniques such as X-ray crystallography.  If the binding site and the function of the 
receptor is known or if the protein has been co-crystallized with a ligand, an 
analysis of the binding-site characteristics and interactions with the ligand can lead 
to important insights for the design or the docking of ligand molecules (Sotriffer and 
Klebe, 2002, Bitetti-Putzer et al., 2001). 
 
5.1.3.3 Searching and pose prediction 
Searching for the binding mode with highest score of any molecule is done by 
trying a number poses then keeping only energetically preferred poses. That 
means finding the correct orientation of the molecule in the active site, in addition, if 
the molecule is flexible the degrees of freedom include translational and rotational 
degrees of freedom of the ligand as a whole need to be searched. 
 
5.1.3.4 Scoring 
Many of the scoring functions fall into one of two main groups. One main group 
comprises knowledge-based scoring functions that are derived using statistics for 
the observed interatomic contact frequencies and/or distances in a large database 
of crystal structures of protein–ligand complexes (Gohlke et al., 2000). 
 
The other group is scoring energy component methods based on physical 
interaction terms (Gohlke and Klebe, 2001). These methods are based on the 
assumption that the change in free energy upon binding of a ligand to its target can 
be decomposed into a sum of individual contributions. Although this is an 
approximations, these methods are very appealing as these simplifications result in 
functions that can be evaluated very rapidly, using regression-based methods, 
which assume often linear statistical relationship between the total free-energy 
change upon binding and a number of terms that characterize the binding event 
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such as hydrogen bonds and ion pairs, the amount of buried and contact surface, 
and molecular flexibility of the ligands. A training set of crystal structures of ligand-
protein complexes and associated binding affinity data is used to optimize the 
coefficients of the regression equation. Many popular scoring functions have been 
derived this way including the one we are using in this study: GOLD score. GOLD 
is based on a genetic algorithm that mimics the process of evolution by applying 
genetic operators to a collection of poses for a given ligand called a population of 
chromosomes (GA). GOLD chromosomes contain conformational information of 
the flexible parts of the protein (OH of Ser, Thr and Tyr as well as lysine NH3+) and 
of the ligand, as well as hydrogen bonds and lipophilic interactions. Chromosome 
decoding yields the corresponding 3D pose for the ligand, which is followed by a 
least-square (LS) fitting procedure (Bartolini et al., 2003), with the objective to 
maximize the overlap between ligand and receptor features. The energy of the 
resulting pose (fitness) consists of three terms: (1) hydrogen-bonding energy, (2) 
internal energy of the ligand, and (3) steric interaction energy. The population of 
chromosomes evolves through sequential application of genetic operations. Newly 
generated chromosomes are decoded, the fitness of the corresponding pose 
evaluated, and the chromosome is kept if it is fitter than the least-fit chromosome in 
the pool. After the application of a predefined number of genetic operations, the 
algorithm terminates, and the poses with the highest scores are saved (Jones et 
al., 1997).  
 
5.1.3.5 Acetylcholinesterase (AChE) 
AChE, one of the most essential enzymes in the family of serine hydrolases, 
catalyzes the hydrolysis of neurotransmitter acetylcholine, which plays a key role in 
memory and cognition. The physiological role of the AChE in neural transmission 
has been well known, however the role of AChE in neurodegenerative disease has 
been renewed owing to the evidences that support the role of this enzyme in 
accelerating the aggregation and deposition of the β-amyloid peptide (see chapter 
2). 
 
The binding pocket of AChE is a long and narrow region which consists of 2 
separated ligand binding sites: the catalytic (central) site and the peripheral anionic 
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site (Raves et al., 1997, Kryger et al., 1999, Harel et al., 1996). The catalytic site is 
the binding site of classical AChE inhibitors, such as tacrine and huperzine A, 
which has been studied thoroughly. On the contrary, the function of the peripheral 
site has not been elucidated clearly as yet. Recent studies have demonstrated that 
the peripheral site might accelerate the aggregation and deposition of beta-amyloid 
peptide, which is considered as another cause of AD (McLaurin et al., 2000, 
Bartolini et al., 2003). Therefore, it is supposed that an ideal AChE inhibitor should 
bind to the catalytic and peripheral sites simultaneously, which could disrupt the 
interactions between the enzyme and the beta amyloid peptide, and hence slow 
down the progression of the disease (Munoz-Muriedas et al., 2004, Du and Carlier, 
2004). 
 
In order to further elucidate the mechanism of A. citrodora component on the 
enzyme and provide hints for a new derivative design, molecular docking and 
three-dimensional quantitative structure molecular docking studies were carried 
out, this virtual screening approach, was used to identify novel AChE inhibitors with 
high selectivity. The potential hit compounds obtained from this study can be 
further evaluated by in vitro and in vivo tests.  
  
Chapter 5 
 
91 
 
5.2 Materials and Methods 
5.2.1 Plant Material 
Fresh leaves of A. citrodora were collected from University of Jordan Faculty of 
Agriculture Botanic garden, spring 2011, when growth rate was maximal. The plant 
was authenticated by Professor Suleiman Al-Olimat from the Faculty of Pharmacy, 
University of Jordan, where the voucher specimen (herbarium number AC-V1) is 
kept. Leaves were dried carefully in the shade at room temperature and then 
homogenized to fine powder and stored in air within tight bottles. 
 
5.2.2 Essential Oils Preparation 
500g of dried leaves of A. citrodora were hydro-distilled with one Litre of water 
using a Clevenger-type apparatus (JSOW, India) for 3 hours. Essential oils 
obtained were dried with anhydrous sodium sulphate and stored at 4°C in amber 
glass vials until analysis. For all experiments, dilutions of pure Essential oils stock 
was performed fresh on the day of the assay. 
 
5.2.3 Solid Phase Fractionation System 
Agilent 971-FP Flash Purification System (Agilent, www.varianinc.com) was used 
for SPE of the essential oils. 100 µL of the essential oils was loaded onto a 4 g 
silica cartridge (SF10-4g) that is conditioned with pentane. The elution of the SPE 
cartridge was performed using a vacuum manifold at a velocity of 3 ml/sec using 
the following solvent sequence: Fraction I: pentane100%. Fraction II: pentane/ethyl 
ether 90:10. - Fraction III: ethyl ether 100%. 
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Fig 5.1  
Agilent 971-FP Flash Purification System.  
 
 
 
Fig 5.2 
Agilent silica cartridge (SF10-4g) 
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Solid Phase Extraction System 971-FP Flash Purification System (Agilent - Dr Mike 
Carroll, University of Newcastle) was used for SPE of the A. citrodora EO. 971-FP 
is a high throughput, high recovery system for sample purification. It allows the 
setting up of multiple solvent systems for continuous availability without interrupting 
fractionation procedure and equipped with Low Pulse Pump which provides an 
even solvent flow. 100 µL of the essential oils was loaded on to a 4 g silica 
cartridge. The number of active sites available on the sorbent cannot be exceeded 
by the number of molecules of compound or otherwise breakthrough will occur. 
Therefore, 4 g silica cartridge (SF10-4g) was chosen for 100 µL of essential oil the 
silica cartridge had previously been conditioned with pentane.  Wetting and 
conditioning the sorbent allows alkyl chains, on the surface of the silica, to be 
solvated to ensure good contact between the sample and the sorbent preventing 
poor recoveries. Silica sorbent is stable within a pH range of approximately 2 to 7.5 
and is chemically stable to virtually all organic solvents.  The elution of the SPE 
cartridge was performed using a vacuum manifold at a velocity of 3 ml/sec.  The 
flow rate of the sample through the sorbent is important; excessively rapid flow will 
allow minimal time for the compound–sorbent interaction. This must be carefully 
balanced against the need to pass the entire sample through the cartridge. 
The following solvent sequence was adopted: Fraction I: pentane - 100%. Fraction 
II: pentane/ethyl ether - 90:10. Fraction III: ethyl ether - 100%. 
 
5.2.4 Gas Chromatography-Mass Spectrometry (GC-MS) Analysis 
The GC–MS analyses were performed using Agilent 7890Agas chromatogram 
coupled to Agilent 5975C mass spectrometer (Agilent – Dr Melanie-Jayne Howes. 
Royal Botanic Gardens). Chromatography was performed on Column: DB-5MS, 30 
m x 0.25 mm I.D., 0.25 µm (J. & W. Scientific, USA) using a temperature program 
of 40–300°C at a rate of 3°C min-1. The carrier gas was helium at a flow rate of 1 
ml min-1 and the injection volume was 1 µL (split 1:10) at 220°C, via an 
autosampler. Detection was carried out by MS, fitted with electrospray ionization 
(EI) source operated at 70 eV, with a source temperature of 180°C; mass spectra 
were recorded in the 38–600m/z range.  The A. citrodora oils were diluted to 1.0% 
(v/v) with diethyl ether (GLC pesticide residue grade, Fisher Scientific, UK) prior to 
analysis. Retention indices (RIs) were determined in relation to a series of n-
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alkanes (C10–C16, Supelco, UK) and compounds were identified by comparing the 
RIs and mass spectra with published data. Percentage compositions of detected 
compounds were calculated by integrating all peaks in total ion chromatograms. 
 
 
5.2.5 Virtual screening for Anticholinesterase Inhibitors 
The crystal structure of human AChE (PDB:4EY7) was used in the study (Fig 5.3).  
A centre was established around the determined binding site. 15Å radius was 
chosen to form the search space. Default settings for small molecule-protein 
docking were used throughout the simulations. The structure of human AChE 
(PDB:4EY7)  in complex with donepezil is depicted as a ribbon diagram in (Fig 5.4).  
 
Molecular docking GOLD version 3.0.1 (Cambridge Crystallographic Data Centre, 
Cambridge, UK) was employed to investigate the binding mode.  The default 
parameters of genetic algorithms (GA) were applied to search a reasonable binding 
conformation of the flexible ligands.  The maximum number of GA runs was set to 
10 for each compound. (ChemPLP) scoring function was used to evaluate the 
docking conformations. (ChemPLP) is the default scoring function in GOLD and on 
the whole was the best performing scoring function at both pose prediction and 
virtual screening. Docked conformations were saved in MOL2 format and then 
imported into Hermes for further analysis. The donepezil pose derived from GOLD 
was used as the reference compound for alignment. In order to consider the 
influence of crystallized water molecules on docking, donepezil was docked into 
the binding pocket with and without water molecules, separately docking 
conformations of donepezil superimposed with the X-ray crystal structure very well, 
which indicated that the co crystallized water had little impact on docking. 
 
Eighty eight (88) AChE inhibitors in this study (including donepezil, galantamine, 
huperzine, rivastigmine and tacrine) were taken from (Lu et al., 2011), all of which 
were reported by the same laboratory which employed similar experimental 
conditions and procedures to obtain bioactivity data for the compounds. The in vitro 
bioactivities of the collected inhibitors were expressed as the concentration of the 
test compounds that inhibited the activity of AChE by 50% (IC50) and listed in 
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Appendix I. The 3D chemical structures of these acetylcholinesterase inhibitors 
were sketched using ChemBioDraw Ultra (Ver12.0.2.1076 Cambridge Soft Corp., 
Cambridge, MA) then saved in .mol file formats. These were considered the 
training set. All chemical constituents of A. citrodora EO (Appendix II) were 
sketched using ChemBioDraw Ultra (Ver12.0.2.1076 Cambridge Soft Corp., 
Cambridge, MA) and saved in .mol file format as well.  Each compound was tested 
for 10 genetic algorithm runs, producing 10 different poses for each compound, 
with the top 5 conformations saved for analysis. The optimal docking protocol and 
scoring function (CHEMPLP) was chosen and the output options created sub 
directories for each ligand conformation docked in order of best fit. 
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Fig 5.3 
Structure of human AChE depicted as a ribbon diagram. The two independent molecules in 
the asymmetric unit of the crystal are green and blue (PDB:4EY7). 
 
 
Fig 5.4 
The structure of AChE in complex with donepezil (PDB:4EY7) is depicted as a ribbon 
diagram. The two independent molecules A and B in the asymmetric unit of the crystal are 
coloured yellow and red respectively. Bound donepezil is shown in stick representation and 
coloured black. Protein Glycosylation is shown as sticks. Arrows depict the entrance of the 
active site gorge in the physiological dimer (Cheung et al., 2012). 
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5.3 Results 
5.3.1 GC/MS Analysis of A. citrodora EO 
The chemical compositions of the EOs from A. citrodora collected from Jordan are 
summarized in (Table 5.2) Eighty three compounds were identified. The chemical 
composition of the essential oil in the order of retention time is listed in Appendix II.  
 
 
Table 5.2 (GC/MS) analysis of A. citrodora fresh and dry essential oil: Percentage 
composition of top main constituents. 
Compound Chemical structure Fresh Dry 
Limonene 
 
13.6% 20.1% 
Caryophyllene oxide 
 
2.2% 8.4% 
Curcumene 
 
3.5% 6.3% 
Spathulenol 
 
3.1% 5.0% 
1,8-Cineole 
 
9.2% 9.4% 
Geranial 
 
20.1% 6.3% 
Neral 
 
15.1% 3.7% 
α-Terpineol   
 
3.6% 3.6% 
6-Methyl-5-hepten- 2-one    1.5% 3.4% 
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5.3.2 Solid Phase Extraction of A. citrodora EO Constituents 
Solid phase extraction was performed using the following conditions: 
Sample: A. citrodra essential oil 
Sorbent: 4 g silica cartridge (SF10-4g) 
Conditioning: The cartridge was conditioned with 5 ml pentane 
Loading: 100 µL of A. citrodra essential oil was loaded onto the cartridge. 
Elution:  
Flow rate of 1 ml/sec. 
- Fraction I: pentane100%. 
- Fraction II: pentane/ethyl ether 90:10. 
- Fraction III: ethyl ether 100%. 
Percent composition of A. citrodora EO and its fractionation are shown in Appendix 
III. Fraction I contained only hydrocarbons; fraction II carbonyl compounds, ethers, 
esters and tertiary alcohols; Fraction III primary alcohols, acids and diols. The 
recoveries were satisfactory for almost all analytes. Table 5.3 shows an example of 
the eluted compounds in each fraction. 
 
Table 5.3 Examples of the compounds found in each SPE fractions  
Fraction I 
  
Fraction II 
 
Fraction III 
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5.3.3 Structure based virtual screening of A. citrodora EO 
constituents for anticholinesterase inhibitors 
The top scoring hits from A. citrodora EO constituents were imported to Hermes 
software to view crystal structures with docked ligands (Fig 5.8 to 5.14). The scores 
of these top hits had values comparable to those possessed by optimal 
conformations of huperzine, rivastigmine, donepezil and galantamine in the active 
site.  
 
 
 Fig 5.5 
Structure of human AChE. 15Å radius from centre of the binding site from AChE 
(PDB:4EY7) with docked donepezil was defined as the search space shown in Blue, 
done by GOLD Molecular docking version 3.0.1. 
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Fig 5.6  
A magnification of the defined 15Å radius search space with donepezil docked: A 
space fill model. GOLD Molecular docking version 3.0.1 
 
Figure 5.7 
Close up views of the AChE active site with bound a) huperzine A, b) galantamine, 
and c) donepezil. Carbons are in pink in the ligands and light yellow in residues of 
the complex (Cheung et al., 2012). 
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Fig 5.8 
1st Ranked Hit: Close up views of the rhAChE active site with bound β-Curcumene, 
(carbon atoms in green) showing Ligand-Protein interactions points (yellow) at TYR 341, 
TYR337, HIS 447, β-Curcumene have the highest hit score of PLP 75.64 
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Fig 5.9  
2nd Ranked Hit: Close up views of the rhAChE active site with bound Curcumene, 
(carbon atoms in green) showing Ligand-Protein interactions points (yellow) at TYR 341, 
TYR 337, PHE 338. 
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Fig 5.10 
3rd Ranked Hit: Close up views of the rhAChE active site with bound Bisabolene (carbon 
atoms in green) showing Ligand-Protein interactions points (yellow) at TYR 341, TYR 337, 
TRP 286, PHE 338 and VAL 294. 
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Fig 5.11 
4th Ranked Hit: Close up views of the rhAChE active site with bound β-
Sesquiphellandrene (carbon atoms in green) showing Ligand-Protein interactions points 
(yellow) at TYR 341, PHE 338, VAL 294. 
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Fig 5.12 
5th Ranked Hit: Close up views of the rhAChE active site with bound Geranyl Acetate 
(Carbon atoms shown in green, Oxygen atoms in red) showing Ligand-Protein interactions 
points (yellow) at TYR 341, PHE 338, PHE 295, HIS 447. 
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Fig 5.13 
6th Ranked Hit: Close up views of the rhAChE active site with bound trans-Calamenene, 
(Carbon atoms in green) showing Ligand-Protein interactions points (yellow) at TYR 341, 
TYR337, PHE338, HIS 447, TRP86, and ASP74. 
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Fig 5.14 
7nd Ranked Hit: Close up views of the rhAChE active site with bound Caryophyllene 
oxide (Carbon atoms shown in green, Oxygen atoms in red) showing Ligand-Protein 
interactions points (yellow) at TYR 341, TYR337, TYR124 HIS 447. 
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5.4 Discussion 
5.4.1 Gas Chromatography-Mass Spectrometry (GC-MS) analysis 
The chemical composition of the essential oil from leaves of A. citrodora of 
Jordanian origin is listed in appendix II, Eighty three (83) chemicals were identified. 
The essential oil was characterized by the presence of terpenoids, monoterpenes 
and sesquiterpenes, and 6-methyl-5-hepten-2-one, the main constituents were 
Limonene (12.14%)   Caryophyllene oxide (10.44 %), Curcumene (9.17 %), 
Spathulenol (7.16 %), 1,8-Cineole (7.94%), all of which constitute 47% of the total 
oil (Table 5.1),  followed by  Geranial (4.03 %) and  Neral (2.55%), α-Terpineol  
(3.27%) and 6-Methyl-5-hepten- 2-one  (2.37%) (Table 5.2). These results are in 
agreement with the literature (Montes et al., 1973, Kaiser and Lamparsky, 1976, 
Velasco-Negueruela et al., 1993, Bellakhdar et al., 1994, Zygadlo et al., 1994, 
Özek et al., 1996, Terblanché and Kornelius, 1996, Carnat et al., 1999, Pascual et 
al., 2001, Crabas et al., 2003, Kim and Lee, 2004, Sartoratto et al., 2004, Santos-
Gomes et al., 2005, Argyropoulou et al., 2007)  The oil was devoid of compounds 
from the phenylpropanoid pathway (Crabas et al., 2003, Santos-Gomes et al., 
2005). 
 
Limonene is the component most abundant in essential oils of the genus Lippia, 
followed by p-cymene, a-pinene, camphor, b-caryophyllene, linalool and thymol in 
a decreasing order (Pascual et al., 2001, Terblanché and Kornelius, 1996) and 21 
(Kim and Lee, 2004, Zygadlo et al., 1994). In our study, -pinene, β-caryophyllene 
and linalool, p-cymene, and thymol were also identified at low levels. A. citrodora is 
characterized by high contents of monoterpenes and sesquiterpenes. Terpenoids 
comprise a very large group of natural products and comprise two or more 
branched 5 carbon units, formed from mevalonic acid. Skeletons consisting of 
multiplets of 2, 3, 4 or 6 of these linked together in many different ways are found in 
a variety of mostly cyclic compounds including monoterpenes (10 carbons in the 
skeleton), sesquiterpenes (15 carbons), diterpenes (20 carbons) and triterpenoids 
(30 carbons), respectively. These compounds tend to be lipophilic, so they are able 
to cross the blood-brain barrier. Also, monoterpenes, and some of the 
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sesquiterpenes, are volatile, and are responsible for the strong odours and flavours 
of many herbs, spices and traditional medicines.    
 
It should be emphasized that a variety of geographical and ecological factors can 
lead to qualitative and quantitative differences in the essential oil produced. A 
number of other factors can influence its composition, such as the developmental 
stage of the plant, its physiology, the age of leaves and the growing conditions 
(Bellakhdar et al., 1994, Zygadlo et al., 1994, Santos-Gomes et al., 2005). The 
composition of the oil is also affected by the isolation method and the conditions of 
analysis (Crabas et al., 2003, Kim and Lee, 2004, Sartoratto et al., 2004, Santos-
Gomes et al., 2005). 
 
5.4.2 Solid Phase Extraction 
Although SPE is a well-established sample preparation technique with broad 
applications base, only a small number of studies have utilized SPE for the 
fractionation of essential oils. (Antonelli and Fabbri, 1999) used SPE for the 
fractionation of tarragon (Artemisia dracunculus) and rose (Rosa damascena) 
essential oils, (500 mg / 3 mL silica cartridge that had previously been conditioned 
with 3 mL of pentane) using the following solvent sequence: Fraction A: 3 mL of 
pentane; Fraction B: 6 mL of pentane/ethyl ether 90:10; Fraction C: 3 mL of ethyl 
ether. Essential oil components were pre-separated into three fractions with 90 % 
mean recovery of the analytes.  Fraction A contained hydrocarbons; B, contained 
esters, ethers, oxides, carbonyl compounds and tertiary alcohols; and C, which 
contained other alcohols, acids and diols. (Dawidowicz and Dybowski, 2010) used 
a SPE column packed with octadecyl silica sorbent to separate oxygenated 
compounds with low molecular mass from the rest of the essential oil components 
using 68% methanol. Oxygenated compounds of low molecular mass occurring in 
essential oils of Salvia officinalis, Artemisia absinthium, Artemisia vulgaris, and 
Thuja occidentalis completely eluted from the SPE column using this method. The 
average recovery of these compounds in methanolic fraction was almost 100%, 
whereas the average recovery of the remaining essential oil compounds were all 
above 90% and satisfactory for preliminary separation of essential oils for analytical 
and preparative purposes.  
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The solid Phase Extraction System 971-FP Flash Purification System (Agilent) was 
used for SPE of the A. citrodora EO. The system allows the establishment of 
multiple solvent systems for continuous availability without interrupting the 
fractionation procedure and is equipped with Low Pulse Pump which provides an 
even solvent flow. 4 g silica cartridge (SF10-4g) was chosen for 100 µl of essential 
oil for normal phase SPE where the sorption of the functional groups of the 
compound from a non-polar solvent to the polar surface of the stationary phase. 
The mechanism of sorption involves polar interactions such as hydrogen bonding, 
dipole–dipole interactions, π–π interactions and induced dipole–dipole interactions.  
 
To achieve retention, the interaction between the solute and the stationary phase 
must dominate. Fraction I contained all hydrocarbons; fraction II carbonyl 
compounds, ethers, esters and tertiary alcohols; Fraction II primary alcohols, acids 
and diols. The recoveries were satisfactory for almost all the analytes. This method 
was successful in fractionating the essential oil into three distinct fractions in one 
simple step easily, quickly and using small amounts of organic solvents.  
 
To test whether the SPE developed for A. citrodora EO is also useful for the 
fractionation of essential oils from other plants containing the same or similar main 
components. The same protocol was applied for the fractionation of the Lavender 
(Lavandula angustifolia Mill.) EO. The method was equally successful in 
fractionating lavender essential oil into three fractions with more than 90% recovery 
(Appendix VI) opening the way for the possibility of using this method for other 
essential oils and for utilizing SPE for comparing between different essential oils 
specific fractions.  
 
SPE will allow fractions of the essential oil with close chemical moieties to be 
tested in vivo and in vitro for beneficial properties in neurodegenerative diseases, 
and results can be compared with whole essential oil, to uncover what part of the 
oil hold the active components and if there are any synergistic, anti-synergistic or 
masking effects among different essential oil constituents. This will make it easier 
to characterize the molecules responsible for any beneficial activity. 
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5.4.3 Virtual Screening for Anticholinesterase Inhibitors 
Acetylcholinesterase (EC 3.1.1.7) belongs to carboxyl esterase family of enzymes. 
It is a serine protease that hydrolyses the neurotransmitter ACh with high catalytic 
activity (Lewis et al., 2002). AChE can be found mainly at neuromuscular junctions 
and cholinergic brain synapses, where its activity serves to terminate synaptic 
transmission. X-ray structures of AChE co-crystallized with various ligands provide 
insights into the essential structural elements essential to its catalytic mechanism. 
The active site of AChE comprises of 2 sub sites: the anionic site and the esteratic 
sub site (Greenblatt et al., 1999). The anionic sub site accommodates the positive 
quaternary amine of ACh, however, the cationic moieties of different substrates are 
not bound by a negatively-charged amino acid in the enzymatic anionic site, but 
rather by interaction with 14 aromatic residues that line the gorge leading to the 
active site (Inestrosa et al., 2008). Crystal structure analysis showed that the active 
site of AChE enzyme spans a gorge about 20 Å in length which is lined by 14 
aromatics residues, and is conserved across different species. The function of the 
AChE enzyme is mainly controlled by tryptophan residues (Gupta et al., 2011). 
 
Many essential oils and their monoterpene constituents have been investigated for 
their effects on AChE, For example, the essential oils from Melissa officinalis and 
Rosmarinus officinalis have been reported to inhibit erythrocyte AChE in vitro 
(Perry et al., 1996). However these monoterpene AChE inhibitors were weak 
compared with the anti-AChE alkaloid like physostigmine (Perry et al., 2000). Of 
the essential oil constituents from different medicinal plants 1,8-cineole and 
camphor have shown activity against human erythrocyte AChE (Adewusi et al., 
2010). -terpinene, and -pinene; geraniol and linalool were also found to be weak 
inhibitors of human erythrocyte AChE (Miyazawa et al., 1997, Perry et al., 2000). 
Other monoterpenes that are reported to inhibit AChE include citral, bornyl acetate, 
geraniol and limonene, which are inhibitors of electric eel AChE as well (Ryan and 
Byrne, 1988).  
 
Monoterpenes consist of a hydrocarbon skeleton which may contribute to their anti-
AChE activity. The hydrophobic active site of AChE is reported to be susceptible to 
hydrophobic interactions (Hansch and Deutsch, 1966). Monoterpenes may be 
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cyclic (e.g. 1,8-cineole and -pinene) or acyclic (e.g. geraniol and linalool), a 
feature that may also influence anti-AChE activity.  This structural diversity of the 
active anti-AChE terpenoids some of which bear no obvious resemblance to ACh 
complicates the prediction of potential structure activity relationships. 
 
Most crystallographic studies of AChE involve the electric ray (Torpedo californica) 
homologues. Although there are 100 AChE structures deposited in the Protein 
Data Bank, only five human AChE structures of the catalytic core have been solved 
to date. Donepezil binds to rhAChE in a significantly different conformation than it 
does to Torpedo californica AChE (tAChE) thus exemplifying how the human 
enzyme is more accurate for the study of drug binding (Cheung et al., 2012). 
 
This study was able to use a recombinant human form of the enzyme at a 
resolution of 2.15 Å representing a good platform for structure-based ligand 
modelling and docking. Top 7 scoring hits showed high similarities in the protein 
residues with which they interact both amongst themselves, and known inhibitors 
like Huperzine A and Donepezil (Table 5.4). The most common interactions were 
with TYR 341 + 337, PHE 338 and HIS 447 respectively. The majority of these 
interactions are manifested in hydrogen bonding, hydrophobic and π-π 
interactions.   
 
Hydrogen bonds, and strong hydrophobic interactions formed between the 
inhibitors and the nearby AChE side chains serve dual roles: 1) to inhibit the 
catalytic activity of AChE by competing with ACh binding site and 2) to prevent 
amyloid fibrillogenesis by blocking the Ab recognition zone at the peripheral site. 
Potential clinical relevance of these compounds requires further investigation. 
Considering the relatively weak anti-AChE activity of terpenoids reported to date, it 
is unlikely that they may be used therapeutically for cognitive disorders. However, 
analogues of active terpenoid compounds may be developed to enhance efficacy. 
And these findings indicate that plants may yield novel AChE inhibitors, other than 
alkaloids, which may have advantages in relation to efficacy and adverse-effect 
profile. 
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Table 5.4 
Ligand-Protein interactions between top hits compounds and AChE active site 
 
 
In light of the knowledge gained from the observations of the interactions between 
AChE and potential inhibitors, it can be seen that the combination of molecular 
docking, and virtual screening efforts is a promising strategy for discovering more 
effective inhibitory compounds from essential oils that will impact future 
experimental studies on these constituents. 
 TYR 
133 
TYR 
337 
TYR 
341 
TYR 
124 
TRP 
86 
TRP 
286 
PHE 
338 
PHE 
295 
HIS 
447 
VAL 
294 
ASP 
74 
Huperzine A X X          
Donepezil  X X  X X      
β-Curcumene  X X      X   
Curcumene  X X    X     
Bisabolene  X X   X X   X  
trans-Calamenene  X X  X  X  X  X 
Caryophyllene oxide  X X X     X   
β-Sesquiphellandrene   X    X   X  
Geranyl Acetate   X    X X X   
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Chapter 6 
General Discussion and Future Directions 
 
6.1 General Discussion 
Medicinal plant products have a long history of use for treating neurological 
symptoms. Yet the study of the mechanisms of action for neuroactive natural 
medicinal products is in its infancy. With new advances in scientific techniques we 
are able to take a closer look at the therapeutic actions of the complex biologically 
active molecules that have arisen as a result of natural selection, over perhaps 300 
million years. This thesis brings together contemporary perspectives and research 
methods to try to understand the mechanisms underlying the neuroactive actions of 
plant based natural products and to validate their use in neurotherapies.  
 
Interest in medicinal plant research and the aroma-therapeutic effects of EOs in 
humans has increased in recent years, especially for the treatment of pathologies 
with profound social impact such as AD. Several plant species are used in medical 
herbalism for their effects on anxiety, restlessness, excitability and depression. 
These include lemon balm (Melissa officinalis), lavender (Lavandula angustifolia), 
chamomile (Matricaria chamomilla), bergamot (Monarda species), neroli (Citrus 
aurantium) and valerian (Valeriana officinalis) (Perry et al., 2006, Elliott et al., 2007). 
Several recent clinical trials have concurred with the value of aromatherapy in people 
with dementia (Perry et al., 2006, Kennedy et al., 2011). The safety of these EO 
based approaches has also been established in clinical populations. Despite this, 
however, the central mechanisms by which the EOs exert their effects are largely 
unknown. 
A. citrodora (Verbenaceae) is an aromatic plant that is cultivated in some parts of 
Jordan, mainly for its food and medicinal purposes.  Some plant material described 
as M. officinalis (known in Arabic as ‘melissa’) was identified as A. citrodora  (also 
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known locally as melissa); both species have similar traditional uses and  produce a 
yellow to light green EO with special aroma similar to that of lemon (Abuhamdah et 
al., 2005). M. officinalis has been of particular interest on account of its sedative; 
cognitive-enhancing, and anxiolytic-like effects, all relevant pathophysiological 
actions seen in AD (Viola et al., 1995, Akhondzadeh et al., 2003, Kennedy et al., 
2003, Kennedy et al., 2004, Abu-Hamdah et al., 2005, Perry and Perry, 2006, Elliott 
et al., 2007, Kennedy and Wightman, 2011). Limited data are available which explore 
the effects of A. citrodora oils pertinent to AD, in comparison with M. officinalis. 
Detailed pharmacological research is required to verify their effectiveness. The goal 
of this present study was the phytochemical and biological evaluation of a 
traditionally used Jordanian medicinal plant, A. citrodora (which is accessible, 
abundant and has been subjected to limited neurological assessment) as a potential 
source of novel neuroactives in order to address the primary hypothesis cited in 
Chapter 1.  
The first step in the A. citrodora EO pharmacological screen was the investigation of 
the binding activity of the EOs to the well-known ligand-gated ion channel receptor 
molecular targets in a series of dose–response competition binding experiments. 
Based on [35S] TBPS, [3H] flunitrazepam and [3H] MK-801 binding assays, no 
significant inhibitory effect was observed for A. citrodora EOs derived from fresh or 
dried leaves, spanning a wide concentration range. In contrast, A. citrodora essential 
oil inhibited [3H] nicotine binding to well washed rat forebrain membranes, with mean 
apparent IC50 of 0.0018 mg/ml. This pharmacological profile is in marked contrast to 
our previous published findings with the essential oils derived from the European 
Melissa EO (M. officinalis) which displayed no apparent binding affinity for neuronal 
nicotinic receptors, but showed a clear binding affinity for the channel site of the 
GABAAR, previously proposed to be due to the presence of the component, ocimine 
(Mahita et al., 2014). Neuronal nicotinic acetylcholine receptors represent novel 
targets for CNS therapeutics, and may have substantial roles in mediating 
antinociception and modulating cognitive performance. Furthermore, there is 
growing evidence that nicotinic agonists are neuroprotective both in vitro and in vivo 
via α4β2 and α7 neuronal nicotinic receptor subtypes (Chapter 1). Additional studies 
are required to confirm the pharmacological identity (agonist or antagonist) of the A. 
citriodora essential oil.  
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Many medicinal plants have been the basis for the successful development of 
cholinesterase inhibitors, used successfully in dementia therapeutics. The next step 
of this thesis was the screening of A. citrodora EO for anti-cholinesterase properties. 
Both EOs from dried and fresh leaves elicited an effective acetylcholinesterase 
inhibitory activity. Dried leaves oil showed a more clear AChE inhibitory activity than 
fresh oil, which may be related to higher respective levels of limonene and 
caryophyllene oxide. The need for a rapid search for small molecules that may bind 
to targets of biological interest is of crucial importance in the drug discovery process. 
One way of achieving this is in silico or virtual screening of large compound 
databases to identify a set of compounds that contains relatively many hits against 
the target. If a three-dimensional (3D) model of the target is available, then structure-
based virtual screening can be performed, utilising a docking program. Herein, a 
recombinant human form of the anticholinesterase enzyme was used for the first 
time as a platform for structure-based ligand modelling and docking. The seven top 
scoring hits in the A. citrodora EO show complementarities with the protein residues 
with which they interact common to themselves, and known prototypical AChE 
inhibitors. The majority of these interactions are manifested in hydrogen bonding, 
hydrophobic and π-π interactions.  Furthermore, bisabolene and trans-calamenene 
displayed the most interactions and are the only ones which interact with key 
tryptophan residues, as seen with the protype, donepezil. Although some of the hits 
are already reported  to have anti AChE activity such as curcumene (Fujiwara et al., 
2010), caryophyllene oxide (Savelev et al., 2003, Costa et al., 2012)  and β-
sesquiphellandrene (Bonesi et al., 2010) the remaining hits, such as bisabolene and 
trans-calamenene have not been reported to date and could present novel AChE 
inhibitors. Although the potential clinical relevance of these virtual screening results 
requires further investigation, these findings indicate that plant essential oils may 
yield further novel AChE inhibitors, other than alkaloids, which may have advantages 
in relation to efficacy and adverse-effect profile.  
 
A. citrodora EO, both dried and fresh, also exhibited potent radical scavenging 
activity and iron (II) chelating properties, which may, in addition to the nicotinic 
receptor activity, may underlie the neuroprotective characteristics displayed. 
Hydrogen peroxide accumulates during the incubation of β-amyloid and both show 
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a close synergistic action in neurodegenerative diseases. The ability of fresh A. 
citrodora EO to significantly ameliorate both hydrogen peroxide and Aβ-induced 
neurotoxicity offers scope for this oil to be utilised in vivo. 
 
The next question posed by this thesis: what are the bioactive constituents which 
underpin these useful pharmacological properties? Using state-of-the art GC/MS 
analysis at Kew Gardens Research laboratory, the chemical composition of the 
essential oil derived from the leaves of A. citrodora was determined; More than eighty 
components, comprising of mainly mono-and sesquiterpenoids, were detected in the 
EOs obtained from Jordanian A. citrodora dried or fresh leaves (Table 5.2). The 
essential oil was characterized by the presence of terpenoids, monoterpenes and 
sesquiterpenes, and 6-methyl-5-hepten-2-one, the main constituents being 
limonene, caryophyllene oxide, curcumene, spathulenol, 1,8-cineole constituting 
47% of the total oil. Other major constituents include geranial, neral, α-terpineol and 
6-methyl-5-hepten- 2-one. Irrespective of whether derived from dried or fresh leaves, 
limonene, geranial, neral and 1,8-cineole were the dominating monoterpenoids. The 
qualitative composition of the EOs from fresh and dried A. citrodora leaves was 
similar, although quantitative differences were observed; notably, the EO from fresh 
leaves contained a higher percentage composition of geranial and neral (isomeric 
monoterpenoids collectively known as citral) compared to the EO from dried leaves; 
whilst dried leaves EO contained a higher percentage of limonene, compared to the 
fresh leaves EO. The fraction of monoterpene was enriched, mainly due to an 
increase in the contribution of limonene with the dried leaf oil. Importantly, all other 
components remained more or less unchanged both qualitatively and quantitatively. 
The monoterpenoids limonene, geranial, neral and 1,8-cineole have previously been 
reported as some of the main constituents of EOs from A. citrodora (including EOs 
documented from species described as synonyms for A. citrodora) (Montes et al., 
1973, Özek et al., 1996, Terblanché & Kornelius, 1996, Carnat et al., 1999, Pascual 
et al., 2001).  It is essential to characterise the chemical composition of EOs 
investigated  pharmacologically, as oil composition from a particular species may 
vary considerably due to various factors, including genetic and environment 
influences. Indeed, A. citrodora oil composition is reported to differ due to plant 
growth stage and harvest time, whether wild or cultivated and geographical origin 
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(Zygadlo et al., 1994, Sartoratto et al., 2004, Argyropoulou et al., 2007, Gil et al., 
2007, Santos-Gomes et al., 2005, Di Leo Lira et al., 2008, Zoubiri & Baaliouamer, 
2011). 
 
We were interested to compare the chemical composition of A. citrodora and M. 
officinalis, to provide scientific evidence for similarity between these two plant 
species and acceptance or otherwise, for using them as alternatives for each other 
in traditional medicine market across the world. This further addresses the primary 
hypothesis posed in Chapter 1. The EOs shared common components, but there 
were clear differences in the quantity of these particular chemicals. The main 
components detected in M. officinalis were the monoterpenoids, neral and geranial 
while in lemon verbena, these were limonene, neral, geranial, and 1,8-cineole. Both 
have the sesquiterpenoid, caryophyllene oxide whereas A. citrodora also have 
curcumene and spathulenol (Table 6.1). There were chemical differences in the 
quantity and constituents of the EOs obtained from two plants species, which may 
furthermore explain the different pharmacological profiles (Table 6.2). 
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Table 6.1  
Comparison of A. citrodora and M. officinalis primary constituents 
 
Aloysia citrodora  
 
Melissa officinalis 
 
Neral 15.1% 
Geranial 20.1% 
Limonene 13.6% 
1,8-cineole 9.2% 
 
Neral 24.2% 
Geranial 33.5% 
 
Caryophyllene oxide 2.2% 
Curcumene 3.5% 
Spathulenol 3.1% 
 
Caryophyllene oxide 12.2% 
 
Table 6.2 
Comparison between A. citrodora and M. officinalis essential oil pharmacological 
profile 
  
Aloysia citrodora 
 
Melissa officinalis 
Radioligand receptor binding  Conc. dependent inhibition of [3H] 
nicotine binding to neuronal nicotinic 
receptor.  
Conc. dependent 
inhibition of [35S] TBPS 
binding to GABAAR 
Anti-AChE activity Conc. dependent inhibition. No apparent inhibition. 
DPPH radical scavenging  Radical-scavenging activity. Radical-scavenging 
activity. 
Ferrous ion chelating  Metal chelating activity. No apparent activity. 
 
The GC/MS analysis of A. citrodora EO showed that it contains a variety of volatile 
molecules such as terpenes and terpenoids, phenol-derived aromatic components 
and aliphatic compounds, all of which belong to different classes of hydrocarbons, 
aldehydes, ketones, esters, and alcohols.  Thus, to fractionate the essential oil prior 
to analysis was the logical next step, as the fractionation process will increase the 
concentration of the components and consequently ease the subsequent analysis. 
Furthermore, fractions can be compared with the original whole essential oil, to 
uncover which part of the oil holds the active components and if there are any 
synergistic, anti-synergistic or masking effects among different essential oil 
constituents. Many methods of essential oil fractionation have been reported in 
literature. Some of them are time consuming and use large volumes of solvents 
others need a highly technological approach such as LC-GC or multidimensional gas 
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chromatography. This thesis reports a simple, inexpensive method that uses silica 
SPE to carry out a fractionation of different essential oils. This method was 
successful in fractionating essential oils into three distinct fractions in one simple 
step easily, quickly and using small amounts of organic solvents. This protocol 
successfully separated the oils into hydrocarbons; carbonyl compounds, ethers, 
esters and tertiary alcohols; primary alcohols, acids and diols. The putative AChE 
actives identified by the computer modelling were fractionated in two separate 
fractions, the hydrocarbons: β-curcumene, curcumene, bisabolene, trans-
calamenene, and β-sesquiphellandrene, while geranyl acetate and caryophyllene 
oxide were fractionated together. In light of these results, it can be seen that the 
combination of SPE fractionation linked with molecular docking, and virtual screening 
efforts offers a promising strategy for discovering further neuroactive chemotypes 
from essential oils that will direct future experimental studies on essential oil 
products. 
 
Overall, this thesis reports that although the two “Melissa” plants are used 
traditionally for similar therapeutic uses, they display distinct chemical compositions, 
pharmacological properties and neuroprotective abilities. We propose that the 
combination of positive activities (Figure 6.1) provide a strong case for the use of A. 
citrodora essential oil as a therapeutic agent for a range of neurodegenerative 
diseases.  
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Fig 6.1  
Summary of useful A. citrodora  properties pertinent to neurodegenerative disease   
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6.2 Future Directions 
This project demonstrated that the A. citrodora EO displays a wide range of useful 
pharmacological properties which are worthy of further study in vivo. Utilising a range 
of our all-in-one behavioural tests (Ennaceur et al., 2010), it can be assessed 
whether the EO has positive effects on a range of behavioural aspects pertinent to 
neurodegenerative diseases (both motor, affective and cognitive). The new SPE 
protocol developed in this study can be used for the fractionation of other plant 
essential oils which would make further testing and analysis easier and more 
effective; in fact, this could be used as a standard protocol for essential oils in 
general. It would be important to screen A. citrodora EO fractions produced by the 
SPE method using the same tests performed for the whole crude oil to compare and 
contrast the results, and address the issues of pharmacological synergy and 
interference. Structure based virtual screening can be performed using the 
anticholinesterase inhibitor model developed in this study for other medicinal plant 
products in order to expand the panel of putative novel AChE inhibitors. The seven 
hits require urgent validation to confirm the utility of this methodology. Furthermore, 
more complex targets could be studied in a similar fashion (voltage-gated sodium 
channel, nAChR, GABAAR channel etc). This will naturally be more demanding due 
to the lack of high-quality, high-resolution structural information for these targets.  
 
Collectively, the results accumulated in this thesis provide a better understanding of 
the pharmacology of the A. citrodora EO and its constituents relating to its potential 
use in treating neurodegenerative diseases. 
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Appendix I 
Virtual Screening for Anticholinesterase Inhibitors Training Set  
no. IC50 (mM) pIC50 
1 0.05 7.30
2 0.0111 7.95
3 0.014 7.85
4 0.00513 9.71
5 0.00216 9.33
6 0.0026 9.41
7 0.00106 9.03
8 0.00165 8.78
9 0.00154 8.81
10 0.00257 8.59
11 0.424 6.37
Cl
R1
2
n
Structure
n
0
2
6
4
5
3
R1
H
H
Cl
Cl
n
2
3
2
R1
n'
10
6
8 H
H
12 0.00183 8.74
13 0.0161 7.79
14 0.00332 8.48
15 0.0257 7.59
16 0.00483 8.32
17 0.0159 7.80
18 0.00141 8.85
19 0.0724 7.14
20 0.0077 8.11
n R1 R2 R3Ar
R1
(CH2)2CO(CH2)2
21 5 Et H CH2 0.00155 8.81
22 5 Et Br CH2 0.00266 8.58
23 2 Et H CH2 0.00225 8.65
24 3 Et H CH2 0.0136 7.87
25 4 Et H CH2 0.00236 8.63
26 5 Et H (CH2)2 0.0173 7.76
27 5 Me H CH2 0.0778 7.11
28 5 Et H CH2 0.0733 7.13
29 5 Et H CH2 0.0511 7.29
30 5 Et H CH2 0.0138 7.86
31 5 Et H CH2 0.0719 7.14
32 5 Et H CH2 0.0604 7.22
33 5 Et H CH2 0.125 6.90
34 5 Et H CH2 0.133 6.88
35 5 Et H CH2 0.192 6.72
36 0.0407 7.39
37 0.127 6.90
38 0.0105 7.98
39 0.127 6.90
40 0.281 6.55
R1
2-MeOC6H4
2-MeOC6H4
2-MeOC6H4
2-MeOC6H4
2-MeOC6H4
2-MeOC6H4
2-MeOC6H4
C6H5
4-MeOC6H4
3-MeOC6H4
2-MeC6H4
2-thienyl
2-pyridyl
3-pyridyl
4-pyridyl
41 0.177 6.75
42 0.987 6.01
43 0.368 6.43
44 24.6 4.61
45 0.366 6.44
46 0.122 6.91
47 0.0621 7.21
48 0.714 6.15
49 2.26 5.65
50 0.281 6.55
chain R3
51 para CH3 1.23 5.91
52 meta CH3 2.02 5.69
53 meta C2H5 1.59 5.80
54 18.1 4.74
55 80.5 4.09
OCH3
H
R2
H
OCH3
m -CH3
o -OCH3
m -OCH3
OCH3
R2
OCH3
OCH3
OCH3
OCH3
OCH3
NH2
OCH3
OCH3
p -OCH3
H
OCH3
OCH3
OCH3
H
OCH3
OCH3
OCH3
OCH3
R1
R1
OCH3
OCH3
OCH3
R1
OCH3
R2
OCH3
OCH3
OCH3
R3
o -NO2
m -NO2
p -NO2
o -CH3
n R1 R2 R3 R4 R5
56 5 H H Me H H 7.78 5.11
57 7 H H Me H H 2.82 5.55
58 8 H H Me H H 10.3 4.99
59 7 OCH3 OCH3 Me H H 2.32 5.63
60 7 H H Me H OCH3 40 4.40
61 7 H H Et OCH3 H 3.15 5.50
62 0.183 7.74
63 0.00404 8.39
64 0.00088 9.06
65 0.00081 9.09
66 0.00665 8.18
3
R1
(CH2)5
CH2NHCOCONHCH2
n n' R1
0 7 Cl
n
2
67 8.55 5.07
68 0.00037 9.43
n R1 R2
69 5 H CH2 0.123 6.91
70 5 Et CH2 0.593 6.23
71 5 Et CH2 2.31 5.64
R3 R4
72 CH3 H 0.0445 7.35
73 0.0105 7.98
2-NO2C6H4
R1 R2
OCH3 OCH3
R1
Ar
2-MeOC6H4
2-ClC6H4
R1 R2 R3 R4
74 H H H H 152 3.82
75 H H H H 388 3.41
76 H H H H 626 3.20
77 H H H H 908 3.04
78 H H OCH3 H 360 3.44
79 Cl H H H 433 3.36
80 H Cl H H 594 3.23
81 H H Cl H 1050 2.98
82 CH3 H H H 565 3.25
83 OCH3 OCH3 H H 138 3.86
84 OCH3 H H OCH3 127 3.90
85 OCH3 OCH3 OCH3 H 155 3.81
86 0.0003 9.52
87 0.00032 9.49
n
3
7
12
7
7
7
7
7
7
7
7
n
9
10
11
 
 
 
 
 
Appendix II 
GC/MS Analysis of Aloysia citrodora Essential Oil 
PHYTOCHEMICAL ANALYSIS 
5th July 2013 
BI 21372, 22729 – 22757 
 
 
Aloysia citriodora Palau# Essential Oil  
and Fractions (V2 – V5)  
  
GC-MS Analysis 
Sample preparation 
Oil (BI 21372 stored at 6°C in the dark, since Feb 2012): 1/100 dilution in diethyl ether. 
Fractions analysed without dilution. 
 
Method 
GC: Agilent 7890A 
Column: 30 m x 0.25 mm i.d. x 0.25 µm DB-5MS (J. & W. Scientific)  
Temp prog.: 40-300ºC @ 3ºC/min 
Carrier gas: Helium (flow: 1ml/min) 
Injection temp.: 220 °C 
MS: Agilent 5975C 
Source: EI (70 eV) 
Source temp.: 180 °C 
Scan range: 38-600 m/z  
 
#Synonym: Aloysia triphylla (L'Hér.) Britton 
 
 
Table 1. Percentage composition of detected compounds (based on all detected peaks assigned as oil constituents). 
Compound Retention 
time (min) 
Aloysia oil 
dried 
(BI 21372) 
 
Percentage 
composition 
(TIC) and 
[RI]*  
Fraction V2 
1/3  
(BI 22729) 
 
Percentage 
composition 
(TIC) and 
[RI]* 
Fraction V2 
2/3  
(BI 22730) 
 
Percentage 
composition 
(TIC) and 
[RI]* 
Fraction V4 
1/11   
(BI 22737) 
 
Percentage 
composition 
(TIC) and 
[RI]* 
Fraction V4 
2/11  
(BI 22738) 
 
Percentage 
composition 
(TIC) and 
[RI]* 
Fraction V4 
3/11 
(BI 22739) 
 
Percentage 
composition 
(TIC) and 
[RI]* 
RI 
(published) 
Salvene 7.8 0.03 
[820] 
Tr 
[820] 
Nd Nd Tr 
[820] 
Nd (Z)-: 847 
(E)-: 858 
α-Thujene 11.7 0.07 
[906] 
0.11 
[906] 
Nd Nd Tr 
[906] 
Nd 924 
α-Pinene 12.0 0.44 
[914] 
0.82 
[914] 
Nd Tr 
[914] 
0.98 
[914] 
Nd 932 
Camphene 12.8 Tr 
[931] 
Tr 
[931] 
Nd Nd Nd Nd 946 
Sabinene 13.8 0.92 
[954] 
1.52 
[954] 
Nd Nd 1.68 
[954] 
Nd 969 
β-Pinene 14.0 0.08 
[959] 
0.14 
[959] 
Nd Nd Nd Nd 974 
1-Octen-3-ol 14.1 0.55 
[961] 
Tr 
[961] 
0.05 
[961] 
Nd Nd 0.01 
[961] 
974 
6-Methyl-5-hepten-
2-one 
14.4 2.37 
[966] 
2.42 
[966] 
Nd Nd 2.40 
[966] 
Nd 981 
Myrcene 14.6 0.20 
[971] 
0.32 
[971] 
Nd Nd Nd Nd 988 
α-Terpinene 15.9 0.01 
[1001] 
Tr 
[1001] 
Nd Nd Nd Nd 1014 
Cymene 16.3 0.46 
[1009] 
0.49 
[1009] 
Nd Nd 0.50 
[1009] 
Nd o-: 1022 
p-: 1020 
Limonene 16.6 12.14 
[1015] 
20.24 
[1014] 
Nd 100.00 
[1014] 
23.08 
[1014] 
Tr 
[1014] 
1024 
1,8-Cineole 16.7 7.94 
[1018] 
11.44 
[1018] 
Nd Nd 13.49 
[1018] 
Tr 
[1017] 
1026 
β-Ocimene 17.4 0.04 
[1032] 
Tr 
[1032] 
Nd Nd Nd Nd (Z)-: 1032 
(E)-: 1044 
Bergamal 17.7 0.07 
[1040] 
Tr 
[1040] 
Nd Nd Nd Nd 1051 
γ-Terpinene 18.0 0.16 
[1046] 
0.28 
[1046] 
Nd Nd 0.29 
[1046] 
Nd 1054 
cis-Sabinene hydrate 18.6 0.96 
[1059] 
0.09 
[1059] 
7.17 
[1059] 
Nd 0.70 
[1059] 
Tr 
[1059] 
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Compound Retention 
time (min) 
Aloysia oil 
fresh 
(BI 21372) 
 
Percentage 
composition 
(TIC) and 
[RI]*  
Fraction V2 
1/3  
(BI 22729) 
 
Percentage 
composition 
(TIC) and 
[RI]* 
Fraction V2 
2/3  
(BI 22730) 
 
Percentage 
composition 
(TIC) and 
[RI]* 
Fraction V4 
1/11   
(BI 22737) 
 
Percentage 
composition 
(TIC) and 
[RI]* 
Fraction V4 
2/11  
(BI 22738) 
 
Percentage 
composition 
(TIC) and 
[RI]* 
Fraction V4 
3/11 
(BI 22739) 
 
Percentage 
composition 
(TIC) and 
[RI]* 
RI 
(published) 
Perillene 19.9 Tr 
[1089] 
0.07 
[1089] 
Nd Nd Nd Nd 1102 
Linalool 20.0 0.61 
[1091] 
0.16 
[1091] 
1.43 
[1091] 
Nd 0.40 
[1091] 
Nd 1095 
trans-Sabinene 
hydrate 
20.1 0.41 
[1093] 
Nd 2.88 
[1093] 
Nd Tr 
[1093] 
10.23 
[1093] 
1098 
α-Pinene oxide 20.3 0.12 
[1098] 
Tr 
[1098] 
Nd Nd Tr 
[1097] 
Nd 1099 
cis-Rose oxide 20.5 0.06 
[1102] 
Tr 
[1102] 
Nd Nd Nd Nd 1106 
trans-Thujone 20.9 0.03 
[1111] 
Tr 
[1111] 
Nd Nd Nd Nd 1112 
trans-p-Mentha-2,8-
dien-1-ol 
21.1 0.48 
[1115] 
Tr 
[1115] 
3.18 
[1115] 
Nd Tr 
[1115] 
12.59 
[1115] 
1119 
α-Campholenal 21.3 0.09 
[1120] 
Tr 
[1121] 
Nd Nd Nd Nd 1122 
cis-Limonene oxide 21.6 0.27 
[1127] 
0.19 
[1127] 
Nd Nd Tr 
[1127] 
Nd 1132 
cis-p-Mentha-2,8-
dien-1-ol 
21.8 0.81 
[1131] 
0.35 
[1132] 
3.06 
[1131] 
Nd Nd 20.73 
[1131] 
1133 
Verbenol 22.2 0.10 
[1141] 
Nd Tr 
[1141] 
Nd Nd Tr 
[1141] 
cis-: 1137 
trans-: 1140 
Citronellal 22.5 0.14 
[1147] 
0.10 
[1147] 
Nd Nd Tr 
[1147] 
Nd 1148 
Sabina ketone 22.8 0.12 
[1154] 
Nd Tr 
[1154] 
Nd Nd Nd 1154 
Rosefuran epoxide 23.4 0.59 
[1166] 
0.58 
[1166] 
Nd Nd 0.13 
[1166] 
Nd 1173 
Terpinen-4-ol 24.0 0.75 
[1179] 
0.51 
[1179] 
2.31 
[1179] 
Nd 0.56 
[1179] 
Nd 1174 
trans-p-Mentha-
1(7),8-dien-2-ol 
24.3 0.30 
[1186] 
Tr 
[1186] 
Tr 
[1186] 
Nd Nd Tr 
[1186] 
1187 
α-Terpineol 24.7 3.27 
[1195] 
0.33 
[1195] 
24.70 
[1194] 
Nd 2.14 
[1194] 
21.19 
[1194] 
1186 
Shisofuran 25.6 0.09 
[1215] 
Tr 
[1215] 
Nd Nd Nd Nd 1198 
trans-Carveol 25.8 0.86 
[1219] 
Nd 3.48 
[1219] 
Nd Tr 
[1219] 
18.24 
[1219] 
1215 
Nerol 26.0 0.24 
[1224] 
Nd Tr 
[1224] 
Nd Nd Nd 1227 
Citronellol 26.1 0.10 
[1227] 
Nd Nd Nd Nd Nd 1223 
cis-p-Mentha-
1(7),8-dien-2-ol 
26.3 0.22 
[1230] 
Nd Tr 
[1230] 
Nd Nd Tr 
[1230] 
1227 
cis-Carveol 26.4 0.39 
[1233] 
Nd Tr 
[1233] 
Nd Nd Tr 
[1233] 
1226 
Neral 26.7 2.55 
[1239] 
2.85 
[1239] 
Tr 
[1239] 
Nd 2.08 
[1239] 
Nd 1235 
Carvone 26.9 1.14 
[1245] 
1.37 
[1245] 
Nd Nd 1.09 
[1245] 
Nd 1239 
Geraniol 27.2 0.25 
[1251] 
Nd Nd Nd Nd Nd 1249 
Piperitone 27.4 0.33 
[1256] 
Tr 
[1256] 
Tr 
[1256] 
Nd Nd Nd 1249 
Geranial 28.1 4.03 
[1270] 
4.64 
[1269] 
Tr 
[1270] 
Nd 3.51 
[1269] 
Nd 1264 
Perilla aldehyde 28.4 0.13 
[1279] 
0.12 
[1278] 
Nd Nd Nd Nd 1269 
(E)-Anethole 28.9 0.35 
[1289] 
0.27 
[1289] 
Nd Nd Tr 
[1289] 
Nd 1282 
Thymol 29.0 0.16 
[1292] 
0.13 
[1292] 
Nd Nd Nd Tr 
[1292] 
1289 
Carvacrol 29.4 0.82 
[1300] 
0.32 
[1300] 
Tr 
[1301] 
Nd Nd 17.01 
[1301] 
1298 
trans-Carvyl acetate 31.0 0.09 
[1335] 
Tr 
[1335] 
Nd Nd Nd Nd 1339 
Piperitenone 31.3 0.06 
[1341] 
Nd Nd Nd Nd Nd 1340 
α-Cubebene 31.7 0.09 
[1350] 
Tr 
[1350] 
Nd Nd Nd Nd 1345 
Eugenol 31.8 0.16 
[1353] 
Tr 
[1354] 
Nd Nd Nd Nd 1356 
α-Ylangene 32.7 0.12 
[1372] 
0.09 
[1372] 
Nd Nd Tr 
[1372] 
Nd 1373 
α-Copaene 33.0 1.62 
[1379] 
2.01 
[1379] 
Nd Tr 
[1379] 
1.12 
[1379] 
Nd 1374 
Compound Retention 
time (min) 
Aloysia oil 
fresh 
(BI 21372) 
 
Percentage 
composition 
(TIC) and 
[RI]*  
Fraction V2 
1/3  
(BI 22729) 
 
Percentage 
composition 
(TIC) and 
[RI]* 
Fraction V2 
2/3  
(BI 22730) 
 
Percentage 
composition 
(TIC) and 
[RI]* 
Fraction V4 
1/11   
(BI 22737) 
 
Percentage 
composition 
(TIC) and 
[RI]* 
Fraction V4 
2/11  
(BI 22738) 
 
Percentage 
composition 
(TIC) and 
[RI]* 
Fraction V4 
3/11 
(BI 22739) 
 
Percentage 
composition 
(TIC) and 
[RI]* 
RI 
(published) 
β-Bourbonene 33.3 0.96 
[1387] 
1.34 
[1387] 
Nd Tr 
[1387] 
0.75 
[1387] 
Nd 1387 
Methyl eugenol 33.9 0.14 
[1400] 
Tr 
[1401] 
Nd Nd Nd Nd 1403 
Sesquithujene 34.1 0.13 
[1404] 
0.12 
[1404] 
Nd Nd Nd Nd 1405 
α-Cedrene 34.7 0.67 
[1418] 
0.91 
[1418] 
Nd  Tr 
[1419] 
0.64 
[1418] 
Nd  1410 
(E)-Caryophyllene 34.9 2.07 
[1421] 
3.20 
[1421] 
Nd Tr 
[1421] 
2.20 
[1421] 
Nd 1417 
β-Cedrene 35.1 0.37 
[1426] 
0.50 
[1426] 
Nd Nd 0.34 
[1426] 
Nd 1419 
β-Copaene 35.3 0.16 
[1431] 
0.21 
[1431] 
Nd Nd Tr 
[1430] 
Nd 1430 
α-Humulene 36.4 0.25 
[1455] 
0.31 
[1455] 
Nd Nd Nd Nd 1452 
Allo-aromadendrene 36.6 0.86 
[1459] 
1.22 
[1459] 
Nd Tr 
[1459] 
0.76 
[1459] 
Nd 1458 
Acoradiene 36.9 0.25 
[1467] 
0.48 
[1467] 
Nd Nd Nd Nd α-: 1464 
β-: 1469 
γ-Muurolene 37.2 0.26 
[1472] 
0.32 
[1472] 
Nd Nd Nd Nd 1478 
Curcumene 37.4 9.17 
[1478] 
15.30 
[1478] 
Nd Nd 12.90 
[1478] 
Nd γ-: 1481 
ar-: 1479 
Bicyclogermacrene 
(+ epi-cubebol**) 
38.1 0.49 
[1492] 
0.53 
[1492] 
epi-cubebol 
Tr [1492] 
Nd epi-cubebol 
0.47 [1492] 
Nd 1500 
(1493) 
α-Muurolene 38.1 0.09 
[1494] 
0.12 
[1494] 
Nd Nd Nd Nd 1500 
Bisabolene 38.5 0.12 
[1502] 
Tr 
[1502] 
Nd Nd Nd Nd β-: 1505 
(Z)-α-: 1506 
β-Curcumene 38.6 0.16 
[1504] 
0.36 
[1504] 
Nd Nd Nd Nd 1514 
γ-Cadinene 38.8 0.39 
[1508] 
0.53 
[1507] 
Nd Nd 0.17 
[1507] 
Nd 1513 
Cubebol 38.8 0.81 
[1510] 
0.10 
[1509] 
3.44 
[1510] 
Nd 0.41 
[1509] 
Nd 1514 
δ-Cadinene 38.9 0.27 
[1512] 
0.41 
[1512] 
Nd Nd Tr 
[1511] 
Nd 1522 
trans-Calamenene 39.1 0.14 
[1515] 
Tr 
[1514] 
Nd Nd Tr 
[1514] 
Nd 1521 
cis-Calamenene 39.5 0.11 
[1523] 
Tr 
[1523] 
Nd Nd Tr 
[1523] 
Nd 1528 
α-Cadinene 39.7 0.23 
[1528] 
Nd Nd Nd Nd Nd 1537 
(E)-Nerolidol 40.6 0.89 
[1549] 
0.33 
[1549] 
Nd Nd 0.32 
[1549] 
Nd 1561 
 
Spathulenol 41.4 7.16 
[1566] 
1.33 
[1564] 
40.54 
[1564] 
Nd 7.44 
[1564] 
Nd 1577 
Caryophyllene oxide 41.6 10.44 
[1571] 
15.29 
[1570] 
Nd Nd 15.45 
[1569] 
Nd 1582 
Globulol 42.6 1.29 
[1593] 
0.95 
[1593] 
Nd Nd 1.31 
[1593] 
Nd 1590 
τ-Cadinola 43.8 1.33 
[1620] 
0.50 
[1620] 
3.46 
[1620] 
Nd 1.29 
[1620] 
Nd - 
Compounds detected in Aloysia oil (BI 21372) were not detected in fractions: V2 3/3 (BI 22731), V2M (BI 22732), V3M (BI 22733), V3 1/3 (BI 
22734), V3 2/3 (BI 22735), V3 3/3 (BI 22736), V4 5/11 (BI 22741), V4 6/11 (BI 22742), V4 7/11 (BI 22743), V4 8/11 (BI 22744), V4 9/11 (BI 
22745), V4 10/11 (BI 22746), V4 11/11 (BI 22747), V5 6/10 (BI 22753), V5 7/10 (BI 22754), V5 8/10 (BI 22755), V5 9/10 (BI 22756), V5 
10/10 (BI 22757). 
Tr: < 0.01 %; Nd: not detected. 
*Experimental retention index (RI) value; **co-elution. 
All compounds identified by comparing retention indices (calculated against an n-alkane series) and by comparing mass spectra with published 
data1, 2, except for acompounds identified by comparison with published mass spectra only1. 
 
 
 
 
 
 
 
 
 
 
 
 
 Table 2. Percentage composition of detected compounds (based on all detected peaks assigned as oil constituents). 
Compound Retention 
time (min) 
Fraction V4 
4/11  
(BI 22740) 
 
Percentage 
composition 
(TIC) and 
[RI]* 
Fraction V5 
1/10 
(BI 22748) 
 
Percentage 
composition 
(TIC) and 
[RI]* 
Fraction V5 
2/10   
(BI 22749) 
 
Percentage 
composition 
(TIC) and 
[RI]* 
Fraction V5 
3/10  
(BI 22750) 
 
Percentage 
composition 
(TIC) and 
[RI]* 
Fraction V5 
4/10 
(BI 22751) 
 
Percentage 
composition 
(TIC) and 
[RI]* 
Fraction V5 
5/10 
(BI 22752) 
 
Percentage 
composition 
(TIC) and 
[RI]* 
RI 
(published) 
Salvene 7.8 Nd Nd Nd Nd Nd Nd (Z)-: 847 
(E)-: 858 
α-Thujene 11.7 Nd Tr 
[906] 
Nd Nd Nd Nd 924 
α-Pinene 12.0 Nd 2.70 
[914] 
Nd Nd Nd Nd 932 
Camphene 12.8 Nd Nd Nd Nd Nd Nd 946 
Sabinene 13.8 Nd 4.27 
[954] 
Nd Nd Nd Nd 969 
β-Pinene 14.0 Nd Nd Nd Nd 
 
Nd Nd 974 
1-Octen-3-ol 14.1 Nd Nd Nd Nd Tr 
[961] 
Nd 974 
6-Methyl-5-hepten-
2-one 
14.4 Nd Nd Nd 7.19 
[966] 
Tr 
[966] 
Nd 981 
Myrcene 14.6 Nd Nd Nd Nd 
 
Nd Nd 988 
α-Terpinene 15.9 Nd Nd Nd Nd 
 
Nd Nd 1014 
Cymene 16.3 Nd Nd Nd Nd 
 
Nd Nd o-: 1022 
p-: 1020 
Limonene 16.6 100.00 
[1014] 
70.66 
[1014] 
100.00 
[1014] 
Nd Nd Nd 1024 
1,8-Cineole 16.7 Nd Nd Nd 59.27 
[1018] 
Nd Nd 1026 
β-Ocimene 17.4 Nd Nd Nd Nd Nd Nd (Z)-: 1032 
(E)-: 1044 
Bergamal 17.7 Nd Nd Nd Nd 
 
Nd Nd 1051 
γ-Terpinene 18.0 Nd Tr 
[1046] 
Nd Nd Nd Nd 1054 
cis-Sabinene hydrate 18.6 Nd Nd Nd Nd 9.38 
[1059] 
Tr 
[1059] 
1065 
Perillene 19.9 Nd Nd Nd 
 
Nd Nd Nd 1102 
Linalool 20.0 Nd Nd Nd Nd Tr 
[1091] 
Nd 1095 
trans-Sabinene 
hydrate 
20.1 Nd Nd Nd Nd Nd Tr 
[1093] 
1098 
α-Pinene oxide 20.3 Nd Nd Nd 
 
Nd Nd Nd 1099 
cis-Rose oxide 20.5 Nd Nd Nd 
 
Nd Nd Nd 1106 
trans-Thujone 20.9 Nd Nd Nd 
 
Nd Nd Nd 1112 
trans-p-Mentha-2,8-
dien-1-ol 
21.1 Nd Nd Nd Nd Tr 
[1115] 
Nd 1119 
α-Campholenal 21.3 Nd Nd Nd 
 
Nd Nd Nd 1122 
cis-Limonene oxide 21.6 Nd Nd Nd 
 
Nd Nd Nd 1132 
cis-p-Mentha-2,8-
dien-1-ol 
21.8 Nd Nd Nd Nd Nd Tr 
[1131] 
1133 
Verbenol 22.2 Nd Nd Nd Nd Nd Nd cis-: 1137 
trans-: 1140 
Citronellal 22.5 Nd Nd Nd 
 
Nd Nd Nd 1148 
Sabina ketone 22.8 Nd Nd Nd 
 
Nd Nd Nd 1154 
Rosefuran epoxide 23.4 Nd Nd Nd Tr 
[1166] 
Nd Nd 1173 
Terpinen-4-ol 24.0 Nd Nd Nd Nd Tr 
[1179] 
Nd 1174 
trans-p-Mentha-
1(7),8-dien-2-ol 
24.3 Nd Nd Nd Nd Nd Nd 1187 
α-Terpineol 24.7 Nd Nd Nd Nd 15.75 
[1194] 
100.00 
[1195] 
1186 
Shisofuran 25.6 Nd Nd Nd 
 
Nd Nd Nd 1198 
trans-Carveol 25.8 Nd Nd Nd Nd Tr 
[1219] 
Nd 1215 
Nerol 26.0 Nd Nd Nd 
 
Nd Nd Nd 1227 
Compound Retention 
time (min) 
Fraction V4 
4/11  
(BI 22740) 
 
Percentage 
composition 
(TIC) and 
[RI]* 
Fraction V5 
1/10 
(BI 22748) 
 
Percentage 
composition 
(TIC) and 
[RI]* 
Fraction V5 
2/10   
(BI 22749) 
 
Percentage 
composition 
(TIC) and 
[RI]* 
Fraction V5 
3/10  
(BI 22750) 
 
Percentage 
composition 
(TIC) and 
[RI]* 
Fraction V5 
4/10 
(BI 22751) 
 
Percentage 
composition 
(TIC) and 
[RI]* 
Fraction V5 
5/10 
(BI 22752) 
 
Percentage 
composition 
(TIC) and 
[RI]* 
RI 
(published) 
Citronellol 26.1 Nd Nd Nd 
 
Nd Nd Nd 1223 
cis-p-Mentha-
1(7),8-dien-2-ol 
26.3 Nd Nd Nd Nd Nd Nd 1227 
cis-Carveol 26.4 Nd Nd Nd 
 
Nd Nd Nd 1226 
Neral 26.7 Nd Nd Nd Tr 
[1239] 
8.51 
[1239] 
Nd 1235 
Carvone 26.9 Nd Nd Nd 2.30 
[1246] 
Nd Nd 1239 
Geraniol 27.2 Nd Nd Nd 
 
Nd Nd Nd 1249 
Piperitone 27.4 Nd Nd Nd 
 
Nd Nd Nd 1249 
Geranial 28.1 Nd Nd Nd Nd 21.83 
[1270] 
Nd 1264 
Perilla aldehyde 28.4 Nd Nd Nd 
 
Nd Nd Nd 1269 
(E)-Anethole 28.9 Nd Nd Nd 
 
Nd Nd Nd 1282 
Thymol 29.0 
 
Nd Nd Nd Nd Nd Nd 1289 
Carvacrol 29.4 Nd Nd Nd Nd Tr 
[1301] 
Nd 1298 
trans-Carvyl acetate 31.0 Nd Nd Nd 
 
Nd Nd Nd 1339 
Piperitenone 31.3 Nd Nd Nd 
 
Nd Nd Nd 1340 
α-Cubebene 31.7 Nd Nd Nd 
 
Nd Nd Nd 1345 
Eugenol 31.8 Nd Nd Nd 
 
Nd Nd Nd 1356 
α-Ylangene 32.7 Nd Nd Nd 
 
Nd Nd Nd 1373 
α-Copaene 33.0 Nd Tr 
[1379] 
Nd Nd Nd Nd 1374 
β-Bourbonene 33.3 Nd Tr 
[1387] 
Nd Nd Nd Nd 1387 
Methyl eugenol 33.9 Nd Nd Nd 
 
Nd Nd Nd 1403 
Sesquithujene 34.1 Nd Nd Nd 
 
Nd Nd Nd 1405 
α-Cedrene 34.7 Nd Tr 
[1418] 
Nd Nd Nd Nd 1410 
(E)-Caryophyllene 34.9 Nd 3.60 
[1421] 
Nd Nd Nd Nd 1417 
β-Cedrene 35.1 Nd Nd Nd 
 
Nd Nd Nd 1419 
β-Copaene 35.3 Nd Nd Nd 
 
Nd Nd Nd 1430 
α-Humulene 36.4 Nd Tr 
[1455] 
Nd Nd Nd Nd 1452 
Allo-aromadendrene 36.6 Nd Tr 
[1459] 
Nd Nd Nd Nd 1458 
Acoradiene 36.9 Nd Nd Nd Nd Nd Nd α-: 1464 
β-: 1469 
γ-Muurolene 37.2 Nd Nd Nd 
 
Nd Nd Nd 1478 
Curcumene 37.4 Nd 18.77 
[1478] 
Nd Nd Nd Nd γ-: 1481 
ar-: 1479 
Bicyclogermacrene 
(+ epi-cubebol**) 
38.1 Nd Nd Nd Nd Nd Nd 1500 
(1493) 
α-Muurolene 38.1 Nd Nd Nd 
 
Nd Nd Nd 1500 
Bisabolene 38.5 Nd Nd Nd Nd Nd Nd β-: 1505 
(Z)-α-: 1506 
β-Curcumene 38.6 Nd Nd Nd 
 
Nd Nd Nd 1514 
γ-Cadinene 38.8 Nd Tr 
[1507] 
Nd Nd Nd Nd 1513 
Cubebol 38.8 Nd Nd Nd Nd Tr 
[1510] 
Nd 1514 
δ-Cadinene 38.9 Nd Tr 
[1512] 
Nd Nd Nd Nd 1522 
trans-Calamenene 39.1 Nd Nd Nd 
 
Nd Nd Nd 1521 
Compound Retention 
time (min) 
Fraction V4 
4/11  
(BI 22740) 
 
Percentage 
composition 
(TIC) and 
[RI]* 
Fraction V5 
1/10 
(BI 22748) 
 
Percentage 
composition 
(TIC) and 
[RI]* 
Fraction V5 
2/10   
(BI 22749) 
 
Percentage 
composition 
(TIC) and 
[RI]* 
Fraction V5 
3/10  
(BI 22750) 
 
Percentage 
composition 
(TIC) and 
[RI]* 
Fraction V5 
4/10 
(BI 22751) 
 
Percentage 
composition 
(TIC) and 
[RI]* 
Fraction V5 
5/10 
(BI 22752) 
 
Percentage 
composition 
(TIC) and 
[RI]* 
RI 
(published) 
cis-Calamenene 39.5 Nd Nd Nd 
 
Nd Nd Nd 1528 
Nerolidol 40.6 Nd Nd Nd Nd Nd Nd (E)-: 1561 
(Z)-: 1531 
Spathulenol 41.4 Nd Nd Nd Nd 44.53 
[1564] 
Nd 1577 
Caryophyllene oxide 41.6 Nd Nd Nd 31.24 
[1569] 
Nd Nd 1582 
Globulol 42.6 Nd Nd Nd 
 
Nd Nd Nd 1590 
τ-Cadinola 43.8 Nd Nd Nd Nd Tr 
[1620] 
Nd - 
Compounds detected in Aloysia oil (BI 21372) were not detected in fractions: V2 3/3 (BI 22731), V2M (BI 22732), V3M (BI 22733), V3 1/3 (BI 
22734), V3 2/3 (BI 22735), V3 3/3 (BI 22736), V4 5/11 (BI 22741), V4 6/11 (BI 22742), V4 7/11 (BI 22743), V4 8/11 (BI 22744), V4 9/11 (BI 
22745), V4 10/11 (BI 22746), V4 11/11 (BI 22747), V5 6/10 (BI 22753), V5 7/10 (BI 22754), V5 8/10 (BI 22755), V5 9/10 (BI 22756), V5 
10/10 (BI 22757). 
Tr: < 0.01 %; Nd: not detected. 
*Experimental retention index (RI) value; **co-elution. 
All compounds identified by comparing retention indices (calculated against an n-alkane series) and by comparing mass spectra with published 
data1, 2, except for acompounds identified by comparison with published mass spectra only1. 
 
 
 
 
 
 
 
References 
 
[1] NIST 08. (2008) NIST/EPA/NIH Mass Spectral Database.  National Institute of Standards and 
Technology, Gaithersburg, USA. 
[2] Adams R.P. (2007) Identification of Essential Oil Components by Gas Chromatography / Mass 
Spectroscopy.  Allured Publishing Corporation, Illinois, USA. 
 
 
 
 
 
 
Appendix III 
SPE of Aloysia Citrodora Essential Oil 
v1
Hexane
Diethyl Ether
SF10-4g
11/9/2011 10:36:41 PM
Sample ID: 
Solvent A:
Solvent B:
Column:
Start Time:
Column Station: 1
Detectors: UV: 254nm, 300nm, 399nm, 200nm
AU Graph
254nm
300nm
399nm
200nm
Gradient Graph
Page 1 of 2 11/9/2011Agilent 971-FP Version: 3.2.743
Solvent Details
%B Time %B Time
0 00:00 10 06:00
0 03:00 100 06:00
10 03:00 100 09:00
Tube Map
Rack: 1 18 x 150 mm (1)
1Rack:
Peak Tube Number Volume (CV) Volume (ml)
1 Instance: 18 x 150 mm
 6.00 1  1.001
 6.00 2  1.001
 6.00 3  1.001
 6.00 4  1.001
 6.00 5  1.001
 6.00 6  1.001
 6.00 7  1.001
 6.00 8  1.001
 6.00 9  1.001
 6.00 10  1.001
 5.40 11  0.901
 5.40 12  0.901
 6.00 13  1.001
 6.00 14  1.001
 6.00 15  1.001
 5.40 16  0.901
 6.00 17  1.001
 6.00 18  1.001
 6.00 19  1.001
 6.00 20  1.001
 6.00 21  1.001
 6.00 22  1.001
 6.00 23  1.001
 6.00 24  1.001
 6.00 25  1.001
 6.00 26  1.001
 5.40 27  0.901
 159.60 26.60Total:
Page 2 of 2 11/9/2011Agilent 971-FP Version: 3.2.743
Aloysia citrodoria Essential Oil and Fractions (L1, L2, L3) 
GC-MS Analysis 
Sample preparation 
Oil: 1/100 dilution in diethyl ether. 
Fractions analysed without dilution. 
Method 
GC: Perkin-Elmer AutoSystem XL 
Column: 30 m x 0.25 mm i.d. x 0.25 μm DB-5MS (J. & W. Scientific) 
Temp prog.: 40-300ºC @ 3ºC/min 
Carrier gas: Helium (flow: 1ml/min) 
Injection temp.: 220 °C 
MS (quadrupole): Perkin-Elmer TurboMass (quadrupole) 
Source: EI (70 eV) 
Source temp.: 180 °C 
Scan range: 38-600 m/z 
Scan time: 0.50 s 
Inter-scan delay: 0.20 s 
 Aloysia  
 
Percentage composition 
Fraction I 
100% 
Pet Ether 
Percentage 
composition 
Fraction II 
90% PetEther 
10% DiethylEther 
Percentage  composition 
Fraction III 
100%  DiethylEther 
Percentage 
composition 
Salvene  
 0.03 Tr 0 0 
α-Thujene 
0.07 0.11 0  
α-Pinene 
0.44 0.82 0  
Camphene 
Tr Tr 0  
Sabinene 
0.92 1.52 0  
β-Pinene 
0.08 0.14 0  
1-Octen-3-ol 
0.55 Tr 0.05 Tr 
6-Methyl-5-hepten-2-one 
2.37 2.42 0 7.19 
Myrcene 
0.20 0.32 0  
α-terpinene 
 0.01 Tr 0  
Cymene 
 0.46 0.49 0  
Limonene 
12.14 20.24 0  
1,8-Cineole 
7.94 11.44 0 59.27 
β-Ocimene 
0.04 Tr 0  
Bergamal 
0.07 Tr 0  
γ-Terpinene 
0.16 0.28 0  
cis Sabinene hydrate 
0.96 0.09 7.17 9.38 
Perillene 
Tr 0.07 0  
Linalool 
0.61 0.16 1.43 Tr 
trans Sabinene hydrate 
 0.41 0 2.88  
 
    
α-Pinene oxide 
 0.12 Tr 0  
cis-Rose oxide 
0.06 Tr 0  
Trans-Thujone 
0.03 Tr 0  
trans-p-Mentha-2,8-dien-
1-ol 
0.48 Tr 3.18 Tr 
α-Campholenal 
0.09 Tr 0  
cis-Limonene oxide 
0.27 0.19 0  
cis-p-Mentha-2,8-dien-1-ol 
 0.81 0.35 3.06  
verbenol 
0.10 0 Tr  
Citronellal 
0.14 0.10 0  
Sabina ketone 
0.12 0 Tr  
rosefuran epoxide 
0.59 0.58 0 Tr 
Terpinen-4-ol 
0.75 0.51 2.31 Tr 
trans-p-Mentha-1(7),8-dien-2-ol 0.30 Tr Tr  
α-Terpineol 
3.27 0.33 24.70 15.75 
Shisofuran 
0.09 Tr 0  
trans-Carveol 
0.86 0 3.48 Tr 
Nerol 
0.24 0 Tr  
Citronellol 
0.10 0 0  
cis-p-Mentha-1(7),8-dien-
2-ol 
0.22 0 Tr  
cis−carveol 
0.39 0 Tr  
Neral 
2.55 2.85 Tr 8.51 
carvone 
1.14 1.37 0  
Geraniol 
0.25 0 0  
Piperitone 
0.33 Tr Tr  
Geranial 
4.03 4.64 Tr 21.83 
Perilla aldehyde 
0.13 0.12 0  
(E)-Anethole 
0.35 0.27 0  
Thymol 
0.16 0.13 0  
Carvacrol 
0.82 0.32 Tr Tr 
trans-Carvyl acetate 
0.09 Tr 0  
Piperitenone 
0.06 0 0  
α-Cubebene 
0.09 Tr 0  
Eugenol 
0.16 Tr 0  
α-Ylangene 
 0.12 0.09 0  
α-Copaene 
1.62 2.01 0  
β-Bourbonene 
 0.96 1.34   
Methyl eugenol  
0.14 Tr   
Sesquithujene 
 0.13 0.12   
α-Cedrene 
 0.67 0.91   
(E)-Caryophyllene 
2.07 3.20   
β-Cedrene 
0.37 0.50   
β-Copaene 
0.16 0.21   
α-Humulene 
0.25 0.31   
Allo-aromadendrene 
0.86 1.22   
Acoradiene 
 0.25 0.48   
γ-Muurolene 
0.26 0.32   
Curcumene  
9.17 
 
15.30   
Bicyclogermacrene 
(+ epi-cubebol**) 
0.49 0.53 Tr  
α-Muurolene 
0.09 0.12   
Bisabolene  
0.12 Tr   
β-Curcumene  
0.16 
 
0.36   
γ-Cadinene 
0.39 0.53   
  
 
Cubebol 
 0.81 0.10 3.44 Tr 
δ-Cadinene 
0.27 0.41   
trans-Calamenene 
 0.14 Tr   
cis-Calamenene 
 0.11 Tr   
α-Cadinene 
0.23 0   
(E)-Nerolidol  
0.89 
 
0.33   
Spathulenol 
 7.16 1.33 40.54 44.53 
Caryophyllene oxide 
10.44 15.29   
Globulol 
 1.29 0.95   
-Cadinol 
 1.33 0.50 3.46 Tr 
 
 
 
 
 
Appendix IV 
SPE of Lavandula angustifolia Essential Oil 
Lav
Pet Ether
Diethyl Ether
SF10-4g
3/10/2010 6:12:37 PM
Sample ID: 
Solvent A:
Solvent B:
Column:
Start Time:
Column Station: 1
Detectors: UV: 254nm, 300nm, 399nm, 200nm
AU Graph
254nm
300nm
399nm
200nm
Gradient Graph
Page 1 of 3 3/10/2010Varian 971-FP Version: 3.1.469
Solvent Details
%B Time %B Time
0 00:00 100 04:00
0 01:20 100 05:20
10 01:20 100 06:00
10 04:00 100 09:00
Tube Map
Rack: 2 Instance: 1
Rack: 3 Instance: 1
Page 2 of 3 3/10/2010Varian 971-FP Version: 3.1.469
1Rack:
Peak Tube Number Volume (CV) Volume (ml)
2 Instance: 
 3.00 14  0.501
 3.00 15  0.501
 3.00 16  0.501
 2.40 17  0.401
 2.40 18  0.401
 2.40 19  0.401
 3.00 20  0.501
 3.00 21  0.501
 3.00 22  0.501
 3.00 23  0.501
 3.00 24  0.501
 2.40 25  0.401
 3.00 26  0.501
 3.00 27  0.501
 3.60 28  0.601
 3.00 29  0.501
 3.00 30  0.501
 3.00 31  0.501
 3.00 32  0.501
 2.40 33  0.401
 3.60 34  0.601
 3.60 35  0.601
 3.00 36  0.501
 3.60 37  0.601
 3.60 38  0.601
 3.00 39  0.501
 3.60 40  0.601
1Rack:
Peak Tube Number Volume (CV) Volume (ml)
3 Instance: 
 4.20 1  0.701
 3.00 2  0.501
 3.00 3  0.501
 3.00 4  0.501
 3.00 5  0.501
 3.00 6  0.501
 2.40 7  0.401
 3.00 8  0.501
 3.00 9  0.501
 2.40 10  0.401
 2.40 11  0.401
 2.40 12  0.401
 3.00 13  0.501
 3.00 14  0.501
 3.00 15  0.501
 3.00 16  0.501
 3.00 17  0.501
 3.00 18  0.501
 3.00 19  0.501
 3.00 20  0.501
 3.00 21  0.501
 3.00 22  0.501
 2.40 23  0.401
 2.40 24  0.401
 3.60 25  0.601
 154.80 25.80Total:
Page 3 of 3 3/10/2010Varian 971-FP Version: 3.1.469
Lavandula angustifolia Mill. Essential Oil and Fractions (L1, L2, L3) 
GC-MS Analysis 
Sample preparation 
Oil: 1/100 dilution in diethyl ether. 
Fractions analysed without dilution. 
Method 
GC: Perkin-Elmer AutoSystem XL 
Column: 30 m x 0.25 mm i.d. x 0.25 μm DB-5MS (J. & W. Scientific) 
Temp prog.: 40-300ºC @ 3ºC/min 
Carrier gas: Helium (flow: 1ml/min) 
Injection temp.: 220 °C 
MS (quadrupole): Perkin-Elmer TurboMass (quadrupole) 
Source: EI (70 eV) 
Source temp.: 180 °C 
Scan range: 38-600 m/z 
Scan time: 0.50 s 
Inter-scan delay: 0.20 s 
 Lavender  Oil 
 
Percentage 
composition 
Fraction I  
100%Pet Ether 
Percentage  
composition 
Fraction II 
90% PetEther  
10% DiethylEther 
Percentage  composition 
Fraction III 
100%  DiethylEther 
Percentage  
composition 
Tricyclene 
Tr 0.1 0 0 
α-Thujene 
Tr 0.3 
 
 
Tr 0.1 
α-Pinene 
0.1 0.7 
 
Tr 
 
Tr 
Camphene 
0.1 0.8 
 
0 
 
0 
Sabinene 
Tr 0.2 
 
0 
 
0 
β-Pinene 
Tr 0.2 
 
0 
 
0 
1-Octen-3-ol 
0.4 
 
0 
 
Tr 1.4 
3-Octanone 
0.1 0.1 0.1 
 
Tr 
Myrcene 
0.5 2.6 0.1 
 
Tr 
α-Phellandrene 
Tr Tr 
 
 
0 
 
 
0 
2-δ-Carene 
0.3 2.1 
 
 
0 
 
 
0 
Hexyl acetate 
0.1 
 
Tr 0.1 
 
0 
p-Cymene 
0.1 0.6 0.1 0.1 
o-Cymene 
0.3 1.5 
 
 
Tr 
 
 
Tr 
Limonene 
0.8 2.8 
 
 
Tr 
 
 
Tr 
β-Phellandrene 
Tr 1.8 
 
 
0 
 
 
Tr 
1,8-Cineole 
1.4 
 
0 2.5 
 
Tr 
(Z)-β-Ocimene 
2.6 13.8 0.2 0.2 
(E)-β-Ocimene 
1.5 8.3 0.1 0.2 
γ-Terpinene 
0.1 0.4 
 
 
0 
 
 
0 
trans-Linalool 
oxide  
0.1 
 
0 
 
0 0.3 
Terpinolene 
Tr 0.5 
 
 
0 
 
 
0 
cis-Linalool 
oxide 
(furanoid) 0.1 
 
0 
 
0 0.1 
Dehydro-
linalool Tr Tr 
 
0 
 
0 
Perillene 
Tr Tr 
 
 
0 
 
 
0 
Linalool 
40.4 0.4 30.9 66.2 
1-Octen-3-
ylacetate 
1.0 0.6 1.2 
 
0 
Allo-ocimene 
Tr 0.2 
 
0 
 
0 
trans-Sabinol 
Tr Tr Tr Tr 
Camphor 
0.3 
 
 
0 0.4 
 
 
Tr 
3-Neo / 3-
Neoiso-
thujanol Tr Tr Tr Tr 
Borneol 
0.8 
 
 
0 
 
 
0 2.7 
Terpinen-4-ol 
3.1 
 
Tr 2.7 1.4 
Cryptone 
0.4 
 
0 
 
0 1.2 
Hexyl 
butanoate 0.1 0.3 0.1 
 
0 
α-Terpineol 
1.7 
 
Tr 
 
Tr 4.8 
Isobornyl 
formate 
0.2 0.1 
 
0 
 
0 
Cumin 
aldehyde 0.2 
 
0 0.2 
 
0 
Linalyl acetate 
30.2 17.5  49.8 0.1 
Tetrahydro-
lavandulylaceta
te 
Tr 
 
 
Tr 
 
 
Tr 0.1 
Lavandulyl 
acetate 
2.0 0.4 3.2 0.1 
Hexyl tiglate 
Tr Tr 
 
0 
 
0 
  
Neryl acetate 
0.4 0.1  0.6 
 
0 
α-Copaene 
Tr 
 
0 
 
0 
 
0 
Linalyl 
isobutanoate 
0.8 0.1 0.1 
 
 
0 
β-Bourbonene 
0.8 0.1 
 
 
 
0 
 
 
 
0 
7-epi-
Sesquithujene 
0.1 0.2 
 
 
 
 
0 
 
 
 
 
0 
cis-α-
Bergamotene 
Tr 0.1 
 
 
0 
 
 
0 
(E)-
Caryophyllene 
4.9 20.7 
 
 
 
Tr 
 
 
 
0 
trans-α-
Bergamotene 
0.2 0.7 
 
 
0 
 
 
0 
(E)-β-Farnesene 
1.5 6.3 
 
0 
 
0 
γ-Muurolene 
0.5 2.1 
 
 
 
0 
 
 
 
0 
γ-Cadinene 
0.2 0.8 
 
 
 
0 
 
 
 
0 
Caryophyllene 
oxide 
0.4 0.1 0.4 0 
